Agonist tumor necrosis factor receptor superfamily peptides
By developing agonistic TNFR2 binding peptides, the problem of enhanced survival and proliferation of regulatory Treg cells was solved, effective treatment of autoimmune diseases and inflammation was achieved, the proliferation and activity of Treg cells and MDSCs were promoted, and T effector cells were inhibited. , enhances TNFR2 signaling.
Patent Information
- Application Number
- CN201980089022.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-11-15
- Filing Date
- 2019-11-15
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2039-11-15
AI Technical Summary
The prior art is difficult to effectively enhance the survival and proliferation of regulatory Treg cells, resulting in poor treatment of diseases such as autoimmune diseases, graft-versus-host disease, allograft rejection, allergic reactions, asthma and inflammation.
Developing agonist tumor necrosis factor receptor 2 (TNFR2) binding peptides, including single-chain polypeptides, antibodies and antigen-binding fragments that bind epitopes within specific domains of TNFR2, with superior TNFR2 agonist properties that promote Treg cells and myeloid sources Sexually inhibits cell proliferation and activity and activates related cells through the TNFR2 signaling pathway.
It significantly promotes the proliferation and activity of Treg cells and MDSCs, inhibits T effector cells, enhances TNFR2 signaling, and is used to treat autoimmune diseases, inflammation and neurodegenerative diseases.
Smart Images

Figure BDA0003162355730000411 
Figure BDA0003162355730000791 
Figure BDA0003162355730000792
Abstract
Description
[0001] Sequence Listing
[0002] This application contains a sequence listing, which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. The ASCII copy was created on November 15, 2019, named 00786-582WO2_SEQUENCE_LISTING_11.15.19_ST25, and is 28,722 bytes in size. Background Art
[0003] Maintaining control over both cell-mediated and humoral immune responses is an important aspect of healthy immune system activity. Abnormal regulation of T-cell and B-cell driven immune responses is associated with a variety of human diseases, as inappropriate increases in immune responses to various self and foreign antigens play a causal role in the pathology of immune diseases such as autoimmune diseases, asthma, allergic reactions, graft-versus-host disease, and transplant rejection. T and B lymphocytes can mediate these diseases by showing reactivity to self-antigens and those derived from non-threatening sources, such as allergens or allogeneic transplants. Regulatory T cells (Treg cells) evolved to suppress the activity of immune cells that cross-react with "self" major histocompatibility complex (MHC) proteins and other benign antigens. Treg cells are a heterogeneous group of T cells that can be distinguished based on their unique surface protein expression. The most well-known populations of Treg cells include CD4+, CD25+, FoxP3+ Treg cells, and CD17+ Treg cells. The cells mediate the suppression of autoreactive T cells through a precise mechanism that is currently under investigation, although studies have shown that certain types of Treg cells can inhibit the production of the proliferation-inducing cytokine IL-2 in target T cells and can separate IL-2 from autoreactive cells by virtue of the affinity of CD25 (a subdomain of the IL-2 receptor) for IL-2 (Josefowicz et al., Ann. Rev. Immun., 30:531-564, 2012). In addition, studies have shown that CD4+, CD25+, FoxP3+ Treg cells are also present in B cell-rich areas and can directly inhibit the production of immunoglobulins, rather than attenuating T H 2. The ability of the cells to be active has nothing to do with each other (Lim et al., J. Immunol., 175:4180-4183, 2005).
[0004] Improved therapies that can enhance Treg cell survival and proliferation are urgently needed for the treatment of such diseases as autoimmune diseases, graft-versus-host disease, allograft rejection, allergic reactions, asthma, and inflammation. Summary of the invention
[0005] Described herein are agonistic tumor necrosis factor receptor superfamily polypeptides, e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof. For example, agonistic tumor necrosis factor receptor 2 (TNFR2) binding polypeptides, e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof are provided. Human TNFR2 contains the following four cysteine-rich domains (CRDs): CRD1 (amino acid residues 48-76 of SEQ ID NO: 1), CRD2 (amino acid residues 78-120 of SEQ ID NO: 1), CRD3 (amino acid residues 121-162 of SEQ ID NO: 1), and CRD4 (amino acid residues 162-202 of SEQ ID NO: 1). The agonistic TNFR2 polypeptides described herein include polypeptides that bind to one or more epitopes within CRD1, CRD2, and / or CRD3 of TNFR2, e.g., polypeptides that bind to one or more epitopes of TNFR2 only within CRD1 and / or CRD2, but not within CRD4.
[0006] Agonist TNFR2 polypeptides described herein include antibodies of the human IgG1 isotype, antibodies of the human IgG2 isotype, antibodies of the human IgG3 isotype, and antibodies of the human IgG4 isotype, and antigen-binding fragments thereof, which specifically bind to TNFR2 at one or more of the epitopes detailed above. In some embodiments, the TNFR2 polypeptides of the disclosure contain a mutant human IgG1 or IgG2 heavy chain constant 1 (CH1) domain that lacks a cysteine residue at position 127 of the CH1 domain amino acid sequence, such as a TNFR2 polypeptide (e.g., an antibody or antigen-binding fragment thereof) containing a human IgG1 or IgG2 CH1 domain having a C127S (according to Kabat numbering) mutation. The present disclosure is based, in part, on the surprising discovery that antibodies and antigen-binding fragments thereof exhibit significantly superior TNFR2 agonist properties when these molecules are in the form of the IgG2-B isotype relative to other antibody isotypes.
[0007] Agonist TNFR2 polypeptides described herein also include polypeptides that bind to TNFR2 at at least two sites (e.g., polypeptides having two or more antigen binding sites, wherein TNFR2 is an "antigen"). These binding sites may be spaced apart from each other by less than about Advantageously, the antigen binding sites are spaced less than The agonist TNFR2 polypeptide specifically binds to TNFR2 at one or more of the above epitopes but contains epitopes separated by more than about The polypeptides containing the TNFR2 binding sites of the present disclosure can activate TNFR2 signal transduction with greater potential. For example, the agonist TNFR2 polypeptides of the present disclosure include IgG1 antibodies and antigen-binding fragments thereof, which contain about TNFR2 binding site; and IgG3 antibodies and antigen-binding fragments thereof, which contain TNFR2 binding sites separated by about TNFR2 binding site.
[0008] Also featured are agonist TNFR2 polypeptides that utilize a single disulfide-bonded isoform and pharmaceutical compositions containing the same. For example, pharmaceutical compositions of the present disclosure include pharmaceutical compositions containing an agonist TNFR2 binding polypeptide wherein, for example, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, 99.99% or more of the polypeptide in the pharmaceutical composition is present in a single disulfide-bonded isoform. In contrast to the use of other human IgG2 isoforms (such as IgG2-A, IgG2-A / B 1 and IgG2-A / B 2 ) TNFR2 binding polypeptides using the human IgG2-B isoform exhibited substantially superior TNFR2 agonist effects. Thus, TNFR2 polypeptides using a single disulfide bonded isoform can be prepared as pharmaceutical compositions and administered in the therapeutic methods described herein to promote robust TNFR2 agonistic effects.
[0009] Agonistic TNFR2 polypeptides of the present disclosure exhibit one or more beneficial biological properties, such as the ability to promote proliferation and stabilization of regulatory T cells (Treg cells) and / or myeloid-derived suppressor cells (MDSC). Additionally or alternatively, agonistic TNFR2 polypeptides can be administered to promote reciprocal contraction of T effector cells (e.g., cytotoxic CD8+ T cells) and / or direct killing of T effector cells. This can occur, for example, by indirectly amplifying the proliferation and activity of Treg cells or by directly killing T effector cells. Thus, designating TNFR2 polypeptides as agonists means that they are able to promote the proliferation and activity of Treg cells and / or MDSC, and for clarity, does indicate activation of an undesired T effector cell response. The polypeptides described herein (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) can be used to treat a variety of conditions, including autoimmune diseases, inflammatory diseases, etc., as well as to promote the proliferation, healing, protection and / or regeneration of tissues expressing TNFR2 (such as neurons and brain-related tissues), making the polypeptides of the present disclosure useful, for example, in the treatment of neurological diseases such as Parkinson's disease, multiple sclerosis, Alzheimer's disease, and other neurodegenerative diseases.
[0010] In a first aspect, the invention features polypeptides (such as single chain polypeptides, antibodies, antigen binding fragments thereof, and constructs thereof) that specifically bind to human TNFR2 at an epitope defined by one or more amino acids within cysteine-rich domain (CRD) 1 (CRD1), CRD2, and / or CRD3, and do not specifically bind to human TNFR2 at an epitope defined by one or more amino acids within CRD4. In some embodiments, the polypeptide:
[0011] (a) comprising a human IgG1 or IgG2 CH1 domain having a deletion or substitution at cysteine residue 127;
[0012] (b) containing The distance to the antigen binding site;
[0013] (c) a complementarity determining region - heavy chain 1 (CDR-H1) comprising an amino acid sequence having:
[0014] (i)GZ 1 TFZ 3 Z 2 YZ 3 Z 4 (SEQ ID NO:2);
[0015] (ii) GYTFTDYNI (SEQ ID NO: 3) or an amino acid sequence having up to two conservative amino acid substitutions relative to that sequence; or
[0016] (iii) GYTFTDYNL (SEQ ID NO: 4) or an amino acid sequence having up to two conservative amino acid substitutions relative to this sequence;
[0017] Each Z 1 are independently a naturally occurring amino acid comprising a side chain containing an aromatic substituent;
[0018] Each Z 2 are independently naturally occurring amino acids that contain anionic side chains at physiological pH;
[0019] Each Z 3 are independently naturally occurring amino acids that contain polar, uncharged side chains at physiological pH; and
[0020] Each Z 4 independently leucine or isoleucine; and / or
[0021] (d) contains a framework region having: TJDJSJJJX 1YX 2 X 3 LqCy 4 LJS (SEQ ID NO: 5) or an amino acid sequence of 10 or more residues of SEQ ID NO: 5, wherein each J is independently a naturally occurring amino acid; each X 1 independently A, V or F; each X 2 independently M or I; each X 3 is independently E or Q; and each X 4 are independently S or R.
[0022] In some embodiments, the polypeptide (such as a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, and a construct thereof) contains a human IgG1 or IgG2 CH1 domain that lacks a cysteine residue at position 127 of the amino acid sequence of the IgG1 or IgG2 CH1 domain (according to the Kabat numbering scheme). For example, a polypeptide (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) may contain a human IgG1 or IgG2 CH1 domain that has an amino acid other than cysteine, such as a serine residue, at position 127 of the amino acid sequence of the CH1 domain.
[0023] In some embodiments, the IgG1 CH1 domain has an amino acid sequence that is at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, or 95% identical or higher) to the amino acid sequence of:
[0024] ASTKGPSVFPLAPCSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV (SEQ ID NO:6), e.g., with the proviso that the IgG1 CH1 domain contains a serine residue at position 127 of the amino acid sequence of the IgG1 CH1 domain (according to Kabat numbering, as described herein). For example, the IgG1 CH1 domain can have an amino acid sequence that is at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the amino acid sequence of SEQ ID NO:6, e.g., with the proviso that the IgG1 CH1 domain contains a serine residue at position 127 of the amino acid sequence of the IgG1 CH1 domain. In some embodiments, the IgG1 CH1 domain has an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 6, for example, provided that the IgG1 CH1 domain contains a serine residue at position 127 of the amino acid sequence of the IgG1 CH1 domain. In some embodiments, the IgG1 CH1 domain has an amino acid sequence of SEQ ID NO: 6. In some embodiments, the IgG1 CH1 domain has an amino acid sequence that differs from SEQ ID NO: 6 only by a C127S substitution (according to Kabat numbering, as described herein). In these embodiments, the IgG1 CH1 domain has an amino acid sequence of:
[0025] ASTKGPSVFPLAPSSKSGSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV (SEQ ID NO: 7).
[0026] In some embodiments, the IgG2 CH1 domain has an amino acid sequence that is at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the amino acid sequence of:
[0027] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTV (SEQ ID NO: 8), e.g., with the proviso that the IgG2 CH1 domain contains a serine residue at position 127 of the amino acid sequence of the IgG2 CH1 domain (according to Kabat numbering, as described herein). For example, the IgG2 CH1 domain can have an amino acid sequence that is at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical) to the amino acid sequence of SEQ ID NO: 8, e.g., with the proviso that the IgG2 CH1 domain contains a serine residue at position 127 of the amino acid sequence of the IgG2 CH1 domain. In some embodiments, the IgG2 CH1 domain has an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 8, for example, provided that the IgG2 CH1 domain contains a serine residue at position 127 of the amino acid sequence of the IgG2 CH1 domain. In some embodiments, the IgG2 CH1 domain has an amino acid sequence of SEQ ID NO: 8. In some embodiments, the IgG2 CH1 domain has an amino acid sequence that differs from SEQ ID NO: 8 only by a C127S substitution (according to Kabat numbering, as described herein). In these embodiments, the IgG2 CH1 domain has an amino acid sequence of:
[0028] ASTKGPSVFPLAPSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTV (SEQ ID NO: 9).
[0029] In some embodiments, the polypeptide (eg, single chain polypeptide, antibody, antigen binding fragment thereof, or construct thereof) is of the IgG3 or IgG4 isotype.
[0030] The polypeptide (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) can contain antigen-binding sites (e.g., two or more antigen-binding sites, such as two to ten, two to nine, two to eight, two to seven, two to six, two to five, two or three antigen-binding sites) that are spaced less than about 100 μm from each other. distance (e.g., about to about distance, such as about or In some embodiments, the antigen binding sites are spaced about to about distance, such as about or In some embodiments, the antigen binding sites are spaced about to about distance, such as about or distance.
[0031] For example, a polypeptide (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) can contain antigen-binding sites that are spaced about 1:1 from each other. to about distance, such as about or In some embodiments, the antigen binding sites are spaced about to about distance, for example about or In some embodiments, the antigen binding sites are spaced about to about distance, for example about or In some embodiments, the antigen binding sites are spaced about In some embodiments, the polypeptide (eg, a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) has the above-described antigen-binding arm separation, and an IgG1 isotype.
[0032] In some embodiments, the polypeptide (e.g., single-chain polypeptide, antibody, antigen-binding fragment thereof, or construct thereof) contains antigen-binding sites that are spaced about 100 μg / cm2 from each other. to about distance, such as about or In some embodiments, the antigen binding sites are spaced about to about distance, for example about or In some embodiments, the antigen binding sites are spaced about to about distance, for example about or In some embodiments, the antigen binding sites are spaced about In some embodiments, the polypeptide (eg, a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) has the above-described antigen-binding arm separation, and an IgG3 isotype.
[0033] In some embodiments, the polypeptide (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) contains a CDR-H1 having an amino acid sequence of:
[0034] (a)GZ 1 TFZ 3 Z 2 YZ 3 Z 4 (SEQ ID NO:2);
[0035] (b) GYTFTDYNI (SEQ ID NO: 3) or an amino acid sequence having up to two conservative amino acid substitutions relative to that sequence; or
[0036] (c) GYTFTDYNL (SEQ ID NO: 4) or an amino acid sequence having up to two conservative amino acid substitutions relative to this sequence;
[0037] Each Z 1 are independently a naturally occurring amino acid comprising a side chain containing an aromatic substituent;
[0038] Each Z 2 are independently naturally occurring amino acids that contain anionic side chains at physiological pH;
[0039] Each Z 3 are independently naturally occurring amino acids that contain polar, uncharged side chains at physiological pH; and
[0040] Each Z 4 is independently leucine or isoleucine.
[0041] In some embodiments, the polypeptide (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) specifically binds to human TNFR2 at an epitope defined by one or more amino acids within CRD1, for example, at an epitope defined by amino acid residues 56-60 (KCSPG) within one or more SEQ ID NO: 1. In some embodiments, the polypeptide specifically binds to human TNFR2 at an epitope defined by one or more amino acids within CRD2. In some embodiments, the polypeptide specifically binds to human TNFR2 at an epitope defined by one or more amino acids within CRD3.
[0042] In some embodiments, the polypeptide (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) further contains one or more, or all of the following CDRs:
[0043] (a) CDR-H2 having the amino acid sequence INPNYDST (SEQ ID NO: 10) or an amino acid sequence having up to two conservative amino acid substitutions relative to this sequence;
[0044] (b) CDR-H3 having the amino acid sequence CARGNSWYFDV (SEQ ID NO: 11) or an amino acid sequence having up to two conservative amino acid substitutions relative to that sequence;
[0045] (c) CDR-L1 having the amino acid sequence SSVRY (SEQ ID NO: 12) or an amino acid sequence having up to two conservative amino acid substitutions relative to this sequence;
[0046] (d) a CDR-L2 having the amino acid sequence of LTS, or an amino acid sequence having up to two conservative amino acid substitutions relative to that sequence; and
[0047] (e) CDR-L3 having the amino acid sequence CQQWSSNPLT (SEQ ID NO: 13) or an amino acid sequence having up to two conservative amino acid substitutions relative to this sequence.
[0048] In some embodiments, the polypeptide (e.g., a single chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) contains one or more, or all of the following CDRs:
[0049] (a) CDR-H2 having the amino acid sequence INPNYDST (SEQ ID NO: 10);
[0050] (b) CDR-H3 having the amino acid sequence CARGNSWYFDV (SEQ ID NO: 11);
[0051] (c) CDR-L1 having the amino acid sequence SSVRY (SEQ ID NO: 12);
[0052] (d) CDR-L2 having the amino acid sequence LTS; and
[0053] (e) CDR-L3, which has the amino acid sequence CQQWSSNPLT (SEQ ID NO: 13).
[0054] In some embodiments, CDR-H1 has the amino acid sequence GYTFTDYNI (SEQ ID NO: 3) or an amino acid sequence having up to two conservative amino acid substitutions relative to that sequence.
[0055] In some embodiments, the polypeptide contains the following CDRs:
[0056] (a) CDR-H1 having the amino acid sequence GYTFTDYNI (SEQ ID NO: 3);
[0057] (b) CDR-H2 having the amino acid sequence INPNYDST (SEQ ID NO: 10);
[0058] (c) CDR-H3 having the amino acid sequence CARGNSWYFDV (SEQ ID NO: 11);
[0059] (d) CDR-L1 having the amino acid sequence SSVRY (SEQ ID NO: 12);
[0060] (e) CDR-L2 having the amino acid sequence LTS; and
[0061] (f) CDR-L3 having the amino acid sequence CQQWSSNPLT (SEQ ID NO: 13).
[0062] In some embodiments, the polypeptide (e.g., single chain polypeptide, antibody, antigen binding fragment thereof, or construct thereof) contains a heavy chain variable domain (V H ), the V H The polypeptide has an amino acid sequence that is at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical) to the amino acid sequence of SEQ ID NO: 14. In some embodiments, the polypeptide contains a heavy chain variable domain (V H ), the V HThe polypeptide has an amino acid sequence that is at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical) to the amino acid sequence of SEQ ID NO: 14. In some embodiments, the polypeptide contains a heavy chain variable domain (V H ), the V H having an amino acid sequence that is at least 95% identical (e.g., at least 95%, 96%, 97%, 98%, 99% or 100% identical) to the amino acid sequence of SEQ ID NO: 14. In some embodiments, the polypeptide contains a heavy chain variable domain (V H ), the V H Having the amino acid sequence of SEQ ID NO:14.
[0063] In some embodiments, CDR-H1 has the amino acid sequence GYTFTDYNL (SEQ ID NO: 4) or an amino acid sequence having up to two conservative amino acid substitutions relative to that sequence.
[0064] In some embodiments, the polypeptide contains the following CDRs:
[0065] (a) CDR-H1 having the amino acid sequence GYTFTDYNL (SEQ ID NO: 4);
[0066] (b) CDR-H2 having the amino acid sequence INPNYDST (SEQ ID NO: 10);
[0067] (c) CDR-H3 having the amino acid sequence CARGNSWYFDV (SEQ ID NO: 11);
[0068] (d) CDR-L1 having the amino acid sequence SSVRY (SEQ ID NO: 12);
[0069] (e) CDR-L2 having the amino acid sequence LTS; and
[0070] (f) CDR-L3 having the amino acid sequence CQQWSSNPLT (SEQ ID NO: 13).
[0071] In some embodiments, the polypeptide (e.g., single chain polypeptide, antibody, antigen binding fragment thereof, or construct thereof) contains a heavy chain variable domain (V H ), the V HThe polypeptide has an amino acid sequence that is at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical) to the amino acid sequence of SEQ ID NO: 15. In some embodiments, the polypeptide contains a heavy chain variable domain (V H ), the V H The polypeptide has an amino acid sequence that is at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical) to the amino acid sequence of SEQ ID NO: 15. In some embodiments, the polypeptide contains a heavy chain variable domain (V H ), the V H having an amino acid sequence that is at least 95% identical (e.g., at least 95%, 96%, 97%, 98%, 99% or 100% identical) to the amino acid sequence of SEQ ID NO: 15. In some embodiments, the polypeptide contains a heavy chain variable domain (V H ), the V H Having the amino acid sequence of SEQ ID NO:15.
[0072] In some embodiments, the polypeptide (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) contains a non-natural constant region, such as a human constant region. In some embodiments, the polypeptide lacks all or part of an Fc domain, lacks all or part of a native Fc domain, or lacks all Fc domains.
[0073] In some embodiments, the polypeptide (eg, single-chain polypeptide, antibody, antigen-binding fragment thereof, or construct thereof) contains a framework region having TJDJSJJJX 1 YX 2 X 3 LqCy 4 LJS (SEQ ID NO: 5) or an amino acid sequence of 10 or more residues of SEQ ID NO: 5, wherein each J is independently a naturally occurring amino acid; each X 1 independently A, V or F; each X 2 independently M or I; each X 3 is independently E or Q; and each X 4 are independently S or R. For example, the polypeptide may contain a framework region having an amino acid sequence selected from the group consisting of:
[0074] (a) TVDKSSSTAYMELRSLTS (SEQ ID NO: 16) or an amino acid sequence having up to two conservative amino acid substitutions relative to that sequence;
[0075] (b) TADTSSNTAYIQLSSLTS (SEQ ID NO: 17) or an amino acid sequence having up to two conservative amino acid substitutions relative to this sequence;
[0076] (c) TADTSTDTAYMELSSLRS (SEQ ID NO: 18) or an amino acid sequence having up to two conservative amino acid substitutions relative to this sequence;
[0077] (d) TRDTSISTAYMELSRLTS (SEQ ID NO: 19) or an amino acid sequence having up to two conservative amino acid substitutions relative to that sequence;
[0078] (e) TFYMELSSLRS (SEQ ID NO: 20) or an amino acid sequence having up to two conservative amino acid substitutions relative to that sequence;
[0079] (f) TRDTSISTAYMELNRLTS (SEQ ID NO: 21) or an amino acid sequence having up to two conservative amino acid substitutions relative to that sequence;
[0080] (g) TRDTSTNTVYMELTSLRS (SEQ ID NO: 22) or an amino acid sequence having up to two conservative amino acid substitutions relative to that sequence; and
[0081] (h) TADTSTDRAYMELSSLRS (SEQ ID NO: 23) or an amino acid sequence having up to two conservative amino acid substitutions relative to this sequence.
[0082] In some embodiments, the framework region is located near CDR-H2 in a polypeptide (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof). In some embodiments, the framework region is located near CDR-H3 in a polypeptide. In some embodiments, the framework region is located between CDR-H2 and CDR-H3.
[0083] In some embodiments, the polypeptide (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) specifically binds to an epitope of TNFR2 that corresponds to one or more of the following amino acid residues:
[0084] (a) amino acids 56-60 of SEQ ID NO: 1 (KCSPG);
[0085] (b) amino acids 101-107 of SEQ ID NO: 1 (CSSDQVET);
[0086] (c) amino acids 115-142 of SEQ ID NO: 1
[0087] (NRICTCRPGWYCALSKQEGCRLCAPLRK);
[0088] (d) amino acids 26-45 of SEQ ID NO: 1 (QTAQMCCSKCSPGQHAKVFC);
[0089] (e) amino acids 90-109 of SEQ ID NO: 1 (REQNRICTCRPGWYCALSKQ);
[0090] (f) amino acids 98-117 of SEQ ID NO: 1
[0091] (CRPGWYCALSKQEGCRLCAP);
[0092] (g) amino acids 106-125 of SEQ ID NO: 1
[0093] (LSKQEGCRLCAPLRKCRPGF); and / or
[0094] (h) amino acids 108-127 of SEQ ID NO: 1
[0095] (KQEGCRLCAPLRKCRPGFGV).
[0096] In some embodiments, the polypeptide (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) specifically binds to K D Not more than about 10 nM, such as K D No more than about 1 nM of TNFR2 (eg, human TNFR2). For example, a polypeptide (eg, a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) can specifically bind to K D TNFR2 between about 1 pM and about 10 nM, such as K DAbout 1 pM, 5 pM, 10 pM, 15 pM, 20 pM, 25 pM, 30 pM, 35 pM, 40 pM, 45 pM, 50 pM, 55 pM, 60 pM, 65 pM, 70 pM, 75 pM, 80 pM, 85 pM, 90 pM, 95 pM, 100 pM, 105 pM, 110 pM, 115 pM, 1 20pM, 125pM, 130pM, 135pM, 140pM, 145pM, 150pM, 155pM, 160pM, 165pM, 170 pM, 175pM, 180pM, 185pM, 190pM, 195pM, 200pM, 205pM, 210pM, 215pM, 220pM, 225pM, 230pM, 235pM, 240pM, 245pM, 250pM, 255pM, 260pM, 265pM, 270pM, 27 5pM, 280pM, 285pM, 290pM, 295pM, 300pM, 305pM, 310pM, 315pM, 320pM, 325pM , 330pM, 335pM, 340pM, 345pM, 350pM, 355pM, 360pM, 365pM, 370pM, 375pM, 3 80pM, 385pM, 390pM, 395pM, 400pM, 405pM, 410pM, 415pM, 420pM, 425pM, 430p M, 435pM, 440pM, 445pM, 450pM, 455pM, 460pM, 465pM, 470pM, 475pM, 480pM, 485pM, 490pM, 495pM, 500pM, 505pM, 510pM, 515pM, 520pM, 525pM, 530pM, 535 pM, 540pM, 545pM, 550pM, 555pM, 560pM, 565pM, 570pM, 575pM, 580pM, 585pM ,590pM, 595pM, 600pM, 605pM, 610pM, 615pM, 620pM, 625pM, 630pM, 635pM, 64 0pM, 645pM, 650pM, 655pM, 660pM, 665pM, 670pM, 675pM, 680pM, 685pM, 690p M, 695pM, 700pM, 705pM, 710pM, 715pM, 720pM, 725pM, 730pM, 735pM, 740pM, 7 45pM, 750pM, 755pM, 760pM, 765pM, 770pM, 775pM, 780pM, 785pM, 790pM, 795 pM, 800pM, 805pM, 810pM, 815pM, 820pM, 825pM, 830pM, 835pM, 840pM, 845pM,850pM, 855pM, 860pM, 865pM, 870pM, 875pM, 880pM, 885pM, 890pM, 895pM, 900pM, 905pM, 910pM, 915pM, 920pM, 925pM, 930pM, 935pM, 940pM, 945pM, 950pM, 955pM, 960pM, 965pM, 970pM, 975pM, 980pM, 985pM, 990pM, 995pM, 1nM, 5nM or 10nM, among other values.
[0097] The polypeptide (eg, a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) can specifically bind to TNFR2, thereby forming a k on is at least about 10 4 M -1 s -1 or 10 5 M -1 s -1 The antibody-antigen complex, for example, on In about 1x10 4 M -1 s -1 About 1x10 8 M -1 s -1 For example, a polypeptide (eg, a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) can specifically bind to TNFR2, thereby forming an antibody-antigen complex having a k on About 1x10 4 M -1 s -1 , 2x10 4 M - 1 s -1 , 3x10 4 M -1 s -1 , 4x10 4 M -1 s -1 , 5x10 4 M -1 s -1 , 6x10 4 M -1 s -1 , 7x10 4 M -1 s -1 , 8x10 4 M -1 s -1 , 9x10 4 M -1 s-1 、1x10 5 M -1 s -1 、2x10 5 M -1 s -1 、3x10 5 M -1 s -1 、4x10 5 M -1 s -1 、5x10 5 M -1 s -1 、6x10 5 M -1 s -1 、7x10 5 M -1 s -1 、8x10 5 M -1 s -1 、9x10 5 M -1 s -1 、1x10 6 M -1 s -1 、2x10 6 M -1 s -1 、3x10 6 M -1 s -1 、4x10 6 M -1 s -1 、5x10 6 M -1 s -1 、6x10 6 M -1 s -1 、7x10 6 M -1 s -1 、8x10 6 M -1 s -1 、9x10 6 M -1 s -1 、1x10 7 M -1 s -1 、2x10 7 M -1 s -1 、3x10 7 M -1 s -1 、4x10 7 M-1 s -1 , 5x10 7 M -1 s -1 , 6x10 7 M -1 s -1 , 7x10 7 M -1 s -1 , 8x10 7 M -1 s -1 , 9x10 7 M -1 s -1 or 1x10 8 M -1 s -1 .
[0098] The polypeptide (eg, a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) can specifically bind to TNFR2, thereby forming a k off For example, no more than about 10 -3 s -1 or 10 -4 s -1 Dissociated antibody-antigen complexes, such as off In about 10 -6 s -1 to about 10 -3 s -1 Between (for example, k off About 1x10 -6 s -1 , 2x10 -6 s -1 , 3x10 -6 s -1 , 4x10 -6 s -1 , 5x10 -6 s -1 , 6x10 -6 s -1 , 7x10 -6 s -1 , 8x10 -6 s -1 , 9x10 -6 s -1 , 1x10 -5 s -1 , 2x10 -5 s -1 , 3x10 -5 s -1 , 4x10 -5 s -1 , 5x10 -5 s-1 , 6x10 - 5 s -1 , 7x10 -5 s -1 , 8x10 -5 s -1 , 9x10 -5 s -1 , 1x10 -4 s -1 , 2x10 -4 s -1 , 3x10 -4 s -1 , 4x10 -4 s -1 , 5x10 -4 s -1 , 6x10 -4 s -1 , 7x10 -4 s -1 , 8x10 -4 s -1 , 9x10 -4 s -1 or 1x10 -3 s -1 ).
[0099] The polypeptides described herein (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) can, for example, stimulate TNFR2 signaling in cells expressing TNFR2, such as Treg cells (e.g., expressing CD25 HiTreg cells), myeloid-derived suppressor cells (MDSCs) and / or TNFR2+ tissue cells, such as neurons or other cells of the central nervous system, thereby promoting cell healing, regeneration, proliferation and / or protection. In some embodiments, the polypeptide increases the expression of one or more genes selected from the group consisting of cIAP2, TRAF2, Etk, VEGFR2, PI3K, Akt, proteins involved in angiogenesis pathways, IKK complex, RIP, NIK, MAP3K, proteins involved in NFkB pathways, NIK, JNK, AP-1, MEK (e.g., MEK1, MEK7), MKK3, NEMO, IL2R, Foxp3, IL2, TNF, Lymphotoxin, Lymphotoxin α, Lymphotoxin β, TNFSF18, IL2RA, IKZF2 / 4, CTLA 4, TGFβ, CHUK, NFKBIE, NFKBIA, MAP3K11, TRAF3, relB, TNF, CXCR3, PDL1 (CD274), IL2RA, IL7R, MAP3K1, MAP, MAP3K4, NFKBIB, TANK, TBK1, TNFAIP3, NFKBIA, TNFRSF1B, TRAF2, relB, LTA, EP300 and CREBBP, the above is an evaluation result obtained by observing the increase of one or more of the above gene expressions, or by other gene activation evaluation methods known in the art. For example, the agonist TNFR2 single-chain polypeptide, antibody, antigen-binding fragment thereof and its construct can promote the expression or post-translational modification (e.g., phosphorylation) of one or more proteins involved in the activation of Treg, MDSC and / or TNFR2+ cells. For example, the polypeptide can reduce the expression of IL4.
[0100] For example, the polypeptides of the present disclosure can increase the expression or post-translational modification (e.g., phosphorylation) of one or more proteins selected from the group consisting of cIAP2, TRAF2, Etk, VEGFR2, PI3K, Akt, proteins involved in angiogenesis pathways, IKK complex, RIP, NIK, MAP3K, proteins involved in NFkB pathways, NIK, JNK, AP-1, MEK (e.g., MEK1, MEK7), MKK3, NEMO, IL2R, Foxp3, IL2, TNF, lymphotoxin, lymphotoxin alpha, lymphotoxin beta, TNFSF, relative to the expression or post-translational modification (e.g., phosphorylation) of one or more proteins selected from the group consisting of cIAP2, TRAF2, Etk, VEGFR2, PI3K, Akt, proteins involved in angiogenesis pathways, IKK complex, RIP, NIK, MAP3K, proteins involved in NFkB pathways, NIK, JNK, AP-1, MEK (e.g., MEK1, MEK7), MKK3, NEMO, IL2R, Foxp3, IL2, TNF, lymphotoxin, lymphotoxin alpha, lymphotoxin beta, TNFSF 18, IL2RA, IKZF2 / 4, CTLA4, TGFβ, CHUK, NFKBIE, NFKBIA, MAP3K11, TRAF3, relB, TNF, CXCR3, PDL1(CD274), IL2RA, IL7R, MAP3K1, MAP, MAP3K4, NFKBIB, TANK, TBK1, TNFAIP3, NFKBIA, TNFRSF1B, TRAF2, relB, LTA, EP300 and CREBBP, with an increase of approximately 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%. Exemplary assays that can be used to determine expression levels and phosphorylation states are known in the art and include, for example, Western blotting to determine protein levels and quantitative reverse transcription polymerase chain reaction (RT-PCR) experiments to determine mRNA levels. In some embodiments, TNFR2 polypeptides (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) are dominant TNFR2 agonists, and their agonistic activity can be further enhanced when used in combination with natural TNFR2 ligands such as TNFα, Bacillus Calmette-Guérin (BCG), and / or growth promoters such as IL-2.
[0101] Agonist TNFR2 polypeptides described herein, such as single chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof, can stimulate a metabolic shift from glycolysis to glutaminolysis and fatty acid oxidation in peripheral lymphocytes (e.g., human peripheral lymphocytes), which is also evidenced by increased Treg cell proliferation.
[0102] The agonist TNFR2 polypeptides described herein, e.g., single chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof, can induce an increase in itaconate production, e.g., by about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 200%, 300%, 400%, 500%, 1,000% or more, relative to cells (e.g., peripheral lymphocytes) not treated with the agonist TNFR2 polypeptide.
[0103] The agonist TNFR2 polypeptides described herein (e.g., single chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) may exhibit one or more, or all, of the following properties:
[0104] (a) For example, by binding to and activating TNFR2 on the surface of Treg cells, promoting the proliferation of Treg cells or increasing their stability and maintenance (thereby increasing the number or quality of Treg cells in the cell population relative to the cell population not exposed to the polypeptide, for example, the increase is about 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, 1.9 times, 2.1 times, 2.2 times, 2.3 times, 2.4 times, 2.5 times, 2.6 times, 2.7 times, 2.8 times, 2 ... times, 2.1 times, 2.2 times, 2.3 times, 2.4 times, 2.5 times, 2.6 times, 2.7 times, 2.8 times, 2.9 times, 3 times, 3.1 times, 3.2 times, 3.3 times, 3.4 times, 3.5 times, 3.6 times, 3.7 times, 3.8 times, 3.9 times, 4 times, 4.1 times, 4.2 times, 4.3 times, 4.4 times, 4.5 times, 4.6 times, 4.7 times, 4.8 times, 4.9 times, 5 times, 5.1 times, 5.2 times, 5.3 times, 5.4 times, 5.5 times, 5.6 times, 5.7 times, 5.8 times, 5.9 times, 6 times, 6.1 times, 6.2 times, 6.3 times, 6.4 times, 6.5 times, 6.6 times, 6.7 times, 6.8 times, 6.9 times, 7 times, 7.1 times, 7.2 times, 7.3 times, 7.4 times, 7.5 times, 7.6 times, 7.7 times, 7.8 times, 7.9 times times, 8 times, 8.1 times, 8.2 times, 8.3 times, 8.4 times, 8.5 times, 8.6 times, 8.7 times, 8.8 times, 8.9 times, 9 times, 9.1 times, 9.2 times, 9.3 times, 9.4 times, 9.5 times, 9.6 times, 9.7 times, 9.8 times, 9.9 times, 10 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, 100 times or more);
[0105] (b) for example, by binding to and activating TNFR2 on the surface of MDSC, promoting the proliferation of MDSC or increasing its stability (thereby increasing the number or quality of MDSC in the cell population relative to the cell population not exposed to the polypeptide, for example, by a factor of about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 71, 72, 73, 74, 75 .2 times, 2.3 times, 2.4 times, 2.5 times, 2.6 times, 2.7 times, 2.8 times, 2.9 times, 3 times, 3.1 times, 3.2 times, 3.3 times, 3.4 times, 3.5 times, 3.6 times, 3.7 times, 3.8 times, 3.9 times, 4 times, 4.1 times, 4.2 times, 4.3 times, 4.4 times, 4.5 times, 4.6 times, 4.7 times, 4.8 times, 4.9 times, 5 times, 5. 1 times, 5.2 times, 5.3 times, 5.4 times, 5.5 times, 5.6 times, 5.7 times, 5.8 times, 5.9 times, 6 times, 6.1 times, 6.2 times, 6.3 times, 6.4 times, 6.5 times, 6.6 times, 6.7 times, 6.8 times, 6.9 times, 7 times, 7.1 times, 7.2 times, 7.3 times, 7.4 times, 7.5 times, 7.6 times, 7.7 times, 7.8 times, 7.9 times, 8 times, 8.1 times, 8.2 times, 8.3 times, 8.4 times, 8.5 times, 8.6 times, 8.7 times, 8.8 times, 8.9 times, 9 times, 9.1 times, 9.2 times, 9.3 times, 9.4 times, 9.5 times, 9.6 times, 9.7 times, 9.8 times, 9.9 times, 10 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, 100 times or more);
[0106] (c) killing or inhibiting the expansion of T effector cells, such as CD8+ T cells (thereby reducing the number of CD8+ T effector cells in the cell population relative to the cell population not exposed to the polypeptide, for example, by a factor of about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.1, 4.2, 4.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4. 4 times, 2.5 times, 2.6 times, 2.7 times, 2.8 times, 2.9 times, 3 times, 3.1 times, 3.2 times, 3.3 times, 3.4 times, 3.5 times, 3.6 times, 3.7 times, 3.8 times, 3.9 times, 4 times, 4.1 times, 4.2 times, 4.3 times, 4.4 times, 4.5 times, 4.6 times, 4.7 times, 4.8 times, 4.9 times, 5 times, 5.1 times, 5.2 times, 5.3 times, 5.4 times, 5.5 times, 5.6 times, 5.7 times, 5.8 times, 5.9 times, 6 times, 6.1 times, 6.2 times, 6.3 times, 6.4 times, 6.5 times, 6.6 times, 6.7 times, 6.8 times, 6.9 times, 7 times, 7.1 times, 7.2 times, 7.3 times, 7.4 times, 7.5 times, 7.6 times, 7.7 times, 7.8 times, 7.9 times, 8 times, 8.1 times, 8.2 times, 8.3 times, 8.4 times, 8.5 times, 8.6 times, 8.7 times, 8.8 times, 8.9 times, 9 times, 9.1 times, 9.2 times, 9.3 times, 9.4 times, 9.5 times, 9.6 times, 9.7 times, 9.8 times, 9.9 times, 10 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, 100 times or more); and / or
[0107] (d) promoting proliferation and / or direct expansion of parenchymal cells expressing TNFR2, such as cells of the central and peripheral nervous systems and their associated structures (e.g., an increase of about 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 2.1-fold, 2.2-fold, 2.3-fold, 2.4-fold, 2.5-fold, 2.6-fold, 2.7-fold, 2.8-fold, 2.9-fold, 3-fold, 3.1-fold, 3.2-fold, 3.3-fold, 3.4-fold, 3.5-fold, 3.6-fold, 3.7-fold, 3.8-fold, 3.9-fold, 4-fold, 4.1-fold, 4.2-fold, 4.3-fold, 4.4-fold, 4.5-fold, 4.6-fold, 4.7-fold, 4.8-fold, 4.9-fold, 5-fold, 5.1-fold, 5.2-fold, 5.3-fold, 5.4-fold, 5.5-fold, 5.6-fold, 5.7-fold, 5.8-fold, 5.9-fold, 5.1-fold, 5.2-fold, 5.3-fold, 5.4-fold, 5.5-fold, 5.6-fold, 5.7-fold, 5.8-fold, 5.9-fold, 5.1-fold, 5.2-fold, times, 5.3 times, 5.4 times, 5.5 times, 5.6 times, 5.7 times, 5.8 times, 5.9 times, 6 times, 6.1 times, 6.2 times, 6.3 times, 6.4 times, 6.5 times, 6.6 times, 6.7 times, 6.8 times, 6.9 times, 7 times, 7.1 times, 7.2 times, 7.3 times, 7.4 times, 7.5 times, 7.6 times, 7.7 times, 7.8 times, 7.9 times, 8 times, 8 .1 times, 8.2 times, 8.3 times, 8.4 times, 8.5 times, 8.6 times, 8.7 times, 8.8 times, 8.9 times, 9 times, 9.1 times, 9.2 times, 9.3 times, 9.4 times, 9.5 times, 9.6 times, 9.7 times, 9.8 times, 9.9 times, 10 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, 100 times or more).
[0108] For example, the agonist TNFR2 polypeptides described herein, such as single-chain polypeptides, antibodies, antigen-binding fragments thereof, or constructs, can be used to increase the total amount of Tregs, MDSCs, and / or parenchymal cells in a patient (e.g., a human patient) or a sample (a sample isolated from a patient, such as a human patient receiving treatment for a disease described herein) relative to a patient or sample not treated with the polypeptide, respectively. For example, the parenchymal cell can be one of various subsets of lymphocytes or central nervous system-related cells (e.g., neurons).
[0109] In some embodiments, TNFR2 polypeptides (eg, single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) can be used to increase the number of Treg cells (eg, cells expressing CD25 Hi The invention relates to a method for increasing the proliferation or expansion of parenchymal cells expressing TNFR2, activated Treg cells, MDSCs and / or TNFR2, and / or directly enhancing the proliferation or expansion of parenchymal cells expressing TNFR2. For example, the parenchymal cells can be one of various subsets of lymphocytes or central nervous system-related cells (e.g., neurons).
[0110] The agonistic TNFR2 polypeptides described herein (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) can bind to TNFR2 on the surface of MDSCs, including cells expressing proteins and small molecules selected in whole or in part from the group consisting of: B7-1 (CD80), B7-H1 (PD-L1), CCR2, CD1d, CD1d1, CD2, CD31 (PECAM-1), CD43, CD44, complement component C5a R1, F4 / 80(EMR1), FcγRIII(CD16), FcγRII(CD32), FcγRIIA(CD32a), FcγRIIB(CD32b), FcγRIIB / C(CD32b / c), FcγRI IC (CD32c), FcγRIIIA (CD16A), FcγRIIIB (CD16b), galectin 3, GP130, Gr-1 (Ly-6G), ICAM-1 (CD54), IL-1RI, IL-4Rα, IL -6Rα, integrin α4 (CD49d), integrin αL (CD11a), integrin αM (CD11b), M-CSFR, MGL1 (CD301a), MGL1 / 2 (CD301a / b), MGL2 (CD301b), nitric oxide, PSGL-1 (CD162), L-selectin (CD62L), sialic acid-binding immunoglobulin-like lectin-3 (CD33), transferrin receptor (TfR), VEGFR1 (Flt-1) and VEGFR2 (KDR or Flk-1). In particular, MDSCs do not express a group of proteins selected from the following items: B7-2 (CD86), B7-H4, CD11c, CD14, CD21, CD23 (FcεRII), CD34, CD35, CD40 (TNFRSF5), CD117 (c-kit), HLA-DR and Sca-1 (Ly6). The binding of TNFR2 to MDSC may increase the proliferation or stability of MDSC, for example, by preventing apoptosis of MDSC, and / or may directly expand MDSC. The polypeptides described herein, (such as single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) do not need to promote the proliferation of Treg cells, parenchymal cells (e.g., cells expressing TNFR2), and / or MDSC via TNFα, although in some cases, TNFα or agonist TNFα mutant proteins (e.g., agonist TNFα mutant proteins described in WO2016 / 029043, the disclosure of which is incorporated herein by reference in its entirety) may be combined with the agonist TNFR2 polypeptide of the present disclosure, thereby further enhancing the proliferation effect.
[0111] In some embodiments, the polypeptides described herein (such as single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) can enhance the proliferation of Treg cells with greater potential, and / or directly stabilize or proliferate Treg cells, relative to subjects without autoimmunity, in patients with autoimmune diseases. In some embodiments, the polypeptides described herein (such as single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) can enhance the proliferation of Treg cells with greater potential, and / or directly amplify Treg cells, relative to sites without autoimmunity, in an autoimmune microenvironment.
[0112] In some embodiments, the polypeptides described herein (such as single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) can enhance or stabilize the proliferation of MDSCs with greater potential, and / or directly kill MDSCs, relative to subjects without graft-versus-host disease (GVHD) in patients with GVHD. In some embodiments, the polypeptides described herein (such as single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) can increase the proliferation of MDSCs with greater potential, and / or directly amplify MDSCs, relative to sites without GVHD, in the microenvironment of GVHD.
[0113] For example, the agonist TNFR2 polypeptides described herein (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) can bind to TNFR2 on the surface of cytotoxic T cells of patients with autoimmunity or GVHD, and can increase the proliferation of MDSCs, and / or promote the death of CTLs. For example, the polypeptides described herein (such as single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) can exhibit ICs for amplifying the proliferation of Treg cells and / or MDSCs in the microenvironment of autoimmunity or GVHD. 50 , which is less than the IC of the peptide to amplify the proliferation of Treg cells and / or MDSCs at sites away from the disease 50 , such as a decrease by about 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, 35-fold, 40-fold, 45-fold, 50-fold, 100-fold, 1,000-fold, 10,000-fold or more IC 50 .
[0114] In some embodiments, the polypeptides described herein, such as single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof, can kill or eliminate T effector cells, such as CD8+ cytotoxic T cells, with greater potential in patients with autoimmunity or GVHD relative to subjects without these diseases. In some embodiments, the polypeptides described herein, such as single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof, can shrink T effector cells, such as CD8+ cytotoxic T cells, with greater potential in the microenvironment of autoimmune reactions or GVHD relative to sites without autoimmunity or GVHD.
[0115] For example, in some embodiments, the polypeptides described herein, such as single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof, can kill T effector cells at an EC of less than 100 μg / mL in a subject without an autoimmune disease. 50 EC 50 Direct killing of T effector cells, such as CD8+ cytotoxic T cells, in patients with autoimmune diseases is reduced by, for example, 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, 35-fold, 40-fold, 45-fold, 50-fold, 100-fold, 1,000-fold, 10,000-fold or more.
[0116] In some embodiments, the TNFR2 agonist polypeptide is a polypeptide identified and / or produced by the methods of the present disclosure. The methods of the present disclosure for identifying and / or producing a TNFR2 agonist polypeptide include methods having the following steps:
[0117] (a) contacting the mixture of antibodies and fragments thereof with at least one peptide comprising five or more consecutive or discontinuous amino acid residues in CRD1 and / or CRD2 of TNFR2;
[0118] (b) isolating antibodies or fragments thereof that specifically bind to the peptide from the mixture, thereby producing an enriched antibody mixture containing at least one TNFR2 agonist antibody or antigen-binding fragment; and
[0119] (c) exposing the enriched antibody mixture to at least one peptide containing five or more contiguous or discontinuous amino acid residues in CRD3 and / or CRD4 of TNFR2, and retaining antibodies or fragments thereof that non-specifically bind to the peptide, thereby producing an antibody mixture containing at least one TNFR2 agonist antibody or antigen-binding fragment thereof.
[0120] In some embodiments, the method includes determining one or more amino acid sequences of antibodies or antigen-binding fragments thereof in an antibody-rich mixture. In some embodiments, the peptides described in (a) and / or (c) are bound to a surface. The antibody or its antigen-binding fragment may be expressed on the surface of a phage, a bacterial cell, or a yeast cell. In some embodiments, the antibody or its antigen-binding fragment is expressed as one or more polypeptide chains that are non-covalently bound to a ribosome or covalently bound to an mRNA or cDNA. In some embodiments, the peptides of (a) and / or (c) are conjugated to a detectable marker, such as a fluorescent molecule (e.g., green fluorescent protein, cyan fluorescent protein, yellow fluorescent protein, red fluorescent protein, phycoerythrin, allophycocyanin, hoechst, 4',6-diamidino-2-phenylindole (DAPI), propidium iodide, fluorescein, coumarin, rhodamine, tetramethylrhodamine, or cyanine) or an epitope tag (e.g., maltose binding protein, glutathione-S-transferase, polyhistidine tag, FLAG tag, myc tag, human influenza hemagglutinin (HA) tag, biotin, or streptavidin). In some embodiments, steps (a) and (b) are repeated sequentially one or more times (e.g., one to ten times, two to nine times, three to eight times, or four to seven times, such as two, three, four, five, six, seven, eight, nine, or ten times, or more times).
[0121] In some embodiments, the polypeptide is an antibody or antigen-binding fragment thereof selected from the group consisting of a monoclonal antibody or antigen-binding fragment thereof, a polyclonal antibody or antigen-binding fragment thereof, a human antibody or antigen-binding fragment thereof, a humanized antibody or antigen-binding fragment thereof, a primatized antibody or antigen-binding fragment thereof, a bispecific antibody or antigen-binding fragment thereof, a multispecific antibody or antigen-binding fragment thereof, a dual variable immunoglobulin domain, a monovalent antibody or antigen-binding fragment thereof, a chimeric antibody or antigen-binding fragment thereof, a single-chain Fv molecule (scFv), a diabody, a triabody, a nanobody, an antibody-like protein scaffold, a domain antibody, an Fv fragment, a Fab fragment, a F(ab') fragment, a 2 molecules and tandem scFv (taFv).
[0122] In some embodiments, the polypeptide is a human antibody or antigen-binding fragment thereof, a humanized antibody or antigen-binding fragment thereof, or a chimeric antibody or antigen-binding fragment thereof.
[0123] In some embodiments, the polypeptide is a single chain polypeptide.
[0124] In some embodiments, the polypeptide is a bispecific antibody, such as a bispecific monoclonal antibody, wherein one arm of the antibody specifically binds to TNFR2 and the other arm specifically binds to an immune checkpoint protein, such as PD-1, PD-L1, or CTLA-4, etc. described herein. The arm of the bispecific antibody that specifically binds to TNFR2 can specifically bind, for example, to an epitope of human TNFR2 defined by one or more amino acids within CRD1, CRD2, and / or CRD3, but does not bind to an epitope of human TNFR2 defined by one or more amino acids in CRD4. In some embodiments, the arm of the bispecific antibody that specifically binds to TNFR2 specifically binds to an epitope of human TNFR2 that corresponds to one or more of the following:
[0125] (a) amino acids 56-60 of SEQ ID NO: 1 (KCSPG);
[0126] (b) amino acids 101-107 of SEQ ID NO: 1 (CSSDQVET);
[0127] (c) amino acids 115-142 of SEQ ID NO: 1
[0128] (NRICTCRPGWYCALSKQEGCRLCAPLRK);
[0129] (d) amino acids 26-45 of SEQ ID NO: 1 (QTAQMCCSKCSPGQHAKVFC);
[0130] (e) amino acids 90-109 of SEQ ID NO: 1 (REQNRICTCRPGWYCALSKQ);
[0131] (f) amino acids 98-117 of SEQ ID NO: 1
[0132] (CRPGWYCALSKQEGCRLCAP);
[0133] (g) amino acids 106-125 of SEQ ID NO: 1
[0134] (LSKQEGCRLCAPLRKCRPGF); and / or
[0135] (h) amino acids 108-127 of SEQ ID NO: 1
[0136] (KQEGCRLCAPLRKCRPGFGV).
[0137] In some embodiments, the bispecific antibody contains an arm that specifically binds to TNFR2, such as an epitope of human TNFR2 described above, and an arm that specifically binds to an immune checkpoint protein that specifically binds to PD-1. In some embodiments, the arm of the bispecific antibody that specifically binds to PD-1 is an agonist of PD-1 activity.
[0138] In some embodiments, the bispecific antibody contains an arm that specifically binds to TNFR2, such as an epitope of human TNFR2 described above, and an arm that specifically binds to PD-L1. In some embodiments, the arm of the bispecific antibody that specifically binds to PD-L1 is an agonist of PD-L1 activity.
[0139] In some embodiments, the bispecific antibody contains an arm that specifically binds to TNFR2, such as an epitope of human TNFR2 described above, and an arm that specifically binds to CTLA-4. In some embodiments, the arm of the bispecific antibody that specifically binds to CTLA-4 is an agonist of CTLA-4 activity.
[0140] The second aspect is characterized by a construct containing a first polypeptide domain and a second polypeptide domain. The first polypeptide domain and the second polypeptide domain are each independently an antigen-binding fragment of the first aspect or any embodiment thereof. The first polypeptide domain and the second polypeptide domain can, for example, be bound to each other via a covalent linker, such as containing (for example, being) an amide bond or a disulfide bond.
[0141] The third aspect features a polynucleotide encoding the polypeptide (eg, a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) of the first aspect and / or the construct of the second aspect or any embodiment thereof.
[0142] The fourth aspect is characterized by a vector encoding the polynucleotide of the third aspect. The vector can be an expression vector, such as a eukaryotic expression vector. In some embodiments, the vector is a viral vector, such as an adenovirus (e.g., a serotype 1-57 adenovirus, such as a serotype 2, 5, 11, 12, 24, 26, 34, 35, 40, 48, 49, 50, 52 or Pan9 adenovirus), a retrovirus (e.g., a gamma retrovirus or a lentivirus), a poxvirus, an adeno-associated virus, a baculovirus, herpes simplex virus, or a vaccinia virus (e.g., a modified vaccinia Ankara virus).
[0143] The fifth aspect is characterized by an isolated host cell containing the polynucleotide of the third aspect and / or the vector of the fourth aspect. The host cell can be a prokaryotic cell or a eukaryotic cell, such as a mammalian cell (e.g., a Chinese hamster ovary (CHO) cell or a HEK cell). The host cell can be, for example, a host cell described in Dinnis and James, Biotechnology and Bioengineering 91: 180-189, 2005, the disclosure of which is incorporated herein by reference.
[0144] The sixth aspect features a pharmaceutical composition comprising a polypeptide (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) that specifically binds to human TNFR2 and exhibits an agonistic effect on TNFR2 activity upon binding. The polypeptide can be, for example, the antibody or antigen-binding fragment of the first aspect or any embodiment thereof. In some embodiments, at least 10% of the antibody or antigen-binding fragment thereof in the pharmaceutical composition is present as a single disulfide-bonded isoform, such as an IgG2-B or IgG2-A disulfide-bonded isoform. In some embodiments, about 10% to about 99.999% of the antibody or antigen-binding fragment thereof in the pharmaceutical composition is present in a single disulfide-bonded isoform, such as about 11% to about 99.9%, about 12% to about 99.9%, about 13% to about 99.9%, about 14% to about 99.9%, about 15% to about 99%, about 16% to about 99.9%, about 17% to about 99.9%, about 18% to about 99.9%, about 19% to about 99.9%, about 20% to about 99.9%, about 21% to about 99.9%, about 22% to about 99.9% of the antibody or antigen-binding fragment thereof. % to about 99.9%, about 23% to about 99.9%, about 24% to about 99.9%, about 25% to about 99.9%, about 26% to about 99.9%, about 27% to about 99.9%, about 28% to about 99.9%, about 29% to about 99.9%, about 30% to about 99.9%, about 31% to about 99.9%, about 32% to about 99.9%, about 33% to about 99.9%, about 34% to about 99.9%, about 35% to about 99.9%, about 36% to about 99.9%, about 37% to about 99.9%, about 38% to about 99.9%, about 39% to about 99.9%, about 40% to about 99.9%, about 41% to about 99.9%, about 42% to about 99.9%, about 43% to about 99.9%, about 44% to about 99.9%, about 45% to about 99.9%, about 46% to about 99.9%, about 47% to about 99.9%, about 48% to about 99.9%, about 49% to about 99.9%, about 50% to about 99.9%, about 51% to about 99.9%, about 52% to about 99.9%, about 53% to about 99.9%, about 54% to about 99.9%, about 55% to about 99.9% , about 56% to about 99.9%, about 57% to about 99.9%, about 58% to about 99.9%, about 59% to about 99.9%, about 60% to about 99.9%, about 61% to about 99.9%, about 62% to about 99.9%, about 63% to about 99.9%, about 64% to about 99.9%, about 65% to about 99.9%, about 66% to about 99.9%, about 67% to about 99.9%, about 68% to about 99.9%, about 69% to about 99.9%, about 70% to about 99.9%, about 71% to about 99.9%, about 72% to about 99.9%, about 73% to about 99.9%, about 74% to about 99.9%, about 75% to about 99.9%, about 76% to about 99.9%, about 77% to about 99.9%, about 78% to about 99.9%, about 79% to about 99.9%, about 80% to about 99.9%, about 81% to about 99.9%, about 82% to about 99.9%, about 83% to about 99.9%, about 84% to about 99.9%, about 85% to about 99.9%, about 86% to about 99.9%, about 87% to about 99.9%, about 88% to about 99.9%, about 89% to about 99.9%, about 90% to about 99.9%, about 91% to about 99.9%, about 92% to about 99.9%, about 93% to about 99.9%, about 94% to about 99.9%, about 95% to about 99.9%, about 96% to about 99.9%, about 97% to about 99.9%, about 98% to about 99.9%, about 99% to about 99.9%, about 91% to about 99.9%, about 98% to about 99.9%, about 99% to about About 99.9%, about 87% to about 99.9%, about 88% to about 99.9%, about 89% to about 99.9%, about 90% to about 99.9%, about 91% to about 99.9%, about 92% to about 99.9%, about 93% to about 99.9%, about 94% to about 99.9%, about 95% to about 99.9%, about 96% to about 99.9%, about 97% to about 99.9%, about 98% to about 99.9%, or about 99% to about 99.99%. .
[0145] In some embodiments, at least about 10% of the antibodies or antigen-binding fragments thereof in the pharmaceutical composition are present in a single disulfide-bound isoform. In some embodiments, at least about 15% of the antibodies or antigen-binding fragments thereof in the pharmaceutical composition are present in a single disulfide-bound isoform. In some embodiments, at least about 20% of the antibodies or antigen-binding fragments thereof in the pharmaceutical composition are present in a single disulfide-bound isoform. In some embodiments, at least about 25% of the antibodies or antigen-binding fragments thereof in the pharmaceutical composition are present in a single disulfide-bound isoform. In some embodiments, at least about 30% of the antibodies or antigen-binding fragments thereof in the pharmaceutical composition are present in a single disulfide-bound isoform. In some embodiments, at least about 35% of the antibodies or antigen-binding fragments thereof in the pharmaceutical composition are present in a single disulfide-bound isoform. In some embodiments, at least about 40% of the antibodies or antigen-binding fragments thereof in the pharmaceutical composition are present in a single disulfide-bound isoform. In some embodiments, at least about 45% of the antibodies or antigen-binding fragments thereof in the pharmaceutical composition are present in a single disulfide-bound isoform. In some embodiments, at least about 50% of the antibodies or antigen-binding fragments thereof in the pharmaceutical composition are present in a single disulfide-bonded isoform. In some embodiments, at least about 60% of the antibodies or antigen-binding fragments thereof in the pharmaceutical composition are present in a single disulfide-bonded isoform. In some embodiments, at least about 65% of the antibodies or antigen-binding fragments thereof in the pharmaceutical composition are present in a single disulfide-bonded isoform. In some embodiments, at least about 70% of the antibodies or antigen-binding fragments thereof in the pharmaceutical composition are present in a single disulfide-bonded isoform. In some embodiments, at least about 75% of the antibodies or antigen-binding fragments thereof in the pharmaceutical composition are present in a single disulfide-bonded isoform. In some embodiments, at least about 80% of the antibodies or antigen-binding fragments thereof in the pharmaceutical composition are present in a single disulfide-bonded isoform. In some embodiments, at least about 85% of the antibodies or antigen-binding fragments thereof in the pharmaceutical composition are present in a single disulfide-bonded isoform. In some embodiments, at least about 90% of the antibodies or antigen-binding fragments thereof in the pharmaceutical composition are present in a single disulfide-bonded isoform. In some embodiments, at least about 95% of the antibodies or antigen-binding fragments thereof in the pharmaceutical composition are present in a single disulfide-bonded isoform. In some embodiments, at least about 96% of the antibodies or antigen-binding fragments thereof in the pharmaceutical composition are present in a single disulfide-bonded isoform. In some embodiments, at least about 97% of the antibodies or antigen-binding fragments thereof in the pharmaceutical composition are present in a single disulfide-bonded isoform. In some embodiments, at least about 98% of the antibodies or antigen-binding fragments thereof in the pharmaceutical composition are present in a single disulfide-bonded isoform.In some embodiments, at least about 99% of the antibodies or antigen-binding fragments thereof in the pharmaceutical composition are present in a single disulfide-bonded isoform. In some embodiments, at least about 99.9% of the antibodies or antigen-binding fragments thereof in the pharmaceutical composition are present in a single disulfide-bonded isoform.
[0146] In some embodiments, the antibody or antigen-binding fragment thereof produces only a single detectable band in gel electrophoresis analysis performed under non-reducing conditions.
[0147] In some embodiments, the single disulfide-bonded isoform of the antibody or antigen-binding fragment is IgG2-B, as described herein. In some embodiments, the single disulfide-bonded isoform of the antibody or antigen-binding fragment is IgG2-A, as described herein.
[0148] Additionally or alternatively, the pharmaceutical composition may contain the construct of the second aspect or any embodiment thereof, the polynucleotide of the third aspect or any embodiment thereof, the vector of the fourth aspect or any embodiment thereof, and / or the host cell of the fifth aspect or any embodiment thereof. The pharmaceutical composition may further contain a pharmaceutically acceptable carrier or excipient.
[0149] In some embodiments, the polypeptide (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) is present in the pharmaceutical composition in an amount of about 0.001 mg / ml to about 100 mg / ml, such as about 0.01 mg / ml to about 10 mg / ml.
[0150] The pharmaceutical composition may further contain an additional therapeutic agent, such as an immunotherapeutic agent. In some embodiments, the immunotherapeutic agent is selected from the group consisting of anti-CTLA-4 agonists, anti-PD-1 agonists, anti-PD-L1 agonists, anti-PD-L2 agonists, anti-CD27 agonists, anti-CD30 agonists, anti-CD40 agonists, anti-4-1BB agonists, anti-GITR agonists, anti-OX40 agonists, anti-TRAILR1 agonists, anti-TRAILR2 agonists, anti-TWEAK agonists, anti-TWEAKR agonists, anti-cell surface lymphocyte protein agonists, anti-BRAF agonists, anti-MEK agonists, anti-CD33 agonists, anti-CD20 agonists, anti-HLA-DR agonists, anti-HLA class I agonists, anti-CD52 agonists, anti-A33 agonists, anti-GD3 agonists, anti-PSMA agonists, anti-Ceacan 1 agonists, anti-Galedin 9 agonists, anti-HVEM agonists, anti-VISTA agonists, anti-B7H4 agonists, anti-HHLA2 agonists, anti-CD155 agonists, anti-CD80 agonists, anti-BTLA agonists, anti-CD160 agonists, anti-CD28 agonists, anti-CD226 agonists, anti-CEACAM1 agonists, anti-TIM3 agonists, anti-TIGIT agonists, anti-CD96 agonists, anti-CD70 agonists, anti-CD27 agonists, anti-LIGHT agonists, anti-CD137 agonists The immunotherapeutic agent may be an anti-CTLA-4 agonist, an anti-PD-1 agonist, or an anti-PD-L1 agonist.
[0151] In some embodiments, the immunotherapeutic agent is selected from the group consisting of an agonist anti-CTLA-4 antibody or antigen-binding fragment thereof, an agonist anti-PD-1 antibody or antigen-binding fragment thereof, an agonist anti-PD-L1 antibody or antigen-binding fragment thereof, an agonist anti-PD-L2 antibody or antigen-binding fragment thereof, an agonist anti-CD27 antibody or antigen-binding fragment thereof, an agonist anti-CD30 antibody or antigen-binding fragment thereof, an agonist anti-CD40 antibody or antigen-binding fragment thereof, an agonist anti-4-1BB antibody or antigen-binding fragment thereof, an agonist anti-GITR antibody or antigen-binding fragment thereof, an agonist anti-OX40 antibody or antigen-binding fragment thereof. The invention further comprises an antigen-binding fragment thereof, an agonist anti-TRAILR1 antibody or an antigen-binding fragment thereof, an agonist anti-TRAILR2 antibody or an antigen-binding fragment thereof, an agonist anti-TWEAK antibody or an antigen-binding fragment thereof, an agonist anti-TWEAKR antibody or an antigen-binding fragment thereof, an agonist anti-cell surface lymphocyte protein antibody or an antigen-binding fragment thereof, an agonist anti-BRAF antibody or an antigen-binding fragment thereof, an agonist anti-MEK antibody or an antigen-binding fragment thereof, an agonist anti-CD33 antibody or an antigen-binding fragment thereof, an agonist anti-CD20 antibody or an antigen-binding fragment thereof, an agonist anti-HLA-DR antibody or an antigen-binding fragment thereof, an agonist anti-HLA class I antibody or an antigen-binding fragment thereof, an agonist anti-CD52 antibody or an antigen-binding fragment thereof, an agonist anti-A33 antibody or an antigen-binding fragment thereof, an agonist anti-GD3 antibody or an antigen-binding fragment thereof, an agonist anti-PSMA antibody or an antigen-binding fragment thereof, an agonist anti-Ceacan 1 antibody or an antigen-binding fragment thereof, an agonist anti-Galedin 9 antibody or an antigen-binding fragment thereof, an agonist anti-HVEM antibody or an antigen-binding fragment thereof, an agonist anti-VISTA antibody or an antigen-binding fragment thereof, an agonist anti-B7H4 antibody or antigen-binding fragment thereof, agonist anti-HHLA2 antibody or antigen-binding fragment thereof, agonist anti-CD155 antibody or antigen-binding fragment thereof, agonist anti-CD80 antibody or antigen-binding fragment thereof, agonist anti-BTLA antibody or antigen-binding fragment thereof, agonist anti-CD160 antibody or antigen-binding fragment thereof, agonist anti-CD28 antibody or antigen-binding fragment thereof, agonist anti-CD226 antibody or antigen-binding fragment thereof, agonist anti-CEACAM1 antibody or antigen-binding fragment thereof, agonist anti-TIM3 antibody or antigen-binding fragment thereof, agonist anti-TIGIT antibody or antigen-binding fragment thereof, agonist anti-CD96 antibody or antigen-binding fragment thereof, agonist anti-CD70 antibody or antigen-binding fragment thereof, agonist anti-CD27 antibody or antigen-binding fragment thereof, agonist anti-LIGHT antibody or antigen-binding fragment thereof, agonist anti-CD137 antibody or antigen-binding fragment thereof, agonist anti-DR4 antibody or antigen-binding fragment thereof, agonist anti-CR5 antibody or antigen-binding fragment thereof and antigen-binding fragments thereof, agonist anti-TNFRS antibodies or antigen-binding fragments thereof, agonist anti-TNFR1 antibodies or antigen-binding fragments thereof, agonist anti-FAS antibodies or antigen-binding fragments thereof, agonist anti-CD95 antibodies or antigen-binding fragments thereof, agonist anti-TRAIL antibodies or antigen-binding fragments thereof, agonist anti-DR6 antibodies or antigen-binding fragments thereof, agonist anti-EDAR antibodies or antigen-binding fragments thereof, agonist anti-NGFR antibodies or antigen-binding fragments thereof, agonist anti-OPG antibodies or antigen-binding fragments thereof, agonist anti-RANKL antibodies or antigen-binding fragments thereof, agonist anti-LTβ receptor antibodies or antigen-binding fragments thereof, agonist anti-BCMA antibodies or antigen-binding fragments thereof, agonist anti-TACI antibodies or antigen-binding fragments thereof, agonist anti-BAFFR antibodies or antigen-binding fragments thereof, agonist anti-EDAR2 antibodies or antigen-binding fragments thereof, agonist anti-TROY antibodies or antigen-binding fragments thereof, and agonist anti-RELT antibodies or antigen-binding fragments thereof. For example, the immunotherapeutic agent can be an agonistic anti-CTLA-4 antibody or an antigen-binding fragment thereof, an agonistic anti-PD-1 antibody or an antigen-binding fragment thereof, or an agonistic anti-PD-L1 antibody or an antigen-binding fragment thereof.
[0152] In some embodiments, the immunotherapeutic agent is an agonistic anti-cell surface lymphocyte protein antibody or antigen-binding fragment thereof, such as an antibody or antigen-binding fragment thereof that binds to and promotes the activity of one or more of the following: CD1, CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD9, CD10, CD11, CD12, CD13, CD14, CD15, CD16, CD17, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32, CD33, CD34, CD35, CD36, CD37, CD38, CD39, CD40, CD41, CD42, CD43, CD44, CD45, CD46, CD47, CD48, CD49, CD50, CD51, CD52, CD53, CD54, CD55, CD56, CD57, CD58, CD59, CD60, CD61, CD62, CD63, CD64, CD65 8. CD39, CD40, CD41, CD42, CD43, CD44, CD45, CD46, CD47, CD48, CD49, CD50, CD51, CD52, CD53, CD54, CD55, CD56, CD57, CD58, CD59, CD60, CD61, CD62, CD6 3. CD64, CD65, CD66, CD67, CD68, CD69, CD70, CD71, CD72, CD73, CD74, CD75, CD76, CD77, CD78, CD79, CD80, CD81, CD82, CD83, CD84, CD85, CD86, CD87, CD8 8. CD89, CD90, CD91, CD92, CD93, CD94, CD95, CD96, CD97, CD98, CD99, CD100, CD101, CD102, CD103, CD104, CD105, CD106, CD107, CD108, CD109, CD110, CD C D132, CD133, CD134, CD135, CD136, CD137, CD138, CD139, CD140, CD141, CD142, CD143, CD144, CD145, CD146, CD147, CD148, CD149, CD150, CD151, CD152, CD153, CD154, CD155, CD156, CD157, CD158, CD159, CD160, CD161, CD162, CD163, CD164, CD165, CD166, CD167, CD168, CD169, CD170, CD171, CD172, CD173,CD174, CD175, CD176, CD177, CD178, CD179, CD180, CD181, CD182, CD183, CD184, CD185, CD186, CD187, CD188, CD189, CD190, CD191, CD192, CD193, CD194, CD195, CD196, CD197, CD198, CD199, CD200, CD201, CD202, CD203, CD204, CD205, CD206, CD207, CD208, CD209, CD210, CD211, CD212, CD213, CD214, CD215, CD216, CD217, CD218, CD219, CD220, CD221, CD222, CD223, CD224, CD225, CD226, CD227, CD228, CD229, CD230, CD231, CD232, CD233, CD234, CD235, CD236, CD237, CD238, CD239, CD240, CD241, CD242, CD243, CD244, CD245, CD246, CD247, CD248, CD249, CD250, CD251, CD252, CD253, CD254, CD255, CD256, CD257, CD258, CD259, CD260, CD261, CD262, CD263, CD264, CD265, CD266, CD267, CD268, CD269, CD270, CD271, CD272, CD273, CD274, CD275, CD276, CD277, CD278, CD279, CD280, CD281, CD282, CD283, CD284, CD285, CD286, CD287, CD288, CD289, CD290, CD291, CD292, CD293, CD294, CD295, CD296, CD297, CD298, CD299, CD300, CD301, CD302, CD303, CD304, CD305, CD306, CD307, CD308, CD309, CD310, CD311, CD312, CD313, CD314, CD315, CD316, CD317, CD318, CD319 and / or CD320.
[0153] In some embodiments, the immunotherapeutic agent is an agent that binds to a chemokine or lymphokine (e.g., a polypeptide, an antibody, an antigen binding fragment thereof, a single-chain polypeptide, or a construct thereof). For example, the immunotherapeutic agent may be an agent that binds to and activates one or more or all of CXCL1, CXCL2, CXCL3, CXCL8, CCL2, and CCL5 (e.g., a polypeptide, an antibody, an antigen binding fragment thereof, a single-chain polypeptide, or a construct thereof). In some embodiments, the immunotherapeutic agent may be an agent that binds to and activates one or more or all of CCL3, CCL4, CCL8, and CCL22 (e.g., a polypeptide, an antibody, an antigen binding fragment thereof, a single-chain polypeptide, or a construct thereof).
[0154] In some embodiments, the pharmaceutical composition contains a bispecific antibody, such as a bispecific monoclonal antibody, wherein one arm of the antibody specifically binds to TNFR2 and the other arm specifically binds to an immune checkpoint protein, such as PD-1, PD-L1, or CTLA-4 described herein, etc. The arm of the bispecific antibody that specifically binds to TNFR2 can specifically bind, for example, to an epitope of human TNFR2 defined by one or more amino acids within CRD1, CRD2, and / or CRD3, but not to an epitope defined by one or more amino acids within CRD4.
[0155] In some embodiments, the bispecific antibody contains an arm that specifically binds to TNFR2, such as an epitope of human TNFR2 described above, and an arm that specifically binds to an immune checkpoint protein that specifically binds to PD-1. In some embodiments, the arm of the bispecific antibody that specifically binds to PD-1 is an agonist of PD-1 activity.
[0156] In some embodiments, the bispecific antibody contains an arm that specifically binds to TNFR2, such as an epitope of human TNFR2 described above, and an arm that specifically binds to PD-L1. In some embodiments, the arm of the bispecific antibody that specifically binds to PD-L1 is an agonist of PD-L1 activity.
[0157] In some embodiments, the bispecific antibody contains an arm that specifically binds to TNFR2, such as an epitope of human TNFR2 described above, and an arm that specifically binds to CTLA-4. In some embodiments, the arm of the bispecific antibody that specifically binds to CTLA-4 is an agonist of CTLA-4 activity.
[0158] In some embodiments, the additional therapeutic agent in the pharmaceutical composition is TNFα, an agonistic TNFα mutein (e.g., an agonistic TNFα mutein described in WO 2016 / 029043, the disclosure of which is incorporated herein by reference in its entirety), or BCG.
[0159] In some embodiments, the pharmaceutical composition does not contain an anti-TNFα agent, such as an anti-TNFα antibody or an antigen-binding fragment thereof. In some embodiments, the pharmaceutical composition does not contain infliximab, etanercept, becelimumab, golimumab, or adalimumab.
[0160] The seventh aspect is characterized by a method for producing the polypeptide (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct) of the first aspect and / or the construct of the second aspect or any embodiment thereof. The method may include expressing a polynucleotide encoding the polypeptide or construct in a host cell (e.g., a host cell as described herein) and recovering the polypeptide from the host cell culture medium.
[0161] The eighth aspect is characterized by a method of inhibiting an immune response (such as an immune response mediated by B cells or T cells (e.g., CD8+T effector cells)) of a mammalian subject (e.g., a human subject) by administering to the subject: a polypeptide (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) of the first aspect or any embodiment thereof, a construct of the second aspect or any embodiment thereof, a polynucleotide of the third aspect or any embodiment thereof, a vector of the fourth aspect or any embodiment thereof, a host cell of the fifth aspect or any embodiment thereof, and / or a pharmaceutical composition of the sixth aspect or any embodiment thereof.
[0162] The ninth aspect is characterized by a method for treating an immune disease in a mammalian subject (e.g., a human subject) by administering to the subject: a polypeptide of the first aspect or any embodiment thereof (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof), a construct of the second aspect or any embodiment thereof, a polynucleotide of the third aspect or any embodiment thereof, a vector of the fourth aspect or any embodiment thereof, a host cell of the fifth aspect or any embodiment thereof, and / or a pharmaceutical composition of the sixth aspect or any embodiment thereof.
[0163] In some embodiments, the subject requires tissue or organ regeneration. The tissue or organ can be, for example, pancreas, salivary gland, pituitary, kidney, heart, lung, hematopoietic system, cranial nerves, heart, aorta, olfactory gland, ear, nerve, head structure, eye, thymus, tongue, bone, liver, small intestine, large intestine, intestinal tract, lung, brain, skin, peripheral nervous system, central nervous system, spinal cord, breast, embryonic structure, embryo or testis.
[0164] In some embodiments, the immune disease is an autoimmune disease, a neurological disorder, an allergy, asthma, macular degeneration, muscular atrophy, abortion-related disease, atherosclerosis, bone loss, a musculoskeletal disease, obesity, GVHD, or allograft rejection.
[0165] In some embodiments, the autoimmune disease is type I diabetes, alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune hemolytic anemia, autoimmune hepatitis, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac dermatitis, chronic fatigue immune dysfunction syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, CREST syndrome, cold agglutinin disease, Crohn's disease, essential mixed cryoglobulinemia, fibromyalgia-fibromyositis, Graves' disease, Guillain-Barré syndrome, in-Barré, Hashimoto's thyroiditis, hypothyroidism, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura (ITP), IgA nephropathy, juvenile arthritis, lichen planus, lupus, Ménière's disease, mixed connective tissue disease, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndrome, polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Raynaud's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, syndrome, Stiff-Man syndrome, Takayasu's arteritis, temporal arteritis / giant cell arteritis, ulcerative colitis, uveitis, vasculitis, vitiligo, or Wegener's granulomatosis.
[0166] In some embodiments, the neurological disorder is a brain tumor, brain metastasis, spinal cord injury, schizophrenia, epilepsy, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's disease, Huntington's disease, or stroke.
[0167] In some embodiments, the allergy is a food allergy, seasonal allergy, pet allergy, urticaria, hay fever, allergic conjunctivitis, poison ivy allergy, oak allergy, mold allergy, drug allergy, dust allergy, cosmetic allergy, or chemical allergy.
[0168] In some embodiments, the allograft rejection is skin graft rejection, bone graft rejection, vascular tissue graft rejection, ligament graft rejection, or organ graft rejection.
[0169] In some embodiments, the ligament graft rejection is a cricothyroid ligament graft rejection, a periodontal ligament graft rejection, a suspensory ligament graft rejection, a volar radiocarpal ligament graft rejection, a dorsal radiocarpal ligament graft rejection, an ulnar collateral ligament graft rejection, a radial collateral ligament graft rejection, a mammary suspensory ligament graft rejection, anterior sacroiliac ligament graft rejection, posterior sacroiliac ligament graft rejection, sacrotuberous ligament graft rejection, sacrospinous ligament graft rejection, arcuate pubic ligament graft rejection, suprapubic ligament graft rejection, anterior cruciate ligament graft rejection, lateral collateral ligament graft rejection, posterior cruciate ligament graft rejection, medial collateral ligament graft rejection, cranial cruciate ligament graft rejection, caudal cruciate ligament graft rejection, or a knee ligament graft rejection.
[0170] In some embodiments, the organ transplant rejection is a cardiac transplant rejection, a lung transplant rejection, a kidney transplant rejection, a liver transplant rejection, a pancreas transplant rejection, an intestinal transplant rejection, or a thymus transplant rejection.
[0171] In some embodiments, GVHD results from a bone marrow transplant or one or more blood cells selected from the group consisting of hematopoietic stem cells, common myeloid progenitor cells, common lymphoid progenitor cells, megakaryocytes, monocytes, basophils, eosinophils, neutrophils, macrophages, T cells, B cells, natural killer cells, and dendritic cells.
[0172] The tenth aspect is characterized by a method of treating an inflammatory disease in a mammalian subject (e.g., a human subject) by administering to the subject: a polypeptide of the first aspect or any embodiment thereof (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof), a construct of the second aspect or any embodiment thereof, a polynucleotide of the third aspect or any embodiment thereof, a vector of the fourth aspect or any embodiment thereof, a host cell of the fifth aspect or any embodiment thereof, and / or a pharmaceutical composition of the sixth aspect or any embodiment thereof.
[0173] In some embodiments, the inflammatory disease is acute or chronic inflammation. In some embodiments, the inflammatory disease is selected from the group consisting of osteoarthritis, fibrotic lung disease, and cardiac inflammation.
[0174] The eleventh aspect features a method of healing, protecting, proliferating and / or regenerating TNFR2+ tissue in a mammalian subject (e.g., a human subject) by administering to the subject: a polypeptide of the first aspect or any embodiment thereof (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof), a construct of the second aspect or any embodiment thereof, a polynucleotide of the third aspect or any embodiment thereof, a vector of the fourth aspect or any embodiment thereof, a host cell of the fifth aspect or any embodiment thereof, and / or a pharmaceutical composition of the sixth aspect or any embodiment thereof.
[0175] In some embodiments, the TNFR2+ tissue is selected from the group consisting of pancreas, salivary gland, pituitary, kidney, heart, lung, hematopoietic system, cranial nerves, heart, aorta, olfactory gland, ear, nerve, eye, thymus, tongue, bone, liver, small intestine, large intestine, gastrointestinal tract, lung, brain, skin, peripheral nervous system, central nervous system, spinal cord, breast, embryonic structure, embryonic, or testicular tissue.
[0176] In some embodiments of the eighth, ninth, tenth and / or eleventh aspects, the method further comprises administering an immunotherapeutic agent to the human. The immunotherapeutic agent can, for example, be selected from the group consisting of an anti-CTLA-4 agonist, an anti-PD-1 agonist, an anti-PD-L1 agonist, an anti-PD-L2 agonist, an anti-CD27 agonist, an anti-CD30 agonist, an anti-CD40 agonist, an anti-4-1BB agonist, an anti-GITR agonist, an anti-OX40 agonist, an anti-TRAILR1 agonist, an anti-TRAILR2 agonist, an anti-TWEAK agonist, an anti-TWEAKR agonist, an anti-cell surface lymphocyte protein agonist, an anti-BRAF agonist, an anti-MEK agonist, an anti-CD33 agonist, an anti-CD20 agonist, an anti-HLA-DR agonist, an anti-HLA class I agonist, an anti-CD52 agonist, an anti-A33 agonist, an anti-GD3 agonist, an anti-PSMA agonist, an anti-Ceacan 1 agonist, an anti-Galedin 9 agonists, anti-HVEM agonists, anti-VISTA agonists, anti-B7H4 agonists, anti-HHLA2 agonists, anti-CD155 agonists, anti-CD80 agonists, anti-BTLA agonists, anti-CD160 agonists, anti-CD28 agonists, anti-CD226 agonists, anti-CEACAM1 agonists, anti-TIM3 agonists, anti-TIGIT agonists, anti-CD96 agonists, anti-CD70 agonists, anti-CD27 agonists, anti-LIGHT agonists, anti-CD137 agonists The immunotherapeutic agent may be an anti-CTLA-4 agonist, an anti-PD-1 agonist, or an anti-PD-L1 agonist.
[0177] The immunotherapeutic agent administered to the human can, for example, be selected from the group consisting of an agonistic anti-CTLA-4 antibody or an antigen-binding fragment thereof, an agonistic anti-PD-1 antibody or an antigen-binding fragment thereof, an agonistic anti-PD-L1 antibody or an antigen-binding fragment thereof, an agonistic anti-PD-L2 antibody or an antigen-binding fragment thereof, an agonistic anti-CD27 antibody or an antigen-binding fragment thereof, an agonistic anti-CD30 antibody or an antigen-binding fragment thereof, an agonistic anti-CD40 antibody or an antigen-binding fragment thereof, an agonistic anti-4-1BB antibody or an antigen-binding fragment thereof, an agonistic anti-GITR antibody or an antigen-binding fragment thereof, an agonistic anti-OX40 antibody or an antigen-binding fragment thereof, an agonistic anti-TRAILR1 antibody or an antigen-binding fragment thereof, an agonistic anti-TRAILR2 antibody or an antigen-binding fragment thereof. , agonist anti-TWEAK antibodies or antigen-binding fragments thereof, agonist anti-TWEAKR antibodies or antigen-binding fragments thereof, agonist anti-cell surface lymphocyte protein antibodies or antigen-binding fragments thereof, agonist anti-BRAF antibodies or antigen-binding fragments thereof, agonist anti-MEK antibodies or antigen-binding fragments thereof, agonist anti-CD33 antibodies or antigen-binding fragments thereof, agonist anti-CD20 antibodies or antigen-binding fragments thereof, agonist anti-HLA-DR antibodies or antigen-binding fragments thereof, agonist anti-HLA class I antibodies or antigen-binding fragments thereof, agonist anti-CD52 antibodies or antigen-binding fragments thereof, agonist anti-A33 antibodies or antigen-binding fragments thereof, agonist anti-GD3 antibodies or antigen-binding fragments thereof, agonist anti-PSMA antibodies or antigen-binding fragments thereof, agonist anti-Ceacan 1 antibodies or antigen-binding fragments thereof, agonist anti-Galedin 9 antibodies or antigen-binding fragments thereof, agonist anti-HVEM antibodies or antigen-binding fragments thereof, agonist anti-VISTA antibodies or antigen-binding fragments thereof, agonist anti-B7H4 antibody or antigen-binding fragment thereof, agonist anti-HHLA2 antibody or antigen-binding fragment thereof, agonist anti-CD155 antibody or antigen-binding fragment thereof, agonist anti-CD80 antibody or antigen-binding fragment thereof, agonist anti-BTLA antibody or antigen-binding fragment thereof, agonist anti-CD160 antibody or antigen-binding fragment thereof, agonist anti-CD28 antibody or antigen-binding fragment thereof, agonist anti-CD226 antibody or antigen-binding fragment thereof, agonist anti-CEACAM1 antibody or antigen-binding fragment thereof, agonist anti-TIM3 antibody or antigen-binding fragment thereof, agonist anti-TIGIT antibody or antigen-binding fragment thereof, agonist anti-CD96 antibody or antigen-binding fragment thereof, agonist anti-CD70 antibody or antigen-binding fragment thereof, agonist anti-CD27 antibody or antigen-binding fragment thereof, agonist anti-LIGHT antibody or antigen-binding fragment thereof, agonist anti-CD137 antibody or antigen-binding fragment thereof, agonist anti-DR4 antibody or antigen-binding fragment thereof, agonist anti-CR5 antibody or antigen-binding fragment thereof and antigen-binding fragments thereof, agonist anti-TNFRS antibodies or antigen-binding fragments thereof, agonist anti-TNFR1 antibodies or antigen-binding fragments thereof, agonist anti-FAS antibodies or antigen-binding fragments thereof, agonist anti-CD95 antibodies or antigen-binding fragments thereof, agonist anti-TRAIL antibodies or antigen-binding fragments thereof, agonist anti-DR6 antibodies or antigen-binding fragments thereof, agonist anti-EDAR antibodies or antigen-binding fragments thereof, agonist anti-NGFR antibodies or antigen-binding fragments thereof, agonist anti-OPG antibodies or antigen-binding fragments thereof, agonist anti-RANKL antibodies or antigen-binding fragments thereof, agonist anti-LTβ receptor antibodies or antigen-binding fragments thereof, agonist anti-BCMA antibodies or antigen-binding fragments thereof, agonist anti-TACI antibodies or antigen-binding fragments thereof, agonist anti-BAFFR antibodies or antigen-binding fragments thereof, agonist anti-EDAR2 antibodies or antigen-binding fragments thereof, agonist anti-TROY antibodies or antigen-binding fragments thereof, and agonist anti-RELT antibodies or antigen-binding fragments thereof. For example, the immunotherapeutic agent can be an agonistic anti-CTLA-4 antibody or an antigen-binding fragment thereof, an agonistic anti-PD-1 antibody or an antigen-binding fragment thereof, or an agonistic anti-PD-L1 antibody or an antigen-binding fragment thereof.
[0178] In some embodiments of the eighth, ninth, tenth and / or eleventh aspects, the method comprises administering to a mammal (e.g., a human) an agonistic anti-cell surface lymphocyte protein antibody or antigen-binding fragment thereof, such as an antibody or antigen-binding fragment thereof that binds to and activates one or more of the following: CD1, CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD9, CD10, CD11, CD12, CD13, CD14, CD15, CD16, CD17, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32, CD33, CD34, CD35, CD36, CD37, CD38, CD39, CD40, CD41, CD42, CD43, CD44, CD45, CD46, CD47, CD48, CD49, CD50, CD51, CD52, CD53, CD54, CD55, CD56, CD57, CD58, CD59, CD60, CD61, CD62, CD63, CD64, CD65 D33, CD34, CD35, CD36, CD37, CD38, CD39, CD40, CD41, CD42, CD43, CD44, CD45, CD46, CD47, CD48, CD49, CD50, CD51, CD52, CD53, CD54, CD55, CD56, CD57, CD58, CD59, CD60, CD61, CD62, CD63, CD64, CD65, CD66, CD67, CD68, CD69, CD70, CD71, CD72, CD73, CD74, CD75, CD76, CD77, CD78, CD79, CD80, CD81, CD82, CD83, CD84, CD85, CD86, CD87, CD88, CD89, CD90, CD91, CD92, CD93, CD94, CD95, CD96, CD97, CD98, CD99, CD100, CD101, CD102, CD103, CD104, CD105, CD1 06. CD107, CD108, CD109, CD110, CD111, CD112, CD113, CD114, CD115, CD116, CD117, CD118, CD119, CD120, CD121, CD122, CD123, CD124, CD125, CD126, CD C D148, CD149, CD150, CD151, CD152, CD153, CD154, CD155, CD156, CD157, CD158, CD159, CD160, CD161, CD162, CD163, CD164, CD165, CD166, CD167, CD168,CD169, CD170, CD171, CD172, CD173, CD174, CD175, CD176, CD177, CD178, CD179, CD180, CD181, CD182, CD183, CD184, CD185, CD186, CD187, CD188, CD189, CD190, CD191, CD192, CD193, CD194, CD195, CD196, CD197, CD198, CD199, CD200, CD201, CD202, CD203, CD204, CD205, CD206, CD207, CD208, CD209, CD210, CD211, CD212, CD213, CD214, CD215, CD216, CD217, CD218, CD219, CD220, CD221, CD222, CD223, CD224, CD225, CD226, CD227, CD228, CD229, CD230, CD231, CD232, CD233, CD234, CD235, CD236, CD237, CD238, CD239, CD240, CD241, CD242, CD243, CD244, CD245, CD246, CD247, CD248, CD249, CD250, CD251, CD252, CD253, CD254, CD255, CD256, CD257, CD258, CD259, CD260, CD261, CD262, CD263, CD264, CD265, CD266, CD267, CD268, CD269, CD270, CD271, CD272, CD273, CD274, CD275, CD276, CD277, CD278, CD279, CD280, CD281, CD282, CD283, CD284, CD285, CD286, CD287, CD288, CD289, CD290, CD291, CD292, CD293, CD294, CD295, CD296, CD297, CD298, CD299, CD300, CD301, CD302, CD303, CD304, CD305, CD306, CD307, CD308, CD309, CD310, CD311, CD312, CD313, CD314, CD315, CD316, CD317, CD318, CD319 and / or CD320.
[0179] In some embodiments of the eighth, ninth, tenth and / or eleventh aspects, the method comprises administering to a mammal (e.g., a human) an agent that binds and activates a chemokine or lymphokine (e.g., a polypeptide, an antibody, an antigen binding fragment thereof, a single-chain polypeptide, or a construct thereof). For example, an immunotherapeutic agent may be an agent that binds and activates one or more or all of CXCL1, CXCL2, CXCL3, CXCL8, CCL2, and CCL5 (e.g., a polypeptide, an antibody, an antigen binding fragment thereof, a single-chain polypeptide, or a construct thereof). In some embodiments, an immunotherapeutic agent may be an agent that binds and activates one or more or all of CCL3, CCL4, CCL8, and CCL22 (e.g., a polypeptide, an antibody, an antigen binding fragment thereof, a single-chain polypeptide, or a construct thereof).
[0180] In some embodiments of the eighth, ninth, tenth, and / or eleventh aspects, an anti-TNFα agent, such as an anti-TNFα antibody or antigen-binding fragment thereof, is not administered to a mammal (e.g., a human). In some embodiments of the eighth, ninth, tenth, and / or eleventh aspects, infliximab, etanercept, becelimumab, golimumab, or adalimumab is not administered to a mammal (e.g., a human).
[0181] In some embodiments of the eighth, ninth, tenth and / or eleventh aspects, a polypeptide that specifically binds to TNFR2, such as a single chain polypeptide, antibody, antigen-binding fragment thereof, or construct is administered to a mammal (e.g., a human) in an amount of about 0.001 mg / kg to about 100 mg / kg, for example, in an amount of about 0.01 mg / kg to about 10 mg / kg.
[0182] The twelfth aspect is characterized by a kit comprising a polypeptide of the first aspect or any embodiment thereof (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof), a construct of the second aspect or any embodiment thereof, a polynucleotide of the third aspect or any embodiment thereof, a vector of the fourth aspect or any embodiment thereof, a host cell of the fifth aspect or any embodiment thereof, and / or a pharmaceutical composition of the sixth aspect or any embodiment thereof.
[0183] In some embodiments, the kit contains instructions for transfecting the vector into a host cell. Additionally or alternatively, the kit may contain instructions for expressing a polypeptide (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) in a host cell. The kit may include reagents that can be used to express a polypeptide (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) in a host cell. In some embodiments, the kit includes instructions for administering a medicament to a mammal (e.g., a human), such as a human patient suffering from a cell proliferation disorder and / or an infectious disease as described herein. In some embodiments, the kit contains instructions for preparing or using a medicament.
[0184] definition
[0185] As used herein, the term "about" refers to a value that is no more than 10% above or below the value being described. For example, the term "about 5 nM" means a range of 4.5 nM to 5.5 nM.
[0186] As used herein, the terms "agonist TNFR2 antibody" and "agonist TNFR2 antibody" refer to a TNFR2 antibody that is capable of promoting or increasing the activation of TNFR2 and / or enhancing one or more signal transduction pathways mediated by TNFR2. For example, the agonist TNFR2 antibodies of the present invention can promote or increase the proliferation of a Treg cell population. The agonist TNFR2 antibodies of the present invention can promote or increase TNFR2 activation by binding to TNFR2, for example, thereby inducing conformational changes that render the receptor biologically active. For example, the agonist TNFR2 antibody can nucleate TNFR2 trimerization in a manner similar to the interaction between TNFR2 and its cognate ligand TNFα, thereby inducing TNFR2-mediated signal transduction. The agonist TNFR2 antibodies of the present invention can be capable of inducing proliferation of CD4+, CD25+, FOXP3+ Treg cells. The agonistic TNFR2 antibodies of the invention can also, for example, inhibit the proliferation of B lymphocytes and / or cytotoxic T lymphocytes (e.g., CD8+ T cells) by activating immunoregulatory Treg cells or by directly binding to TNFR2 on the surface of immune effector cells (such as autoreactive cytotoxic T cells) and inducing apoptosis. Unless otherwise indicated, the terms "agonist TNFR2 antibody" and "agonistic TNFR2 antibody" also include antibody fragments that retain the ability to bind to TNFR2 and enhance TNFR2 signaling, such as those described below.
[0187] As used herein, the term "antibody" (Ab) refers to an immunoglobulin molecule that specifically binds to or immunoreacts with a specific antigen, and includes polyclonal, monoclonal, genetically modified, and other modified forms of antibodies, including but not limited to chimeric antibodies, humanized antibodies, heteroconjugate antibodies (e.g., bi-, tri- and tetra-specific antibodies, diabodies, triabodies and tetrabodies), and antigen-binding fragments of antibodies, including, for example, Fab', F(ab'), 2 , Fab, Fv, recombinant IgG (rlgG) fragments and scFv fragments. In addition, unless otherwise indicated, the term "monoclonal antibody" (mAb) is intended to include intact molecules, as well as antibody fragments (such as, for example, Fab and F(ab')) that are capable of specifically binding to a target protein. 2 fragments). Fab and F(ab') 2 Fragments lack the Fc portion of intact antibodies, are cleared more rapidly from the animal's circulation, and may have less nonspecific tissue binding than intact antibodies (see Wahl et al., J. Nucl. Med. 24:316, 1983; incorporated herein by reference).
[0188] As used herein, the term "antigen-binding fragment" refers to one or more fragments of an antibody that retain the ability to specifically bind to a target antigen. The antigen-binding function of an antibody can be performed by a fragment of a full-length antibody. Antibody fragments can be, for example, Fab, F(ab') 2 , scFv, SMIP, diabody, triabody, affibody, nanobody, aptamer or domain antibody. Examples of binding fragments encompassed by the term "antigen-binding fragment" of an antibody include, but are not limited to: (i) Fab fragments, consisting of V L 、V H , C L and C H 1 domain-consisting monovalent fragment; (ii) F(ab') 2 A fragment comprising a bivalent fragment of two Fab fragments linked by a disulfide bond at the hinge region; (iii) a fragment consisting of V H and C H (iv) a single-arm V fragment of the antibody; L and V H The Fv fragment composed of the structural domain, (v) includes V H and V L (vi) dAb fragments (Ward et al., Nature 341:544-546, 1989) consisting of V H Domain composition; (vii) dAb, which consists of V H or V L(viii) a separate complementarity determining region (CDR); and (ix) a combination of two or more separate CDRs that may be optionally connected by a synthetic linker. In addition, although the two domains V of the Fv fragment L and V H Encoded by separate genes, they can be joined using recombinant methods via a linker that allows them to form a single protein chain, with V L and V H The regions are paired to form monovalent molecules (called single-chain Fv (scFv); see, e.g., Bird et al., Science 242:423-426, 1988, and Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883, 1988). These antibody fragments can be obtained using conventional techniques known to those skilled in the art, and the utility of the fragments can be screened in the same manner as intact antibodies. Antigen-binding fragments can be produced by recombinant DNA technology, enzymatic or chemical cleavage of intact immunoglobulins, or in some embodiments, by chemical peptide synthesis methods known in the art.
[0189] As used herein, the terms "anti-TNFR2 antibody", "TNFR2 antibody", "anti-TNFR2 antibody portion" and / or "anti-TNFR2 antibody fragment" and the like include any protein or peptide-containing molecule that includes at least a portion of an immunoglobulin molecule that is capable of specifically binding to TNFR2, such as but not limited to at least one complementarity determining region (CDR) of a heavy or light chain or a ligand binding portion thereof, a heavy or light chain variable region, a heavy or light chain constant region, a framework region or any portion thereof. TNFR2 antibodies also include antibody-like protein scaffolds, such as the tenth fibronectin type III domain ( 10 Fn3) contains BC, DE and FG structural loops with similar structure and solvent accessibility to antibody CDRs. 10 The tertiary structure of the Fn3 domain is similar to that of the IgG heavy chain variable region, and one skilled in the art can, for example, replace residues from the CDRH-1, CDRH-2, or CDRH-3 regions of a TNFR2 monoclonal antibody with 10 The residues of the BC, DE, and FG loops of Fn3 grafted the CDRs of the TNFR2 monoclonal antibody onto the fibronectin scaffold. 10The use of Fn3 domains as scaffolds for epitope grafting is described in, for example, WO 2000 / 034784, the disclosure of which is incorporated herein by reference. Additional scaffold proteins encompassed by the terms "anti-tumor necrosis factor receptor 2 antibody," "TNFR2 antibody," and the like include peptide-Fc fusion proteins (described in, for example, WO 2012 / 122378; and US 8,633,297; the disclosures of which are each incorporated herein by reference).
[0190] As used herein, the term "bispecific antibody" refers to a monoclonal antibody, typically a human antibody or a humanized antibody, that has binding specificity for at least two different antigens. The bispecific TNFR2 antibodies of the present invention can have binding specificity for TNFR2 and any other antigen (e.g., for a cell surface protein, a receptor, a receptor subunit, or a tissue-specific antigen). The bispecific antibody can also be an antibody or antigen-binding fragment thereof that includes two separate antigen-binding domains (e.g., two scFvs connected by a linker). The scFvs can bind to the same antigen or different antigens.
[0191] As used herein, the term "chimeric" antibody refers to an antibody having a variable domain sequence (e.g., CDR sequence) derived from an immunoglobulin of one source organism (such as a rat or mouse), and a constant region derived from an immunoglobulin of a different organism (e.g., a human, another primate, a pig, a goat, a rabbit, a hamster, a cat, a dog, a guinea pig, a member of the Bovidae family (such as cattle, bison, buffalo, elk, and yak, etc.), a cow, a sheep, a horse, or a bison, etc. Methods for producing chimeric antibodies are known in the art. See, e.g., Morrison, 1985, Science 229(4719): 1202-7; Oi et al., 1986, BioTechniques 4: 214-221; Gillies et al., 1985, J. Immunol. Methods 125: 191-202; U.S. Pat. Nos. 5,807,715; 4,816,567; and 4,816,397; which are incorporated herein by reference.
[0192] As used herein, the term "complementarity determining region" (CDR) refers to the hypervariable region found in both the light chain and heavy chain variable domains. The highly conserved portion of the variable domain is called the framework region (FR). As understood in the art, the amino acid positions describing the hypervariable region of an antibody can vary, depending on the background and various definitions known in the art. Some positions within the variable domain can be considered as hybrid hypervariable positions, because these positions can be considered to be within the hypervariable region under one set of criteria, and these positions can be considered to be outside the hypervariable region under another set of criteria. One or more of these positions can also be found in the hypervariable region of amplification. The present invention includes antibodies comprising modifications at these hybrid hypervariable positions. The variable domains of native heavy and light chains each contain four framework regions, which are mainly in a β-sheet structure and are connected by three CDRs, which form loops that connect and in some cases form a part of the β-sheet structure. The CDRs in each chain are held together by the FR regions in the order of FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, and together with the CDRs in other antibody chains contribute to the formation of the antibody target binding site (see Kabat et al., Sequences of Proteins of Immunological Interest (National Institute of Health, Bethesda, Md. 1987; which is incorporated herein by reference). As used herein, unless otherwise indicated, the numbering of immunoglobulin amino acid residues is according to the numbering system for immunoglobulin amino acid residues of Kabat et al.
[0193] As used herein, the term "conservative mutation", "conservative substitution" or "conservative amino acid substitution" refers to the substitution of one or more amino acids with one or more amino acids that exhibit similar physicochemical properties (such as polarity, electrostatic charge and / or steric bulk). These properties for each of the twenty naturally occurring amino acids are summarized in Table 1 below.
[0194] Table 1. Representative physicochemical properties of natural amino acids
[0195]
[0196] As can be seen from the table, conservative amino acid families include, for example, (i) G, A, V, L, I, P, and M; (ii) D and E; (iii) C, S, and T; (iv) H, K, and R; (v) N and Q; and (vi) F, Y, and W. Thus, a conservative mutation or substitution is one that replaces an amino acid with a member of the same amino acid family (e.g., Ser for Thr or Lys for Arg).
[0197] As used herein, the term "conjugate" refers to a compound formed by chemical bonding of a reactive functional group of one molecule to an appropriate reactive functional group of another molecule. A conjugate can also be produced, for example, as two polypeptide domains covalently bound to each other as part of a single polypeptide chain synthesized by translation of a single RNA transcript encoding the two polypeptides in frame with each other.
[0198] As used herein in the context of TNFR2 agonists, the term "construct" refers to a fusion protein containing a first polypeptide domain bound to a second polypeptide domain. The polypeptide domains can each independently be an agonist TNFR2 single-chain polypeptide, for example, as described herein. The first polypeptide domain can be covalently bound to the second polypeptide domain, for example, through a linker (such as a peptide linker or a disulfide bond, etc.). Exemplary linkers that can be used to connect the polypeptide domains of the agonist TNFR2 construct include, but are not limited to, those described in Leriche et al., Bioorg. Med. Chem., 20: 571-582 (2012), the disclosure of which is incorporated herein by reference in its entirety.
[0199] As used herein, the term "derivatized antibody" refers to an antibody modified by a chemical reaction to cleave residues or to add a chemical portion that is not produced from an isolated antibody. Derivatized antibodies can be obtained by glycosylation, acetylation, pegylation, phosphorylation, amidation, by adding known chemical protection / blocking group derivatization, proteolytic cleavage and / or connection with cell ligands or other proteins. Any of a variety of chemical modifications can be performed by known techniques, including but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin using established procedures, etc. In addition, derivatives can contain one or more non-natural amino acids, for example, using amber suppression technology (see, for example, U.S. Patent No. 6,964,859; It is incorporated herein by reference).
[0200] As used herein, the term "diabody" refers to a bivalent antibody comprising two polypeptide chains, wherein each polypeptide chain comprises a V and a V connected by a linker (e.g., a linker consisting of five amino acids). H and V LDomain, the linker is too short to achieve intramolecular association of VH and VL domains on the same peptide chain. This configuration forces each domain to pair with a complementary domain on another polypeptide chain, thereby forming a homodimer structure. Therefore, the term "trivalent antibody" refers to a trivalent antibody comprising three peptide chains, each of which contains a VH domain and a VL domain connected by an extremely short linker (e.g., a linker consisting of 1-2 amino acids) to achieve intramolecular association of VH and VL domains in the same peptide chain. In order to fold into their native structure, peptides configured in this way usually undergo trimerization so that the VH and VL domains of adjacent peptide chains are spatially adjacent to each other to achieve correct folding (see Holliger et al., Proc. Natl. Acad. Sci. USA 90: 6444-48, 1993; which is incorporated herein by reference).
[0201] As used herein, a "disulfide-bonded isoform" of an antibody or antigen-binding fragment thereof is a form of the antibody or antigen-binding fragment thereof that has a specific internal disulfide bonding pattern. Disulfide-bonded isoforms are structural isomers of a given antibody or antigen-binding fragment thereof that do not differ from one another in amino acid sequence but exhibit different disulfide bond connectivity. For example, in the case of a human IgG2 antibody or variants thereof, the antibody may exist in one of four possible disulfide-bonded isoforms, denoted herein as isoforms IgG2-A, IgG2-B, IgG2-A / B, IgG2-C, IgG2-D ... 1 and IgG2-A / B 2 The disulfide bonding connectivity within each of these isoforms is Figure 5A – Graphically displayed in 5D.
[0202] As used herein, a "dominant agonist" of TNFR2 is an agonist (e.g., an agonist polypeptide, such as a single-chain polypeptide, antibody, or antigen-binding fragment thereof) that is able to promote TNFR2 activation even in the absence of a TNFR2 ligand (e.g., TNFα). For example, in the absence of a native TNFR2 ligand (e.g., TNFα), if the EC of the agonist is 50The increase is less than 200% (e.g., less than 200%, 100%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 1% or less), then the TNFR2 agonist is a dominant agonist. TNFR2 activation can be, for example, by measuring the proliferation of TNFR2+ cells (such as Treg cells, MDSCs, parenchymal cells and central nervous system cells, etc.), and by measuring the activation of NFκB signaling (e.g., by monitoring the expression of one or more genes selected from the group consisting of CHUK, NFKBIE, NFKBIA, MAP3K11, TRAF2, TRAF3, relB and cIAP2 / BIRC3 in a gene expression assay) for assessment.
[0203] As used herein, "dual variable domain immunoglobulin" ("DVD-Ig") refers to an antibody that combines the target-binding variable domains of two monoclonal antibodies through a linker to produce a tetravalent, dual-targeting single agent. (Gu et al., Meth. Enzymol., 502:25-41, 2012; which is incorporated herein by reference). Linkers suitable for use in the DVD light chains described herein include the linkers shown in Table 2.1 on page 30 of Gu et al.: short kappa linker ADAAP (SEQ ID NO: 24) (mouse) and TVAAP (SEQ ID NO: 25) (human); long kappa linker ADAAPTVSIFP (SEQ ID NO: 26) (mouse) and TVAAPSVFIFPP (SEQ ID NO: 27) (human); short lambda linker QPKAAP (SEQ ID NO: 28) (human); long lambda linker QPKAAPSVTLFPP (SEQ ID NO: 29) (human); GS-short linker GGSGG (SEQ ID NO: 30), GS-medium linker GGSGGGGSG (SEQ ID NO: 31), and GS-long linker GGSGGGGSGGGGS (SEQ ID NO: 32) (all GS linkers are mouse or human linkers). Suitable linkers for DVD heavy chains include those identified in Table 2.1 on page 30 of Gu & Ghayur, 2012, Methods in Enzymology 502:25-41, incorporated herein by reference: short linkers AKTTAP (SEQ ID NO:33) (mouse) and ASTKGP (SEQ ID NO:34) (human); long linkers AKTTAPSVYPLAP (SEQ ID NO:35) (mouse) and ASTKGPSVFPLAP (SEQ ID NO:36) (human); GS-short linker GGGGSG (SEQ ID NO:37), GS-medium linker GGGGSGGGGS (SEQ ID NO:38), and GS-long linker GGGGSGGGGSGGGG (SEQ ID NO:39) (all GS linkers are mouse or human linkers).
[0204] As used herein, the term "endogenous" describes a molecule (e.g., a polypeptide, nucleic acid, or cofactor) that is naturally present in a particular organism (e.g., a human) or a particular location in an organism (e.g., an organ, tissue, or cell, such as a human cell).
[0205] As used herein, the term "epitope" refers to a portion of an antigen that is recognized and bound by a polypeptide (such as an antibody, antigen-binding fragment thereof, single-chain polypeptide, or construct described herein). In the context of a protein antigen (e.g., TNFR2, e.g., human TNFR2 set forth in SEQ ID NO:1 or TNFR2 of a non-human mammal (e.g., a non-human mammal described herein), an epitope can be a continuous epitope, which is a single uninterrupted stretch of one or more amino acids covalently linked to one another by peptide bonds, wherein the constituent amino acids of the epitope are bound by a polypeptide (e.g., an antibody, antigen-binding fragment thereof, single-chain polypeptide, or construct). An exemplary assay for determining binding of an agonistic TNFR2 polypeptide to specific amino acids within an antigen is described in Example 1 below. A continuous epitope can, for example, consist of 1, 5, 10, 15, 20, or more amino acids within an antigen (such as a TNFR2 protein described herein (e.g., human TNFR2 set forth in SEQ ID NO:1)). For example, a continuous epitope can consist of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 or more amino acids within the antigen. Examples of continuous epitopes on TNFR2 bound by agonist polypeptides (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs described herein include the KCSPG motif (SEQ ID NO: 40), and one or more continuous residues or all residues of the corresponding region on the TNFR2 protein of non-human mammals (e.g., bison, cattle, and other animals described herein). In some embodiments, an epitope can be a discontinuous epitope containing two or more amino acid stretches, each of which is separated from each other by one or more intermediate amino acid residues in the amino acid sequence of the antigen. A discontinuous epitope can, for example, consist of a stretch of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acid residues, such as containing (i) one or more amino acids within the KCSPG motif of human TNFR2 (SEQ ID NO:40), or an equivalent region of non-human TNFR2, and (ii) one or more amino acids elsewhere within the cysteine-rich domain 1 (CRD1, residues 48-76) of human TNFR2, or an equivalent region of non-human TNFR2.
[0206] As used herein, the term "exogenous" describes a molecule (e.g., a polypeptide, a nucleic acid, or a cofactor) that does not naturally occur in a particular organism (e.g., a human) or a particular location in an organism (e.g., an organ, tissue, or cell, such as a human cell). Exogenous materials include those materials provided to an organism or culture extracted therefrom from an external source.
[0207] As used herein, the term "framework region" or "FW region" includes amino acid residues adjacent to CDRs. FW region residues may be present in, for example, human antibodies, rodent-derived antibodies (e.g., mouse antibodies), humanized antibodies, primatized antibodies, chimeric antibodies, antibody fragments (e.g., Fab fragments), single-chain antibody fragments (e.g., scFv fragments), antibody domains, bispecific antibodies, and the like.
[0208] As used herein, the term "fusion protein" refers to a protein connected to another molecule by a covalent bond. Fusion protein can be chemically synthesized by, for example, an amide bond formation reaction between the N-terminus of a protein and the C-terminus of another protein. Alternatively, a fusion protein containing a protein covalently bound to another protein can be recombinantly expressed in a cell (e.g., a eukaryotic cell or a prokaryotic cell) by the expression of a polynucleotide encoding the fusion protein (e.g., from a vector or a cell genome). Fusion protein can contain a protein covalently bound to a joint, and the joint is covalently bound to another molecule. Examples of joints that can be used to form fusion proteins include peptide-containing joints, such as those containing naturally occurring or non-naturally occurring amino acids. In certain embodiments, it may be desirable to include D-amino acids in the joint, because these residues do not exist in naturally occurring proteins, and therefore have greater tolerance to the degradation of endogenous proteases. The linker can be prepared using a variety of strategies well known in the art and, depending on the reactive component of the linker, can be cleaved by enzymatic hydrolysis, photolysis, hydrolysis under acidic conditions, hydrolysis under basic conditions, oxidation, disulfide reduction, nucleophilic cleavage, or organometallic cleavage (Leriche et al., Bioorg. Med. Chem., 20:571-582, 2012).
[0209] As used herein, the term "heterospecific antibody" refers to a monoclonal antibody, preferably a human or humanized antibody, having binding specificity to at least two different antigens. Traditionally, the recombinant production of heterospecific antibodies is based on the co-expression of two immunoglobulin heavy chain-light chain pairs, wherein the two heavy chains have different specificities (Milstein et al., Nature 305:537, 1983). Similar procedures are disclosed, for example, in WO 93 / 08829, U.S. Patent Nos. 6,210,668; 6,193,967; 6,132,992; 6,106,833; 6,060,285; 6,037,453; 6,010,902; 5,989,530; 5,959,084; 5,959,083; 5,932,448; 5,833,985; 5,821,333; 5,807,706; 5,643,759, 5,601,819; 5,582,996, 5,496,549, 4,676,980, WO 91 / 00360, WO 92 / 00373, EP 03089, Traunecker et al., EMBO J. 10:3655 (1991), Suresh et al., Methods in Enzymology 121:210 (1986); which are incorporated herein by reference. Heterospecific antibodies can include Fc mutations that force the correct chain association in multispecific antibodies, as described in Klein et al., mAbs 4 (6): 653-663, 2012; which are incorporated herein by reference.
[0210] As used herein, the term "human antibody" refers to an antibody in which substantially every portion of the protein (e.g., CDR, framework, C L , C H Domains (e.g., C H 1. C H 2. C H 3) Hinge, (V L 、V H)) is essentially non-immunogenic in humans, with only minimal sequence changes or variations. Human antibodies can be produced in human cells (e.g., by recombinant expression), or produced by non-human animals or prokaryotic or eukaryotic cells that can express functionally rearranged human immunoglobulin (e.g., heavy chain and / or light chain) genes. In addition, when the human antibody is a single-chain antibody, it may include a linker peptide that is not found in natural human antibodies. For example, Fv may include a linker peptide, such as two to about eight glycine or other amino acid residues, which connects the variable region of the heavy chain and the variable region of the light chain. Human antibodies can be prepared by a variety of methods known in the art, including phage display methods using antibody libraries derived from human immunoglobulin sequences. See U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT Publications WO 1998 / 46645; WO 1998 / 50433; WO 1998 / 24893; WO 1998 / 16654; WO 1996 / 34096; WO 1996 / 33735; and WO 1991 / 10741; which are incorporated herein by reference. Human antibodies can also be produced using transgenic mice that are incapable of expressing functional endogenous immunoglobulins, but that can express human immunoglobulin genes. See, e.g., PCT Publications WO 98 / 24893; WO 92 / 01047; WO 96 / 34096; WO 96 / 33735; U.S. Pat. Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598; which are incorporated herein by reference.
[0211] As used herein, the term "humanized" antibody refers to a form of non-human (e.g., murine) antibody that is a chimeric immunoglobulin, immunoglobulin chain, or fragment thereof (such as Fv, Fab, Fab', F(ab') 2Or other target binding subdomains of antibodies), which contain minimal sequences derived from non-human immunoglobulins. Typically, a humanized antibody will substantially comprise all of at least one and typically two variable domains, wherein all or substantially all of the CDR regions correspond to those of non-human immunoglobulins. All or substantially all of the FR regions may also be those of human immunoglobulin sequences. A humanized antibody may also comprise at least a portion of an immunoglobulin constant region (Fc), typically a portion of a human immunoglobulin consensus sequence. Methods for antibody humanization are known in the art. See, e.g., Riechmann et al., Nature 332:323-7, 1988; U.S. Pat. Nos. 5,530,101; 5,585,089; 5,693,761; 5,693,762; and 6,180,370 to Queen et al.; EP 239400; PCT Publication WO 91 / 09967; U.S. Pat. No. 5,225,539; EP 592106; and EP 519596; which are incorporated herein by reference.
[0212] As used herein, the term "hydrophobic side chain" refers to an amino acid side chain that exhibits low solubility in water relative to, for example, the steric or electronic properties of the chemical moiety present in the side chain. Examples of amino acids containing hydrophobic side chains include amino acids containing unsaturated aliphatic hydrocarbons, such as alanine, valine, leucine, isoleucine, proline, and methionine, and amino acids containing aromatic ring systems that are electrostatically neutral at physiological pH, such as tryptophan, phenylalanine, and tyrosine.
[0213] As used herein, the term "immunotherapeutic agent" refers to a compound that specifically binds to an immune checkpoint protein (e.g., an immune checkpoint receptor or ligand) and produces an agonistic effect on a receptor or ligand, thereby promoting signal transduction of a receptor or ligand and, for example, downregulating an immune response, such as an antibody, an antigen binding fragment thereof, a single-chain polypeptide, or a construct as described herein. Immunotherapeutic agents include receptors that can specifically bind to the surface of hematopoietic cells (such as lymphocytes (e.g., T cells)) and activate signal transduction induced by a receptor or ligand, thereby resulting in a compound such as an antibody, an antigen binding fragment, a single-chain polypeptide, or a construct that is tolerant to, for example, endogenous ("self") antigens. The immunotherapeutic agent can enhance the signaling induced by the receptor or ligand, for example, by 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, 100%, 200%, 300%, 400%, 500% or more relative to the signaling induced by the receptor or ligand exhibited in the absence of the immunotherapeutic agent. Exemplary assays that can be used to measure the extent of receptor or ligand signaling include, for example, enzyme-linked immunosorbent assay (ELISA) techniques, techniques for measuring changes in protein expression associated with a particular signal transduction pathway, and polymerase chain reaction (PCR)-based techniques, such as quantitative PCR, reverse transcription PCR, and real-time PCR experiments, which can be used to determine changes in gene expression associated with a particular signal transduction pathway, etc. Examples of immunotherapeutic agents include, for example, antibodies or antigen-binding fragments thereof that specifically bind and activate one or more of the following: OX40L, TL1A, CD40L, LIGHT, BTLA, LAG3, TIM3, Singlecs, ICOS, B7-H3, B7-H4, VISTA, TMIGD2, BTNL2, CD48, KIR, LIR, LIR antibody, ILT, NKG2D, NKG2A, MICA, MICB, CD244, CSF1R, IDO, TGFβ, CD39, CD73, CXCR4, CXCL12, SIRPA, CD47, VEGF, and neuropilin. Specific examples of immunotherapeutic agents that can be used in conjunction with the compositions and methods described herein include agonistic anti-PD-1 antibodies and antigen-binding fragments thereof, as well as agonistic anti-PD-L1 antibodies and antigen-binding fragments thereof, and agonistic anti-CTLA-4 antibodies and antigen-binding fragments thereof.
[0214] As used herein, the term "monoclonal antibody" refers to an antibody that is derived from a single clone (including any eukaryotic, prokaryotic, or phage clone), and not the method by which it is produced.
[0215] As used herein, the term "multispecific antibody" refers to an antibody that exhibits affinity for more than one target antigen. A multispecific antibody may have a structure similar to a complete immunoglobulin molecule and include an Fc region, such as an IgG Fc region. Such structures may include, but are not limited to, IgG-Fv, IgG-(scFv) 2 、DVD-Ig、(scFv) 2 -(scFv) 2 -Fc and (scFv) 2 -Fc-(scFv) 2 In IgG-(scFv) 2 In the case of a scFv, the scFv can be attached to the N-terminus or C-terminus of the heavy or light chain. Exemplary multispecific molecules that include an Fc region and can be incorporated into a TNFR2 antibody or antigen-binding fragment thereof have been reviewed by Kontermann, 2012, mAbs 4(2):182-197, Yazaki et al., 2013, Protein Engineering, Design & Selection 26(3):187-193, and Grote et al., 2012, in Proetzel & Ebersbach (eds.), Antibody Methods and Protocols, Methods in Molecular Biology Vol. 901, Chapter 16:247-263; which are incorporated herein by reference. In some embodiments, an antibody fragment, an IgG or DVD-based fragment or scFv, can be a component of a multispecific molecule that does not have an Fc region. Exemplary multispecific molecules that lack an Fc region and can be incorporated into antibodies or antibody fragments include scFv dimers (diabodies), trimers (triabodies) and tetramers (tetrabodies), Fab dimers (conjugated via adhesion polypeptides or protein domains) and Fab trimers (chemically conjugated) are described by Hudson and Souriau, 2003, Nature Medicine 9:129-134; which is incorporated herein by reference.
[0216] As used herein, the term "myeloid-derived suppressor cell" or "MDSC" refers to cells of the immune system that regulate the activity of a variety of effector cells and antigen-presenting cells, such as T cells, NK cells, dendritic cells, and macrophages. Myeloid-derived suppressor cells are distinguished by their gene expression profile and express all or part of proteins and small molecules selected from the group consisting of: B7-1 (CD80), B7-H1 (PD-L1), CCR2, CD1d, CD1d1, CD2, CD31 (PECAM-1), CD43, CD44, complement component C5a R1, F4 / 80(EMR1), FcγRIII(CD16), FcγRII(CD32), FcγRIIA(CD32a), FcγRIIB(CD32b), FcγRIIB / C(CD32b / c), FcγRII C(CD32c), FcγRIIIA(CD16A), FcγRIIIB(CD16b), galectin-3, GP130, Gr-1(Ly-6G), ICAM-1(CD54), IL-1RI, IL-4Rα, IL -6Rα, integrin α4 (CD49d), integrin αL (CD11a), integrin αM (CD11b), M-CSFR, MGL1 (CD301a), MGL1 / 2 (CD301a / b), MGL2 (CD301b), nitric oxide, PSGL-1 (CD162), L-selectin (CD62L), sialic acid-binding immunoglobulin-like lectin-3 (CD33), transferrin receptor (TfR), VEGFR1 (Flt-1) and VEGFR2 (KDR or Flk-1). In particular, MDSCs do not express a group of proteins selected from the following items: B7-2 (CD86), B7-H4, CD11c, CD14, CD21, CD23 (FcεRII), CD34, CD35, CD40 (TNFRSF5), CD117 (c-kit), HLA-DR and Sca-1 (Ly6).
[0217] As used herein, the term "non-natural constant region" refers to an antibody constant region derived from a source different from the antibody variable region, or a synthetic polypeptide produced by a person, whose amino acid sequence is different from the natural antibody constant region sequence. For example, an antibody containing a non-natural constant region can have a variable region derived from a non-human source (e.g., mouse, rat or rabbit) and a constant region derived from a human source (e.g., human antibody constant region), or a constant region derived from other primates, pigs, goats, rabbits, hamsters, cats, dogs, guinea pigs, members of the Bovidae family (such as cattle, bison, buffalo, elk and yak, etc.), cattle, sheep, horses or bison, etc.).
[0218] As used herein, the term "percent (%) sequence identity" refers to the percentage of amino acid (or nucleic acid) residues that are identical between a candidate sequence and a reference sequence after aligning the sequences and introducing gaps, if necessary, to achieve maximum percent sequence identity (e.g., gaps can be introduced in one or both of the candidate sequence and the reference sequence to achieve optimal alignment, and non-homologous sequences can be ignored for comparison). For the purpose of determining percent sequence identity, alignment can be achieved in various ways within the skill of the art, for example, using publicly available computer software such as BLAST, ALIGN or Megalign (DNASTAR) software. One skilled in the art can determine appropriate parameters for measuring alignment, including any algorithm required to achieve maximum alignment over the full length of the compared sequences. For example, a reference sequence aligned for comparison with a candidate sequence can show that the candidate sequence has 50% to 100% sequence identity over the full length of the candidate sequence or a selected portion of the continuous amino acid (or nucleic acid) residues of the candidate sequence. The length of the candidate sequence aligned for comparison can be, for example, at least 30% (e.g., 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%) of the length of the reference sequence. When a position in the candidate sequence is occupied by the same amino acid residue as the corresponding position in the reference sequence, then the molecules are identical at that position.
[0219] As used herein, the term "primatized antibody" refers to an antibody that contains a framework region of a primate-derived antibody and other regions of an antibody of non-primate origin, such as CDRs and / or constant regions. Methods for producing primatized antibodies are known in the art. See, e.g., U.S. Patent Nos. 5,658,570; 5,681,722; and 5,693,780; which are incorporated herein by reference. For example, the primatized antibodies or antigen-binding fragments thereof described herein can be produced by inserting the CDRs of a non-primate antibody or antigen-binding fragment thereof into an antibody or antigen-binding fragment thereof containing one or more framework regions of a primate.
[0220] As used herein, the term "operably linked" in the context of polynucleotide fragments is intended to mean that the two polynucleotide fragments are linked such that the amino acid sequences encoded by the two polynucleotide fragments remain in frame.
[0221] As used herein, the term "pharmacokinetic profile" refers to the absorption, distribution, metabolism, and clearance of a therapeutic agent (e.g., a polypeptide, such as an agonistic TNFR2 antibody, antigen-binding fragment thereof, single chain polypeptide, or construct of the disclosure) over time after administration of the drug to a patient.
[0222] As used herein, the term "regulatory sequence" includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals) that control, for example, transcription or translation of antibody chain genes. Such regulatory sequences are described in, for example, Goeddel, Gene Expression Technology: Methods in Enzymology 185 (Academic Press, San Diego, CA, 1990); which is incorporated herein by reference.
[0223] As used herein, the term "scFv" refers to a single-chain Fv antibody in which the variable domains of the heavy and light chains of an antibody have been linked to form one chain. The scFv fragment contains one polypeptide chain comprising the variable region (e.g., CDR-L1, CDR-L2, and / or CDR-L3) of an antibody light chain (VL) and the variable region (e.g., CDR-H1, CDR-H2, and / or CDR-H3) of an antibody heavy chain (VH) separated by a linker. The linker connecting the VL and VH regions of the scFv fragment can be a peptide linker composed of proteinogenic amino acids. Other linkers can be used to increase the resistance of the scFv fragment to proteolytic degradation (e.g., linkers containing D-amino acids), to enhance the solubility of the scFv fragment (e.g., hydrophilic linkers, such as linkers containing polyethylene glycol or polypeptides containing repeating glycine and serine residues), to improve the biophysical stability of the molecule (e.g., linkers containing cysteine residues that form intra- or intermolecular disulfide bonds), or to reduce the immunogenicity of the scFv fragment (e.g., linkers containing glycosylation sites). ScFv molecules are known in the art and are described, for example, in U.S. Pat. No. 5,892,019, Flo et al., (Gene 77:51, 1989); Bird et al., (Science 242:423, 1988); Pantoliano et al., (Biochemistry 30:10117, 1991); Milenic et al., (Cancer Research 51:6363, 1991); and Takkinen et al., (Protein Engineering 4:837, 1991). The VL and VH domains of the scFv molecule can be derived from one or more antibody molecules. It will also be understood by those of ordinary skill in the art that the variable regions of the scFv molecules described herein can be modified so that their amino acid sequences are different from the antibody molecules from which they are derived. For example, in one embodiment, nucleotide or amino acid substitutions (e.g., in CDR and / or framework residues) that result in conservative substitutions or changes at amino acid residues can be made. Alternatively or additionally, CDR amino acid residues are mutated using art-recognized techniques to optimize antigen binding.scFv fragments are described in, for example, WO 2011 / 084714; which is incorporated herein by reference.
[0224] As used herein, the phrase "specifically binds" refers to a binding reaction that identifies the presence of an antigen in a heterogeneous population of proteins and other biomolecules (e.g., specifically recognized by an antibody or antigen-binding fragment thereof). An antibody or antigen-binding fragment thereof that specifically binds to an antigen will have a K of less than 100 nM. D For example, an antibody or antigen-binding fragment thereof that specifically binds to an antigen will have a K of at most 100 nM (e.g., between 1 pM and 100 nM).D Binding to an antigen. An antibody or antigen-binding fragment thereof that does not specifically bind to a specific antigen or epitope thereof, for which its K D Greater than 100 nM (e.g., greater than 500 nm, 1 μM, 100 μM, 500 μM, or 1 mM). A variety of immunoassay formats can be used to select antibodies that specifically immunoreact with a particular protein or carbohydrate. For example, solid phase ELISA immunoassays are routinely used to select antibodies that specifically immunoreact with a protein or carbohydrate. For descriptions of immunoassay formats and conditions that can be used to determine specific immunoreactivity, see Harlow & Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Press, New York (1988) and Harlow & Lane, Using Antibodies, A Laboratory Manual, Cold Spring Harbor Press, New York (1999).
[0225] As used herein, the terms "subject" and "patient" refer to an organism that is being treated (e.g., by administering an agonistic TNFR2 polypeptide, such as an antibody, antigen-binding fragment thereof, single-chain polypeptide, or construct described herein) for a particular disease or condition, such as an immune disease (e.g., an autoimmune disease). Examples of subjects and patients include mammals such as humans, primates, pigs, goats, rabbits, hamsters, cats, dogs, guinea pigs, members of the Bovidae family (such as cattle, bison, buffalo, and yaks, etc.), sheep, and horses, etc., that are being treated for an immune disease or condition (e.g., an autoimmune disease, graft-versus-host disease, allograft rejection, allergic reactions, and asthma, etc.). Patients that can be treated using the compositions and methods described herein may have a confirmed disease (e.g., a confirmed immune disease, such as an autoimmune disease), in which case the patient has been diagnosed with the disease and has been showing symptoms of the disease for a long period of time (e.g., over the course of days, weeks, months, or years). Alternatively, a patient may have symptoms of a particular disease, such as an immune disorder as described herein, but has not yet been diagnosed by a physician. Other patients that can be treated using the compositions and methods described herein include those who have been diagnosed with an immune disorder and may or may not have shown symptoms of the disease so far. For example, a patient eligible for treatment using the compositions and methods described herein may be described as diagnosed but asymptomatic, provided that the patient has received a diagnosis of an immune disorder, such as multiple sclerosis, for example, by detecting myelin depletion around one or more neurons of the patient due to autoreactive T cell activity, even though the patient may not have symptoms of multiple sclerosis (e.g., lack of balance, cognitive decline, blurred vision, or decreased coordination, etc.). Another example of a patient diagnosed with an immune condition but asymptomatic includes a patient diagnosed with rheumatoid arthritis, for example, by detecting autoreactive T cells in a lymph sample isolated from the patient, even though the patient has not yet developed symptoms associated with the disease, such as joint pain, joint stiffness, reduced muscle range or movement, etc.
[0226] As used herein, the term "transfection" refers to any of a variety of techniques commonly used to introduce exogenous DNA into prokaryotic or eukaryotic host cells, for example, electroporation, lipofection, calcium phosphate precipitation, DEAE-dextran transfection, and the like.
[0227] As used herein, the term "treat" or "treatment" refers to therapeutic treatment, wherein the purpose is to suppress or slow down (mitigate) undesirable physiological changes or conditions, such as immune conditions (e.g., autoimmune diseases, allergic reactions, graft-versus-host disease, or allograft rejection). Beneficial or desired clinical treatment results include, but are not limited to, alleviation of symptoms, reduction in disease extent, stabilization of the disease state (i.e., no worsening), delay or slowing of disease progression, improvement or alleviation of the disease state, and detectable or undetectable alleviation (partial or complete). Those patients in need of treatment include those patients who already have a condition or condition, as well as those patients who are susceptible to a condition or condition or those patients in which the condition or condition will be suppressed.
[0228] As used herein, the terms "tumor necrosis factor receptor superfamily," "TNFR superfamily," or "TNFRS" refer to a group of type I transmembrane proteins having a carboxyl-terminal intracellular domain and an amino-terminal extracellular domain, characterized by a common cysteine-rich domain (CRD). The TNFR superfamily includes receptors that mediate cellular signaling due to binding to one or more ligands in the TNF superfamily. The TNFR superfamily can be divided into two subgroups: receptors containing an intracellular death domain and receptors lacking this domain. The death domain is an 80 amino acid motif that can propagate the apoptotic signal transduction cascade upon receptor activation. Exemplary TNFR superfamily members containing an intracellular death domain include TNFR1, while TNFR2 represents a TNFR superfamily protein that does not contain this domain. Members of the TNFR superfamily include TNFR1, TNFR2, RANK, CD30, CD40, lymphotoxin beta receptor (LT-βR), OX40, Fas receptor, Decoy receptor 3 (DCR3), CD27, 4-1BB, death receptor 4 (DR4), death receptor 5 (DR5), Decoy receptor 1 (DCR1), Decoy receptor 2 (DCR2), osteoprotegerin, TWEAK receptor, TACI, BAFF receptor, herpes virus entry mediator, nerve growth factor receptor, B cell maturation antigen, glucocorticoid-induced TNFR-related TROY, death receptor 6 (DR6), death receptor 3 (DR3) and ecdysone A2 receptor.
[0229] As used herein, the term "variable region CDR" includes amino acids in a CDR or complementarity determining region, as identified using sequence-based or structure-based methods. As used herein, the term "CDR" or "complementarity determining region" refers to non-contiguous antigen binding sites found in the variable regions of heavy and light chain polypeptides. These specific regions are described in Kabat et al., J. Biol. Chem. 252: 6609-6616, 1977 and Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242, 1991; by Chothia et al. (J. Mol. Biol. 196: 901-917, 1987), and MacCallum et al., (J. Mol. Biol. 262: 732-745, 1996), where the definitions include amino acid residues or subsets of amino acid residues that overlap when compared to each other. In certain embodiments, the term "CDR" is a CDR defined by Kabat based on sequence comparisons.
[0230] As used herein, the term "vector" includes nucleic acid vectors, for example, DNA vectors, such as plasmids, RNA vectors, viruses or other suitable replicons (e.g., viral vectors). A variety of vectors have been developed for delivering polynucleotides encoding exogenous proteins to prokaryotic or eukaryotic cells. Examples of such expression vectors are disclosed in, for example, WO 1994 / 11026; it is incorporated herein by reference. The expression vectors described herein contain polynucleotide sequences and, for example, other sequence elements for protein expression and / or integration of these polynucleotide sequences into the genome of mammalian cells. Certain vectors that can be used to express antibodies and antibody fragments described herein include plasmids containing regulatory sequences, such as promoters and enhancer regions that direct gene transcription. Other useful vectors for expressing antibodies and antibody fragments containing polynucleotides contain polynucleotide sequences that increase the translation rate of these genes or improve the stability or nuclear export of mRNA produced by gene transcription. These sequence elements include, for example, 5' and 3' untranslated regions, internal ribosome entry sites (IRES) and polyadenylation signal sites to direct the efficient transcription of genes carried on the expression vector. The expression vectors described herein may also contain polynucleotides encoding markers for selecting cells containing the vector. Examples of suitable markers include genes encoding resistance to antibiotics such as ampicillin, chloramphenicol, kanamycin or nourseothricin.
[0231] As used herein, the term "VH" refers to the variable region of the immunoglobulin heavy chain of an antibody, including the heavy chain of Fv, scFv or Fab. "VL" refers to the variable region of the immunoglobulin light chain, including the light chain of Fv, scFv, dsFv or Fab. Antibodies (Ab) and immunoglobulins (Ig) are glycoproteins with the same structural characteristics. Although antibodies exhibit binding specificity to specific targets, immunoglobulins include antibodies and other antibody-like molecules that lack target specificity. Natural antibodies and immunoglobulins are usually heterotetrameric glycoproteins of about 150,000 daltons, consisting of two identical light chains (L) and two identical heavy chains (H). Each heavy chain of a natural antibody has a variable domain (VH) at the amino terminus, followed by multiple constant domains. Each light chain of a natural antibody has a variable domain (VL) at the amino terminus and a constant domain at the carboxyl terminus. BRIEF DESCRIPTION OF THE DRAWINGS
[0232] Figure 1 The amino acid sequence of human TNFR2 is shown, with the highlighted regions showing exemplary epitopes that can be bound by the TNFR2 agonistic antibodies of the present disclosure. Human TNFR2 is numbered herein starting with the N-terminal methionine at position 1 and ending with the C-terminal serine at position 461 (SEQ ID NO: 1). All references to amino acid positions in TNFR2 are as follows: Figure 1 The TNFR2 numbering scheme shown is background.
[0233] Figure 2 is a graph showing the proliferative effect of exemplary TNFR2 agonistic antibodies of the present disclosure on Treg cells. The results shown in this figure were obtained by incubating the agonistic TNFR2 antibody TNFRAG1 described herein (at different concentrations (shown along the x-axis)) with Treg cells for 48-72 hours. The values along the y-axis represent the percentage of Treg cells in the cell population studied. The data represent the average of 35 independent experiments.
[0234] Figure 3is a graph showing the effect of the natural TNFR2 agonist TNFα on Treg cell expansion induced by the TNFR2 agonist antibody TNFRAG1 of the present disclosure. The values along the x-axis represent the presence of IL-2, TNFα or antibody TNFRAG1 alone, or the presence of antibody TNFRAG1 in combination with 20ng / ml of TNFα at increasing concentrations in the in vitro Treg cell population. The values along the y-axis represent the percentage of Treg cells in the studied cell population. These data demonstrate that the presence of TNFα further increases the ability of the TNFR2 agonist antibody (such as TNFRAG1) of the present disclosure to stimulate Treg cell proliferation. These data are consistent with the ability of the TNFR2 agonist antibody of the present disclosure to promote TNFR2 activation by binding to TNFR2 monomers to form a trimer structure. This binding event brings the individual TNFR2 molecules into close proximity with each other and spatially exposes sites on the TNFR2 surface that may be bound by endogenous ligands (e.g., TNFα). Without being limited by mechanism, this sequence of events represents a pathway by which TNFR2 agonist polypeptides (eg, single chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs) of the disclosure can achieve TNFR2 activation in vivo.
[0235] Figure 4 is a graph showing the inhibitory effect of anti-TNFα antibodies on the ability of the agonistic TNFR2 antibody TNFRAG1 of the present disclosure to stimulate Treg cell proliferation. The values along the x-axis represent the concentration of anti-TNFα antibodies present in the in vitro Treg cell population in μg / ml. All conditions shown along the x-axis include 2.5 μg / ml of TNFRAG1. The values along the y-axis represent the percentage of Treg cells in the cell population studied.
[0236] Figure 5A –5D is a comparative IgG2-A ( Figure 5A )、IgG2-B( Figure 5B ), IgG2-A / B 1 ( Figure 5C ) and IgG2-A / B 2 ( Figure 5D ) isotypes. Thin lines represent disulfide bonds connecting the various parts of each antibody heavy or light chain, represented by shaded rectangles. The heavy chains are represented by the longer, outermost rectangles of each antibody. In each heavy chain, dark shading represents the constant region and lighter shading represents the variable region. The light chains are represented by the shortest, innermost rectangles of each antibody. In each light chain, darker shading represents the constant region and lighter shading represents the variable region.
[0237] Fig. 6AIt is a graph showing the expression density of TNFR2 in Treg cells from human subjects with cancer, Treg cells from healthy human subjects, and Treg cells from human patients with type 1 diabetes evaluated by immunofluorescence. The mean fluorescence intensity (MFI) of TNFR2 in Treg cells obtained from subjects with cancer was 147.435 (SEM 29.053, n = 10); the MFI of TNFR2 in Treg cells obtained from healthy subjects was 59.055 (SEM 9.545, n = 10); the MFI of TNFR2 in Treg cells obtained from patients with type 1 diabetes was 29.313 (SEM 2.894, n = 24). Grubbs test outliers were removed.
[0238] Figure 6B It is a graph showing the expression density of TNFR2 in T effector (Teff) cells from human subjects with cancer, Teff cells from healthy human subjects, and Teff cells from human patients with type 1 diabetes evaluated by immunofluorescence. The mean fluorescence intensity (MFI) of TNFR2 in Teff cells obtained from subjects with cancer was 32.070 (SEM 6.290, n = 10); the MFI of TNFR2 in Teff cells obtained from healthy subjects was 40.811 (SEM 6.466, n = 10); the MFI of TNFR2 in Teff cells obtained from patients with type 1 diabetes was 66.600 (SEM 1.815, n = 10). Grubbs test outliers were removed.
[0239] Figure 6C Graph showing the effect of agonist TNFR2 antibody TNFRAG1 on Treg cell proliferation after TNFRAG1 was incubated with freshly isolated peripheral human CD4+ cell populations for 48 hours (n=13). The values along the x-axis represent the concentration of the antibody; the values along the y-axis represent the percentage of Treg cells in the lymphocyte population. Data are mean ± SEM.
[0240] Fig.6D is a graph showing the effect of agonist TNFR2 antibody TNFRAG1 on Treg cell proliferation after TNFRAG1 was incubated with freshly isolated peripheral human CD4+ cell populations for 48 hours in the presence of endogenous TNFR2 ligand TNFα (20 ng / ml) (n=2). The values along the x-axis represent the concentration of the antibody; the values along the y-axis represent the percentage of Treg cells in the lymphocyte population. Data are mean ± SEM.
[0241] Fig. 7A It is a F(ab') showing the complementary determining region (CDR) of TNFRAG1 2Figure 2 shows the effect of antibody fragments on Treg cell proliferation. The values along the x-axis represent the concentration of antibody fragments; the values along the y-axis represent the relative increase in the number of Treg cells normalized to Treg cells treated with interleukin 2 (IL-2). Data are mean ± SEM. These data show that F(ab') 2 The functional Fc region absent from the antibody fragment is not essential for TNFRAG1 to induce Treg proliferation.
[0242] Figure 7B is a graph showing the effect of TNFRAG1 on Treg cell proliferation in the presence of cross-linking antibody (2.5 μg / ml). Cross-linking antibody ab9165 (Abcam) binds to the Fc region of adjacent TNFRAG1 antibodies, thereby increasing the local density of TNFRAG1 on the surface of Treg cells. Data are mean ± SEM.
[0243] Figure 7C Two graphs comparing the effect of agonist TNFR2 antibody MR2-1 (Abcam) on Treg cell proliferation in the presence of TNFα (20 mg / ml, left), and the effect of TNFα alone on Treg cell proliferation (right) are shown. The values along the x-axis represent the concentration of TNFR2 agonist; the values along the y-axis represent the relative increase in the amount of Treg cells.
[0244] Fig.7D is a graph showing the effects of IL-2, TNFα and TNFRAG1 on soluble TNFR2 secretion in peripheral human CD4+ cell populations. The values along the y-axis are fluorescence intensity measurements obtained from an enzyme-linked immunosorbent assay (ELISA) quantifying soluble TNFR2.
[0245] Fig. 8A -8E is a graph showing the effect of TNFRAG1 on Treg proliferation in peripheral human lymphocytes. Fig. 8A Shown is the overall trend of decreased CD8+ Teff cells observed when peripheral lymphocytes were incubated with TNFRAG1. Figure 8B The effect of TNFRAG1 on individual Teff cells is shown. Figure 8C Shown is the effect of TNFRAG1 on the amount of Teff cells when incubated with a mixture containing Teff cells and Treg cells at a 4:1 ratio in the absence of rapamycin and TNFα (left), in the absence of rapamycin and the presence of TNFα (middle), or in the presence of rapamycin and the absence of TNFα (right). Fig.8DShown is the effect of TNFRAG1 on the amount of Teff cells when incubated with a mixture containing Teff cells and Treg cells at a 2:1 ratio in the absence of rapamycin and TNFα (left), in the absence of rapamycin and the presence of TNFα (middle), or in the presence of rapamycin and the absence of TNFα (right). Fig. 8E Shown is the effect of TNFRAG1 on the amount of Teff cells when incubated with a mixture containing Teff cells and Treg cells at a 1:1 ratio in the absence of rapamycin and TNFα (left), in the absence of rapamycin and the presence of TNFα (middle), or in the presence of rapamycin and the absence of TNFα (right). In all experiments, cells were incubated with soluble anti-CD3 antibody (Hit3a) and IL-2 (50 U / ml) in 10% FBS RPMI for 4 days.
[0246] Fig.9A The figure shows the effect of TNFRAG1 on gene expression in peripheral human CD4+ cells. The expression of genes characteristic of Treg cells is selectively upregulated (indicated by asterisks).
[0247] Fig. 9B is a graph showing specific genes that are upregulated following incubation of peripheral CD4+ cells with TNFRAG1.
[0248] Fig. 9C It is a graph showing the effect of TNFRAG1 on the expression of genes ETS (left), EP300 (middle) and CREB (right) that are specific to Treg cells. For comparison, cells were treated with IL-2 alone ("None"), TNFRAG1 ("TNFR2 agonist") or TNFR2 antagonist antibody ("TNFR2 antagonist").
[0249] Fig. 10A is a diagram showing the glycolytic pathway, and various genes expressed during glycolysis, and the glutaminolysis pathway, and various genes expressed during glutaminolysis.
[0250] Fig. 10B is a graph showing the effect of TNFRAG1 on the expression of glycolysis-related genes after incubation of TNFRAG1 with peripheral human CD4+ cells. Treg cells are characterized by reduced glycolysis. These data indicate that TNFRAG1 induces an increase in the relative amount of Treg cells after incubation with peripheral human CD4+ cells.
[0251] Fig. 10Cis a graph showing the effect of TNFRAG1 on the expression of genes related to glutaminolysis after incubation of TNFRAG1 with peripheral human CD4+ cells. Treg cells are characterized by increased glutaminolysis. These data indicate that TNFRAG1 induces an increase in the relative amount of Treg cells after incubation with peripheral human CD4+ cells.
[0252] Fig.11A is a diagram showing the Krebs cycle and the effects of early steps in the pathway on upregulation of itaconate, an autoimmune suppressor.
[0253] Fig. 11B is a graph showing the effect of TNFRAG1 on the expression of genes involved in the Krebs cycle after incubation of TNFRAG1 with peripheral human CD4+ cells. These data suggest that TNFRAG1 upregulates the expression of early genes in the Krebs cycle, leading to an increase in itaconate.
[0254] Fig. 11C The graph shows the effect of TNFRAG1 on the expression of KEAP1 (a known inducer of inflammation and autoimmunity) after incubation of TNFRAG1 with peripheral human CD4+ cells.
[0255] Fig. 12A Figure 2 is a graph showing the metabolic preferences of Treg cells. Treg cells exhibit decreased glycolysis, increased glutaminolysis, and increased fatty acid consumption.
[0256] Fig. 12B –12D shows that after TNFRAG1 was incubated with peripheral human CD4+ cells, TNFRAG1 activated the gene CPT1A ( Fig. 12B )、CPT1B( Fig. 12C ) and AMPK( Fig.12D ) expression. These data further demonstrate the ability of TNFRAG1 to selectively induce Treg cell proliferation.
[0257] Fig.13A and 13B is a table showing the results of an ELISA experiment demonstrating the epitopes on TNFR2 to which TNFRAG1 binds. The epitopes in the cysteine-rich domain 2 (CRD2) are indicated with square brackets. Fig.13A and 13B The amino acid sequences shown correspond to SEQ ID NO: 49 to SEQ ID NO: 70 from the first sequence to the last sequence, respectively.
[0258] Fig.14 Structural model of a TNFR2 agonist antibody bound to CRD2 of TNFR2.
[0259] Fig.15 is a table showing the results of ELISA experiments which further confirmed the epitope on TNFR2 bound by TNFRAG1. Fig.15 The amino acid sequences shown in correspond to SEQ ID NO: 49 to SEQ ID NO: 71 from the first sequence to the last sequence, respectively. DETAILED DESCRIPTION
[0260] The agonistic TNFR2 polypeptides described herein, such as single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof, can promote proliferation, protection, healing, and / or regeneration of cells expressing TNFR2. This can be achieved, for example, by binding to TNFR2 (e.g., in regulatory T cells (Treg cells), myeloid-derived suppressor cells (MDSCs), or TNFR2+ somatic cells (e.g., parenchymal cells, such as cells of the central nervous system (e.g., neurons), etc.) and inducing receptor trimerization. The activity of TNFR2 agonist polypeptides can be enhanced by natural ligand TNFα, such as membrane-bound trimeric TNFα. Without being limited by mechanism, this trimerization event can promote TNFR2 activation by bringing individual TNFR2 proteins into close proximity with each other, thereby promoting cell proliferation through the MAPK / NFκB / TRAF2 / 3 pathway. TNFR2 signaling is also characterized by the secretion of soluble TNFR2 (sTNFR2) in a trimeric state, as well as the dual activation of p300 and CBP (two intracellular proteins that bind to the Foxp3 transcription site), thereby enhancing cell stability and maintenance. Importantly, activation of TNFR2 signaling has an inhibitory effect on T effector cells (such as CD8+ T cells). For these cells, TNFR2 agonism leads to cell death.
[0261] The agonistic TNFR2 polypeptides described herein can be used to promote such trimerization events in a variety of TNFR2+ tissues. Thus, the compositions and methods described herein provide important physiological benefits, as the agonistic TNFR2 polypeptides of the present disclosure can be used to increase Treg cell and / or MDSC activity and reduce the activity of T effector cells, thereby inhibiting autoimmunity, graft-versus-host disease (GVHD), inflammation, and graft rejection, as well as other pathologies described herein. The compositions and methods of the present disclosure can also be used to directly kill effector T cells, such as CD8+ T cells, including those that react with endogenous ("self") antigens. The agonistic TNFR2 polypeptides described herein additionally provide the beneficial feature of stimulating the regeneration of TNFR2+ tissues and organs, and can be used to treat a variety of diseases characterized by tissue degeneration and organ failure.
[0262] The TNFR2 polypeptides described herein (e.g., antibodies, antigen-binding fragments thereof, single-chain polypeptides, and constructs) specifically bind to epitopes within TNFR2 that promote receptor activation and the various beneficial biological activities described above. Human TNFR2 contains the following four cysteine-rich domains (CRDs): CRD1 (amino acid residues 48-76 of SEQ ID NO: 1), CRD2 (amino acid residues 78-120 of SEQ ID NO: 1), CRD3 (amino acid residues 121-162 of SEQ ID NO: 1), and CRD4 (amino acid residues 162-202 of SEQ ID NO: 1). The agonist TNFR2 polypeptides described herein specifically bind to TNFR2 at one or more epitopes within CRD1, CRD2, and / or CRD3. In some embodiments, the agonist TNFR2 polypeptide does not bind to an epitope within CRD4. For example, a polypeptide of the present disclosure (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) can bind to human TNFR2 at an epitope corresponding to one or more of the following residues:
[0263] (a) amino acids 56-60 of SEQ ID NO: 1 (KCSPG);
[0264] (b) amino acids 101-107 of SEQ ID NO: 1 (CSSDQVET);
[0265] (c) amino acids 115-142 of SEQ ID NO: 1
[0266] (NRICTCRPGWYCALSKQEGCRLCAPLRK);
[0267] (d) amino acids 26-45 of SEQ ID NO: 1 (QTAQMCCSKCSPGQHAKVFC);
[0268] (e) amino acids 90-109 of SEQ ID NO: 1 (REQNRICTCRPGWYCALSKQ);
[0269] (f) amino acids 98-117 of SEQ ID NO: 1
[0270] (CRPGWYCALSKQEGCRLCAP);
[0271] (g) amino acids 106-125 of SEQ ID NO: 1
[0272] (LSKQEGCRLCAPLRKCRPGF); and / or
[0273] (h) amino acids 108-127 of SEQ ID NO: 1
[0274] (KQEGCRLCAPLRKCRPGFGV),
[0275] Or an equivalent epitope within TNFR2 of a non-human mammal, such as a non-human mammal described herein.
[0276] The present disclosure is based in part on the discovery that agonistic TNFR2 polypeptides (e.g., antibodies, antigen-binding fragments thereof, single-chain polypeptides, and constructs) exhibit substantially improved TNFR2 activation effects when these molecules are of the IgG2-B isotype. As described in the Examples below, it has now been discovered that such TNFR2 polypeptides exhibit surprisingly superior abilities to activate TNFR2 signaling, promote Treg cell and MDSC proliferation, and heal, protect, and regenerate TNFR2-expressing tissues and organs relative to other isotypes of TNFR2 polypeptides.
[0277] Another discovery underlying the present disclosure is the discovery that, relative to a polypeptide that specifically binds to TNFR2 at one or more epitopes as described above, a polypeptide comprising at least one of the epitopes separated from each other by less than about The agonist TNFR2 polypeptides having antigen binding sites separated by about Examples of such polypeptides include IgG1, IgG2, IgG3, and IgG4 antibodies and antigen-binding fragments thereof, which contain about 100,000 antigen binding sites each separated from each other. to about and particularly include IgG1 antibodies and antigen-binding fragments thereof, which contain antigen-binding sites separated from each other by about The antigen binding sites are separated by about IgG3 antibodies and antigen-binding fragments thereof.
[0278] The agonist TNFR2 polypeptides of the present disclosure can be formulated into pharmaceutical compositions. Preferably, the polypeptide is present in the pharmaceutical composition in a single disulfide-bonded isoform. For example, pharmaceutical compositions of the present disclosure include those containing an agonist TNFR2 polypeptide wherein, for example, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, 99.99% or more of the polypeptide is present in a single disulfide-bonded isoform in the pharmaceutical composition. The agonist TNFR2 polypeptides of the present disclosure can advantageously be in the IgG2-B disulfide-bonded isoform, which has surprisingly been found to be superior to other IgG2 disulfide-bonded isoforms, such as IgG2-A, IgG2-A / B 1and IgG2-A / B 2 Isoforms that promote substantially more robust levels of TNFR2 activation. These isoforms Figure 5A -5D. The polypeptides of the present disclosure can be engineered to predominantly adopt the IgG2-B isoform, for example, by introducing mutations into the IgG2 heavy chain constant 1 (CH1) domain that prohibit the formation of other disulfide-bonded isoforms. Exemplary mutations of the amino acid sequence in the human IgG2 CH1 domain that promote the formation of the IgG2-B isoform, when the remaining isoforms described above are excluded, include deletion and / or substitution of the cysteine residue at position 127 (according to the Kabat numbering scheme described herein) of the amino acid sequence of the human IgG2 CH1 domain set forth in SEQ ID NO:8. For example, in order to engineer an IgG2 antibody or antigen-binding fragment thereof to predominantly adopt the IgG2-B isoform, a conservative amino acid substitution can be introduced at cysteine residue 127 of SEQ ID NO:8. An exemplary IgG2 CH1 domain that is predominantly present in the IgG2-B isoform has the amino acid sequence of SEQ ID NO:9, which contains a C127S substitution relative to SEQ ID NO:8.
[0279] The following biological activities are, relative to (i) containing separated from each other by more than Examples of agonistic TNFR2 phenotypes achieved by polypeptides of the present disclosure include:
[0280] (a) For example, by binding to and activating TNFR2 on the surface of Treg cells to enhance the proliferation and / or direct expansion of Treg cells;
[0281] (b) enhancing the proliferation and / or directing expansion of MDSCs, for example, by binding to and activating TNFR2 on the surface of MDSCs;
[0282] (c) depletion of T effector cells, such as CD8+ T cells (e.g., autoreactive CD8+ T cells); and / or
[0283] (d) enhancing the proliferation and / or directing the expansion of parenchymal cells expressing TNFR2.
[0284] The following sections provide a description of exemplary features of the agonistic TNFR2 polypeptides described herein, such as single chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof, and their use in therapeutic methods.
[0285] Agonist TNFR2 peptide
[0286] IgG isotype antibodies promote superior TNFR2 agonism
[0287] As described above and herein, robust TNFR2 activation is achieved by the TNFR2 agonist polypeptides described herein (e.g., antibodies, antigen-binding fragments thereof, single-chain polypeptides, and constructs). Such polypeptides may have one or more, or all, of the CDRs of the agonistic TNFR2 antibody TNFRAG1 described herein, or one or more CDRs having at least 85% sequence identity (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) with the corresponding TNFRAG1 CDRs having a human IgG1, IgG2, IgG3, or IgG4 isotype. Those polypeptides having modified IgG1 and IgG2 isotypes are particularly advantageous, such as those containing a CH1 domain of an isotype that is favorable for IgG2-B disulfide bonding. The disulfide bonding patterns of various isotypes of human IgG2 antibodies are as follows: Figure 5A As shown in –5D. Figure 5B As shown, the IgG2-B isotype exhibits a disulfide bonding pattern that produces a narrower and conformationally restricted structure relative to other IgG2 isotypes. This structure is well suited to bind TNFR2 on the surface of cells (e.g., Treg cells, MDSCs, or parenchymal cells expressing TNFR2) and bring receptor monomers into proximity with each other, thereby promoting receptor trimerization and, in turn, receptor activation.
[0288] In order to stabilize the isotype of IgG2-B disulfide bonds, mutations can be introduced into the IgG2 CH1 domain to prevent or reduce the disulfide bonds between the cysteine residues present in the form of non-bonded thiol in the IgG2-B isotype. Mutations can also be introduced into the IgG2 CH1 domain to prevent the formation of all four isotype variants after the antibody is applied to the patient (e.g., a mammalian patient, such as a human), which may be due to the oxidation and reduction process of cysteine in the body. The example of such mutations is the amino acid substitution or deletion at the residue C127 of the human IgG2 CH1 domain. By deleting this residue and / or modifying this site by amino acid substitution (e.g., conservative amino acid substitution), the disulfide bond binding pattern in the IgG2 isotype population can be biased toward the IgG2-B isotype. A particularly advantageous mutation that can be used to promote the CH1 domain of the IgG2-B isotype is the C127S mutation.
[0289] Spacing between antigen binding sites
[0290] The agonist TNFR2 polypeptides described herein (eg, single chain polypeptides, antibodies, antigen-binding fragments thereof, or constructs thereof) may contain less than The antigen binding sites (i.e., antigen binding arms) of the present disclosure are about 100 to 200 μg / cm2, which is the spacing observed between the antigen binding arms in human IgG2 isotype antibodies. As described in the examples below, it has been found that this spacing produces antibodies with optimal TNFR2 agonist properties. TNFR2 agonist polypeptides of the present disclosure include those containing separations, such as less than about 100 μg / cm2. The distance of the antigen binding arm of the polypeptide, such as or In some embodiments, the antigen binding sites are spaced about to about distance, such as about or In some embodiments, the antigen binding sites are spaced about to about distance, such as about or distance.
[0291] For example, a polypeptide (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) can contain antigen-binding sites that are spaced about 1:1 from each other. to about distance, such as about or In some embodiments, the antigen binding sites are spaced about to about distance, for example about
[0292] or In some embodiments, the antigen binding sites are spaced about to about distance, for example about or In some embodiments, the antigen binding sites are spaced about In some embodiments, the polypeptide (eg, a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) has the above-described antigen-binding arm separation, and an IgG1 isotype.
[0293] In some embodiments, the polypeptide (e.g., single-chain polypeptide, antibody, antigen-binding fragment thereof, or construct thereof) contains antigen-binding sites that are spaced about 100 μg / cm2 from each other. to about distance, such as about or In some embodiments, the antigen binding sites are spaced about to about distance, for example about or In some embodiments, the antigen binding sites are spaced about to about distance, for example about or In some embodiments, the antigen binding sites are spaced about In some embodiments, the polypeptide (eg, a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) has the above-described antigen-binding arm separation, and an IgG3 isotype.
[0294] The TNFR2 agonist polypeptides described herein can have, for example, two, three, four, five or more antigen binding arms separated by the above distances. Examples of antibody fragments having two or more antigen binding arms include, but are not limited to, diabodies, triabodies, F(ab') 2 Molecules and tandem scFv (taFv) molecules, etc. Methods for producing these antibody fragments include peptide synthesis and recombinant protein expression techniques described herein and known in the art.
[0295] There are a variety of methods for measuring the distance between the antigen binding arms of an antibody or antibody fragment. For example, the distance between the antigen binding arms of an antibody or antibody fragment can be measured by using computer software (such as by using and other molecular imaging software) to analyze the three-dimensional structure of antibodies or antibody fragments to determine the distance between the antigen binding arms of the antibody. The three-dimensional structure of polypeptides (such as antibodies and antibody fragments) can be calculated using data obtained from X-ray crystallography experiments and nuclear magnetic resonance (NMR) techniques known in the art. Examples of X-ray crystallography and NMR methods that can be used to obtain three-dimensional polypeptide structures are described, for example, Eigenbrot et al., Journal of Molecular Biology, 229: 969-995, 1993; and Huang et al., Science, 317: 1930-1934, 2007, the disclosures of which are each incorporated herein by reference in their entirety.
[0296] Structural features of the variable and constant regions of agonist TNFR2 polypeptides
[0297] Among the molecular features of agonist TNFR2 polypeptides (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs), the complementarity determining region-heavy chain 1 (CDR-H1) can determine the TNFR2 binding properties of the molecule. In particular, TNFR2 polypeptides having CDR-H1 as described below bind to TNFR2 at one or more epitopes described herein to confer agonist activity. For example, agonist TNFR2 polypeptides of the present disclosure include amino acids having CDR-H1 having an amino acid sequence of:
[0298] (a)GZ 1 TFZ 3 Z 2 YZ 3 Z 4 (SEQ ID NO:2);
[0299] (b) GYTFTDYNI (SEQ ID NO: 3) or an amino acid sequence having up to two conservative amino acid substitutions relative to that sequence; or
[0300] (c) GYTFTDYNL (SEQ ID NO: 4) or an amino acid sequence having up to two conservative amino acid substitutions relative to this sequence;
[0301] Each Z 1 are independently a naturally occurring amino acid comprising a side chain containing an aromatic substituent;
[0302] Each Z 2 are independently naturally occurring amino acids that contain anionic side chains at physiological pH;
[0303] Each Z 3are independently naturally occurring amino acids that contain polar, uncharged side chains at physiological pH; and
[0304] Each Z 4 is independently leucine or isoleucine.
[0305] The presence of the above CDR-H1 motif can confer the ability of a polypeptide (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) to specifically bind to human TNFR2 at an epitope defined by one or more amino acids within CRD1, such as at an epitope defined by one or more amino acid residues 56-60 (KCSPG) within SEQ ID NO: 1. In some embodiments, in the presence of CDR-H1, the polypeptide specifically binds to human TNFR2 at an epitope defined by one or more amino acids within CRD2. In some embodiments, in the presence of CDR-H1, the polypeptide specifically binds to human TNFR2 at an epitope defined by one or more amino acids within CRD3.
[0306] The agonist TNFR2 polypeptides of the present disclosure may further contain one or more, or all, of the following CDRs:
[0307] (a) CDR-H2 having the amino acid sequence INPNYDST (SEQ ID NO: 10) or an amino acid sequence having up to two conservative amino acid substitutions relative to this sequence;
[0308] (b) CDR-H3 having the amino acid sequence CARGNSWYFDV (SEQ ID NO: 11) or an amino acid sequence having up to two conservative amino acid substitutions relative to that sequence;
[0309] (c) CDR-L1 having the amino acid sequence SSVRY (SEQ ID NO: 12) or an amino acid sequence having up to two conservative amino acid substitutions relative to this sequence;
[0310] (d) a CDR-L2 having the amino acid sequence of LTS, or an amino acid sequence having up to two conservative amino acid substitutions relative to that sequence; and
[0311] (e) CDR-L3 having the amino acid sequence CQQWSSNPLT (SEQ ID NO: 13) or an amino acid sequence having up to two conservative amino acid substitutions relative to this sequence.
[0312] In some embodiments, the polypeptide (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) contains a CDR-H1 as described above in combination with one or more, or all, of the following CDRs:
[0313] (a) CDR-H2 having the amino acid sequence INPNYDST (SEQ ID NO: 10);
[0314] (b) CDR-H3 having the amino acid sequence CARGNSWYFDV (SEQ ID NO: 11);
[0315] (c) CDR-L1 having the amino acid sequence SSVRY (SEQ ID NO: 12);
[0316] (d) CDR-L2 having the amino acid sequence LTS; and
[0317] (e) CDR-L3, which has the amino acid sequence CQQWSSNPLT (SEQ ID NO: 13).
[0318] In some embodiments, CDR-H1 has the amino acid sequence GYTFTDYNI (SEQ ID NO: 3) or an amino acid sequence having up to two conservative amino acid substitutions relative to that sequence. For example, an agonist TNFR2 polypeptide described herein can have the following CDRs:
[0319] (a) CDR-H1 having the amino acid sequence GYTFTDYNI (SEQ ID NO: 3);
[0320] (b) CDR-H2 having the amino acid sequence INPNYDST (SEQ ID NO: 10);
[0321] (c) CDR-H3 having the amino acid sequence CARGNSWYFDV (SEQ ID NO: 11);
[0322] (d) CDR-L1 having the amino acid sequence SSVRY (SEQ ID NO: 12);
[0323] (e) CDR-L2 having the amino acid sequence LTS; and
[0324] (f) CDR-L3 having the amino acid sequence CQQWSSNPLT (SEQ ID NO: 13).
[0325] In some embodiments, the polypeptide (e.g., single chain polypeptide, antibody, antigen binding fragment thereof, or construct thereof) contains a heavy chain variable domain (V H ), the V HThe polypeptide has an amino acid sequence that is at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical) to the amino acid sequence of SEQ ID NO: 14. In some embodiments, the polypeptide contains a heavy chain variable domain (V H ), the V H The polypeptide has an amino acid sequence that is at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical) to the amino acid sequence of SEQ ID NO: 14. In some embodiments, the polypeptide contains a heavy chain variable domain (V H ), the V H having an amino acid sequence that is at least 95% identical (e.g., at least 95%, 96%, 97%, 98%, 99% or 100% identical) to the amino acid sequence of SEQ ID NO: 14. In some embodiments, the polypeptide contains a heavy chain variable domain (V H ), the V H Having the amino acid sequence of SEQ ID NO:14.
[0326] In some embodiments, CDR-H1 has the amino acid sequence GYTFTDYNL (SEQ ID NO: 4) or an amino acid sequence having up to two conservative amino acid substitutions relative to that sequence.
[0327] In some embodiments, the polypeptide contains the following CDRs:
[0328] (a) CDR-H1 having the amino acid sequence GYTFTDYNL (SEQ ID NO: 4);
[0329] (b) CDR-H2 having the amino acid sequence INPNYDST (SEQ ID NO: 10);
[0330] (c) CDR-H3 having the amino acid sequence CARGNSWYFDV (SEQ ID NO: 11);
[0331] (d) CDR-L1 having the amino acid sequence SSVRY (SEQ ID NO: 12);
[0332] (e) CDR-L2 having the amino acid sequence LTS; and
[0333] (f) CDR-L3 having the amino acid sequence CQQWSSNPLT (SEQ ID NO: 13).
[0334] In some embodiments, the polypeptide (e.g., single chain polypeptide, antibody, antigen binding fragment thereof, or construct thereof) contains a heavy chain variable domain (V H ), the V H The polypeptide has an amino acid sequence that is at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical) to the amino acid sequence of SEQ ID NO: 15. In some embodiments, the polypeptide contains a heavy chain variable domain (V H ), the V H The polypeptide has an amino acid sequence that is at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical) to the amino acid sequence of SEQ ID NO: 15. In some embodiments, the polypeptide contains a heavy chain variable domain (V H ), the V H having an amino acid sequence that is at least 95% identical (e.g., at least 95%, 96%, 97%, 98%, 99% or 100% identical) to the amino acid sequence of SEQ ID NO: 15. In some embodiments, the polypeptide contains a heavy chain variable domain (V H ), the V H Having the amino acid sequence of SEQ ID NO:15.
[0335] In some embodiments, the polypeptide (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) contains a non-natural constant region, such as a human constant region. In some embodiments, the polypeptide lacks all or part of an Fc domain, lacks all or part of a native Fc domain, or lacks all Fc domains.
[0336] Framework regions of agonistic TNFR2 polypeptides.
[0337] The agonistic TNFR2 polypeptides (eg, single-chain polypeptides, antibodies, antigen-binding fragments thereof, or constructs thereof) of the present disclosure may contain a polypeptide having TJDJSJJJX 1 YX 2 X 3 LqCy 4 LJS (SEQ ID NO: 5) or an amino acid sequence of 10 or more residues of SEQ ID NO: 5, wherein each J is independently a naturally occurring amino acid; each X 1 independently A, V or F; each X 2 independently M or I; each X 3 is independently E or Q; and each X 4are independently S or R. For example, the polypeptide may contain a framework region having an amino acid sequence selected from the group consisting of:
[0338] (a) TVDKSSSTAYMELRSLTS (SEQ ID NO: 16) or an amino acid sequence having up to two conservative amino acid substitutions relative to that sequence;
[0339] (b) TADTSSNTAYIQLSSLTS (SEQ ID NO: 17) or an amino acid sequence having up to two conservative amino acid substitutions relative to this sequence;
[0340] (c) TADTSTDTAYMELSSLRS (SEQ ID NO: 18) or an amino acid sequence having up to two conservative amino acid substitutions relative to this sequence;
[0341] (d) TRDTSISTAYMELSRLTS (SEQ ID NO: 19) or an amino acid sequence having up to two conservative amino acid substitutions relative to that sequence;
[0342] (e) TFYMELSSLRS (SEQ ID NO: 20) or an amino acid sequence having up to two conservative amino acid substitutions relative to that sequence;
[0343] (f) TRDTSISTAYMELNRLTS (SEQ ID NO: 21) or an amino acid sequence having up to two conservative amino acid substitutions relative to that sequence;
[0344] (g) TRDTSTNTVYMELTSLRS (SEQ ID NO: 22) or an amino acid sequence having up to two conservative amino acid substitutions relative to that sequence; and
[0345] (h) TADTSTDRAYMELSSLRS (SEQ ID NO: 23) or an amino acid sequence having up to two conservative amino acid substitutions relative to this sequence.
[0346] The aforementioned amino acid sequence recognizes and binds to MHC class II proteins (including human leukocyte antigen (HLA) DR and DQ, etc.). Generally, antibodies containing amino acid sequences that bind to MHC proteins are found to be engineered to remove such motifs, because antibodies that bind to MHC proteins are easily degraded after administration to patients (e.g., mammalian patients, such as human patients) and are located outside of immune system antigen presenting cells, thereby triggering an inappropriate immune response to the administered antibody. Methods for determining whether a particular amino acid sequence is prone to binding to MHC molecules are known in the art and are described in, for example, Wang et al., BMC Bioinformatics 11:568, 2010; Nielsen et al., BMC Bioinformatics 8:238, 2007; Gonzalez-Galarza et al., Nucleic Acid Research 39:D913-D919, 2011; and Greenbaum et al., Immunogenetics 63:325, 2011, the disclosures of which are each incorporated herein by reference in their entirety.
[0347] Although the above-described framework regions tend to bind to class II MHC molecules, they are not immunogenic peptides. Rather, these amino acid sequences confer high affinity binding to TNFR2. Agonist TNFR2 polypeptides of the disclosure containing any of the foregoing framework region sequences exhibit the unexpected and beneficial property of high TNFR2 affinity without inducing an immunogenic response to the polypeptide upon administration to a patient (e.g., a mammalian patient, such as a human).
[0348] Homogeneity of the TNFR2 agonistic peptide population
[0349] Pharmaceutical compositions can be produced in which the TNFR2 agonist polypeptides described herein (e.g., antibodies, antigen-binding fragments thereof, single-chain polypeptides, or constructs thereof) are present in a single disulfide-bonded isoform. For example, at least 10% or more of the polypeptides in the pharmaceutical composition can be present in a single disulfide-bonded isoform (e.g., IgG2-B isoform). For example, this can be achieved by amino acid substitution or deletion at cysteine residue 127 of the wild-type human IgG1 or IgG2 CH1 domain, thereby preventing or reducing the occurrence of disulfide bonding that may result in isoforms other than, for example, IgG2-B (see, e.g., Figure 5A-5D). Pharmaceutical compositions of the present disclosure include those wherein, for example, from about 10% to about 99.999% of the agonist TNFR2 polypeptide in the pharmaceutical composition is present in a single disulfide-bonded isoform (e.g., IgG2-B isoform). For example, pharmaceutical compositions of the present disclosure include those containing an agonist TNFR2 polypeptide wherein, for example, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, 99.99% or more of the polypeptide in the pharmaceutical composition is present in a single disulfide-bonded isoform.
[0350] Techniques for measuring the relative amounts of the various disulfide-bonded isoforms present in a sample of an agonist TNFR2 polypeptide include liquid chromatography techniques known in the art and described herein, such as those cited in Wypych et al., The Journal of Biological Chemistry, 283:16194-16205, 2008, the disclosure of which is incorporated herein by reference in its entirety.
[0351] Effects on TNFR2 signal transduction cascade
[0352] The agonist TNFR2 polypeptides described herein (e.g., single-chain polypeptides, antibodies, and antigen-binding fragments thereof) are capable of interacting with TNFR2 and enhancing its activity. The TNFR2 polypeptides of the present disclosure can bind to TNFR2 at one or more specific epitopes that are conducive to the formation of TNFR2 trimers by bringing adjacent TNFR2 monomers into close proximity with each other. TNFR2 trimerization is particularly advantageous for receptor activation because it places TNFR2 monomers in a conformation that is spatially accessible to the TNFα binding site. This trimerization event can activate intracellular signaling of TNFR2, which in turn can promote the proliferation of cells expressing TNFR2 (such as Treg cells, MDSCs, and / or TNFR2+ parenchymal cells). TNFR2 activation can also lead to increased expression levels of CD274 (PDL1), PDCD1LG2 (PDL2), CD137 (4-1BB), and IKZF2.
[0353] Although TNFR2 activation causes the expression of a variety of genes that can exert important therapeutic effects, the TNFR2 agonist polypeptides described herein can promote the expression of several proteins with special therapeutic significance. Without being limited by mechanism, the TNFR2 polypeptides described herein can induce TNFR2-mediated cell healing, protection, proliferation and / or regeneration by stimulating the expression of two histone acetyltransferases EP300 and CREB that promote Foxp3 transcription. This biological activity is particularly important because it can promote flux throughout the cell cycle in TNFR2+ cells while causing T effector cell (e.g., CD8+T cell) death. The selective expansion of TNFR2+ cells and the inhibition of T effector cells are some phenotypes that are the basis of the ability of agonist TNFR2 polypeptides to treat autoimmunity, GVHD, inflammation, and other indications described herein.
[0354] For example, activation of TNFR2 can be monitored by measuring the expression of genes associated with MAPK and TRAF2 / 3 signaling cascades, such as genes whose transcription is mediated by NFκB (Faustman, et al., Nat. Rev. Drug Disc., 9:482-493, 2010, the disclosure of which is incorporated herein by reference).
[0355] Dual proliferation and cell killing effects of TNFR2 agonist peptides
[0356] The agonistic TNFR2 polypeptides disclosed herein, such as single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof, can not only promote the proliferation of Treg cells, MDSCs, and / or TNFR2+ parenchymal cells, but can also induce the death of T effector cells (such as CD8+ T effector cells) (e.g., in a patient, e.g., a human patient). An agonist TNFR2 polypeptide described herein can be capable of, e.g., increasing the total amount of Treg cells, MDSCs, and / or TNFR2+ parenchymal cells in a sample treated with an agonist TNFR2 antibody or antigen-binding fragment thereof (such as a sample isolated from a human patient receiving treatment for autoimmunity, GVHD, transplant rejection, allergy, chronic inflammatory disease, asthma, or other diseases described herein) relative to a sample not treated with the agonist TNFR2 antibody or antigen-binding fragment thereof, e.g., by 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% or more. The ability of the agonistic TNFR2 polypeptides (e.g., single chain polypeptides, antibodies, and antigen-binding fragments) described herein to enhance the growth of Tregs, MDSCs, and / or parenchymal cells may be due in part to the ability of these polypeptides to increase the amount of soluble TNFR2 in a sample (e.g., a sample isolated from a human patient receiving treatment for or autoimmunity, GVHD, transplant rejection, allergy, chronic inflammatory disease, asthma, or another disease described herein).
[0357] Stimulation of Treg and MDSC proliferation brings important therapeutic benefits because these cells suppress the activity of T effector cells (such as autoreactive CD8+ T cells, which produce inappropriate immune responses to self tissues). Similarly, direct killing of T effector cells can confer therapeutic activity because TNFR2 agonist polypeptides can be used to reduce the amount of autoreactive T cells in patients with autoimmunity, GVHD, transplant rejection, allergy, chronic inflammatory disease, asthma, or another disease described herein.
[0358] By either or both of these mechanisms, the TNFR2 agonist polypeptides of the disclosure may be used to inhibit an immunological condition in a patient, such as a mammalian patient (eg, a human patient).
[0359] In addition, the ability of the TNFR2 agonist polypeptides of the present disclosure to stimulate the proliferation of TNFR2+ parenchymal cells provides a beneficial effect of inducing tissue and organ regeneration. Exemplary TNFR2+ cells that can be induced to proliferate using the TNFR2 agonist polypeptides of the present disclosure include, but are not limited to, cells of the pancreas, salivary glands, pituitary glands, kidneys, heart, lungs, hematopoietic system, cranial nerves, heart, aorta, olfactory glands, ears, nerves, head structures, eyes, thymus, tongue, bones, liver, small intestine, large intestine, intestinal tract, lungs, brain, skin, peripheral nervous system, central nervous system, spinal cord, breast, embryonic structures, embryos, and testes. Therefore, the TNFR2 agonist polypeptides described herein can be used to treat diseases in which regeneration, protection, and / or healing of one or more of these cell types is desired. Exemplary diseases that can be treated using the TNFR2 agonist polypeptides of the present disclosure are described herein.
[0360] Active (CD25 Hi and CD45RA Low )Selective regulation of reg cells
[0361] The agonist TNFR2 polypeptides described herein (e.g., single-chain polypeptides, antibodies, antigen-binding fragments and constructs thereof) can be capable of enhancing the proliferation or total amount of Treg cells in a sample (e.g., a sample isolated from a human patient receiving treatment for autoimmunity, GVHD, transplant rejection, allergy, chronic inflammatory disease, asthma, or another disease described herein) and can selectively act on Treg cells in an actively dividing state. For example, relative to cells that do not express CD25 Hi and CD45RA Low Treg cells expressing proteins such as CD25 Med and CD45RA Hi The agonistic TNFR2 antibodies or antigen-binding fragments thereof described herein can activate Treg cells expressing CD25 Hi and CD45RA Low The proliferation of Treg cells is increased, for example, by 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% or more.
[0362] TNFR2 agonist polypeptides are not dependent on additional TNFR2 binding agents for activity
[0363] Importantly, agonist TNFR2 polypeptides, such as single-chain polypeptides, antibodies, or antigen-binding fragments thereof described herein, are capable of binding to TNFR2 and enhancing TNFR2-mediated signaling without the need for the natural TNFR2 ligand TNFα. Such agonists are referred to herein as dominant TNFR2 agonists. Agonist TNFR2 polypeptides, such as antibodies, antigen-binding fragments thereof, single-chain polypeptides, and constructs described herein, do not require TNFα to proliferate Treg cells, MDSCs, and / or TNFR2+ parenchymal cells. Unrestricted by mechanism, the agonist TNFR2 polypeptides of the present disclosure can exhibit this property due to the ability of these molecules to bind to TNFR2 at a specific epitope that stabilizes the trimer conformation of the receptor and its adjacent monomers upon binding. This structural configuration enhances NFκB signaling and enhances some of the basic signal transduction cascades associated with activation of Tregs, MDSCs, and TNFR2+ parenchymal cells.
[0364] For example, agonist TNFR2 polypeptides, such as single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof described herein, can bind to TNFR2 on the surface of TNFR2+ cells (such as Treg cells, MDSCs, and / or TNFR2+ parenchymal cells) and enhance the proliferation of such cells in the presence or absence of TNFα. For example, agonist TNFR2 polypeptides described herein can increase the proliferation of such cells by, for example, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 200%, 300%, 400%, 500% or more relative to cells not treated with TNFR2 agonist polypeptides. Agonistic TNFR2 polypeptides (eg, single chain polypeptides, antibodies, or antigen-binding fragments thereof) may exhibit EC in cell proliferation assays. 50 A value that is largely unchanged in the presence or absence of TNFα (e.g., relative to the EC of an agonist TNFR2 polypeptide (e.g., a single chain polypeptide, antibody, or antigen-binding fragment thereof) in the same cell proliferation assay in the absence of TNFα). 50 In the presence of TNFα, EC 50The change is less than 50%, 45%, 40%, 35%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or less than 1%). Examples of Treg assays that can be used to measure the agonistic effects of TNFR2 antibodies are described herein, for example, as described in Example 2 below. Similarly, as assessed by measuring the expression of one or more genes selected from the group consisting of: Foxp3, TNFSFSF18, IL2RA, IKZF2 / 4, CTLA4, TGF-β, CHUK, NFKBIE, NFKBIA, MAP3K11, TRAF2, TRAF3, relB, TNF, CXCR3, PDL1 (CD274), IL2RA, IL7R, MAP3K1, MAP, MAP3K4, NFKBIB, TANK, TBK1, TNF, TNFAIP3, NFKBIA, MAP3K11, TNFRSF1B, TRAF2, relB, LTA, EP300, CREBBP, NFkB signaling proteins, agonistic TNFR2 polypeptides, such as single chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof described herein, can enhance TNFR2 signaling, for example, by 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% or more relative to such cells not treated with TNFR2 agonist polypeptides. Agonistic TNFR2 polypeptides (e.g., single chain polypeptides, antibodies, or antigen-binding fragments thereof) can exhibit EC in such gene expression assays. 50 A value that is largely unchanged or enhanced in the presence or absence of TNFα (e.g., relative to the EC of an agonist TNFR2 polypeptide (e.g., a single chain polypeptide, antibody, or antigen-binding fragment thereof) in the same gene expression assay in the absence of TNFα 50 In the presence of TNFα, EC 50 The change is less than 50%, 45%, 40%, 35%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or less than 1%).
[0365] Antigen-binding fragment activity of full-length TNFR2 agonist antibodies
[0366] The agonistic TNFR2 antibodies described herein can enhance the proliferation of Treg cells, MDSCs and / or parenchymal cells, and / or promote T effector cell death with efficacy similar to that exhibited by antigen-binding fragments of such antibodies. For example, removal of the Fc region of the agonistic TNFR2 antibodies described herein may not alter the ability of the molecule to promote the proliferation of Treg cells, MDSCs and / or parenchymal cells and / or direct killing of T effector cells (e.g., CD8+ autoreactive T cells) in a sample (e.g., a sample isolated from a human patient receiving treatment for autoimmunity, GVHD, allergy, transplant rejection, or another condition described herein). The agonistic TNFR2 antibodies and antigen-binding fragments thereof described herein can, for example, act by pathways other than antibody-dependent cellular toxicity (ADCC), in which the Fc region is required to recruit effector proteins to induce cell death. In addition, the agonist TNFR2 antibody or antigen-binding fragment thereof can exhibit therapeutic activity in a variety of forms, such as single-chain polypeptides (e.g., single-chain polypeptides containing one or more CDRs covalently bound to each other, for example, by amide bonds, thioether bonds, carbon-carbon bonds, or disulfide bonds), monoclonal antibodies or antigen-binding fragments thereof, polyclonal antibodies or antigen-binding fragments thereof, human antibodies or antigen-binding fragments thereof, humanized antibodies or antigen-binding fragments thereof, primatized antibodies or antigen-binding fragments thereof, bispecific antibodies or antigen-binding fragments thereof, multispecific antibodies or antigen-binding fragments thereof, dual variable immunoglobulin domains, monovalent antibodies or antigen-binding fragments thereof, chimeric antibodies or antigen-binding fragments thereof, single-chain Fv molecules (scFv), diabodies, triabodies, nanobodies, antibody-like protein scaffolds, domain antibodies, Fv fragments, Fab fragments, F(ab') fragments, 2 molecules and tandem scFv (taFv), etc.
[0367] Specific binding properties of agonistic TNFR2 peptides
[0368] Specific binding of a polypeptide, such as a single-chain polypeptide, antibody or antibody fragment described herein, to human TNFR2 can be determined by any of a variety of established methods. Affinity can be quantitatively expressed by various measurements, including the antibody concentration required to achieve half-maximal activation of the TNFR2 receptor in vitro or in vivo (EC 50 ) and the equilibrium constant for dissociation of the antibody-TNFR2 complex (K D ). The equilibrium constant K for the interaction of TNFR2 with the antibodies described herein D is the chemical equilibrium constant for the dissociation of the TNFR2 antibody complex into solvent-isolated TNFR2 antibody and antibody molecules that do not interact with each other.
[0369] The polypeptides described herein (e.g., single-chain polypeptides, antibodies, and antigen-binding fragments) include polypeptides with a K of less than 100 nM. DA polypeptide that specifically binds to TNFR2 with a K value of less than 1 nM (e.g., 95 nM, 90 nM, 85 nM, 80 nM, 75 nM, 70 nM, 65 nM, 60 nM, 55 nM, 50 nM, 45 nM, 40 nM, 35 nM, 30 nM, 25 nM, 20 nM, 15 nM, 10 nM, 5 nM, 4 nM, 3 nM, 2 nM, or 1 nM). In some embodiments, the polypeptides described herein (e.g., single chain polypeptides, antibodies, antigen binding fragments and constructs thereof) bind to TNFR2 with a K value of less than 1 nM. D values (e.g., 990 pM, 980 pM, 970 pM, 960 pM, 950 pM, 940 pM, 930 pM, 920 pM, 910 pM, 900 pM, 890 pM, 880 pM, 870 pM, 860 pM, 850 pM, 840 pM, 830 pM, 820 pM, 810 pM, 800 pM, 790 pM, 780 pM, 770 pM, 760 pM, 750 pM, 740pM, 730pM, 720pM, 710pM, 700pM, 690pM, 680pM, 670pM, 660pM, 650pM, 640pM, 630pM, 6 20pM, 610pM, 600pM, 590pM, 580pM, 570pM, 560pM, 550pM, 540pM, 530pM, 520pM, 510pM, 500pM , 490pM, 480pM, 470pM, 460pM, 450pM, 440pM, 430pM, 420pM, 410pM, 400pM, 390pM, 380pM, 370 pM, 360pM, 350pM, 340pM, 330pM, 320pM, 310pM, 300pM, 290pM, 280pM, 270pM, 260pM, 250pM, 2 pM, 40 pM, 230 pM, 220 pM, 210 pM, 200 pM, 190 pM, 180 pM, 170 pM, 160 pM, 150 pM, 140 pM, 130 pM, 120 pM, 110 pM, 100 pM, 90 pM, 80 pM, 70 pM, 60 pM, 50 pM, 40 pM, 30 pM, 20 pM, 10 pM, 5 pM or 1 pM) specifically binds to TNFR2.
[0370] The polypeptides described herein can also be characterized by various in vitro binding assays. D or EC 50Examples of experiments include, for example, surface plasmon resonance, isothermal titration calorimetry, fluorescence anisotropy, ELISA-based assays, gene expression assays, and protein expression assays, among others. ELISA represents a particularly useful method for analyzing antibody activity because such assays generally require minimal concentrations of antibody. A common signal analyzed in a typical ELISA assay is luminescence, which is typically the result of the activity of a peroxidase conjugated to a secondary antibody that specifically binds to a primary antibody (e.g., a TNFR2 antibody described herein). The polypeptides described herein (e.g., single-chain polypeptides, antibodies, and antigen-binding fragments) are capable of binding to TNFR2 and epitopes therein, such as epitopes containing one or more contiguous or discontinuous residues in CRD1, CRD2, and / or CRD3 of human TNFR2. The agonist polypeptides described herein may additionally bind to isolated peptides derived from TNFR2 that structurally pre-organize various residues in a manner that mimics the conformation of the above-mentioned epitopes in the native protein. In a direct ELISA experiment, such binding can be quantified, for example, by analyzing the luminescence generated by incubating an HRP substrate (eg, 2,2'-azido-di-3-ethylbenzothiazoline sulfonate) with the antigen-antibody complex bound to an HRP-conjugated secondary antibody.
[0371] Kinetic properties of agonistic TNFR2 peptides
[0372] In addition to the thermodynamic parameters of TNFR2-polypeptide interactions, the kinetic association and dissociation of the polypeptides described herein with TNFR2 can also be quantitatively characterized. This can be accomplished, for example, by monitoring the rate of formation of polypeptide-antigen (e.g., antibody-antigen) complexes according to established procedures. For example, surface plasmon resonance (SPR) can be used to determine the formation of antibody-TNFR2 complexes (k on ) and dissociation (k off ) rate constant. These data also enabled the calculation of the K for dissociation of the antibody-TNFR2 complex. D ) equilibrium constant, because the equilibrium constant for this unimolecular dissociation can be expressed as k off With k on The ratio of values. SPR is a particularly advantageous technique for determining the kinetic and thermodynamic parameters of receptor-antibody interactions because the experiment does not require the attachment of chemical labels to modify one component. Instead, the receptor is usually immobilized on a solid metal surface that is treated with pulses of solutions with increasing antibody concentrations. Antibody-receptor binding causes a distortion in the reflection angle of incident light on the metal surface, and as the antibody is introduced into the system, the change in refractive index over time can be fitted to established regression models to calculate the association and dissociation rate constants of the antibody-receptor interaction.
[0373] The polypeptides described herein (eg, single chain polypeptides, antibodies, antigen binding fragments and constructs thereof) can exhibit high k when interacting with TNFR2. on and low-k off This is consistent with high affinity receptor binding. For example, the polypeptides described herein may exhibit a k value in the presence of TNFR2. on Value greater than 10 4 M -1 s -1 (For example, 1.0x10 4 M -1 s -1 , 1.5x10 4 M -1 s -1 , 2.0x10 4 M -1 s -1 , 2.5x10 4 M -1 s -1 , 3.0x10 4 M -1 s -1 , 3.5x10 4 M -1 s -1 , 4.0x10 4 M -1 s -1 , 4.5x10 4 M -1 s -1 , 5.0x10 4 M -1 s -1 , 5.5x10 4 M -1 s -1 , 6.0x10 4 M -1 s -1 , 6.5x10 4 M -1 s -1 ,7.0x10 4 M -1 s -1 , 7.5x10 4 M -1 s -1 ,8.0x10 4 M -1 s -1 , 8.5x10 4 M -1 s -1 , 9.0x10 4 M -1 s -1, 9.5x10 4 M -1 s -1 , 1.0x10 5 M -1 s -1 , 1.5x10 5 M -1 s -1 , 2.0x10 5 M -1 s -1 , 2.5x10 5 M -1 s -1 , 3.0x10 5 M -1 s -1 , 3.5x10 5 M -1 s -1 , 4.0x10 5 M -1 s -1 , 4.5x10 5 M -1 s -1 , 5.0x10 5 M -1 s -1 , 5.5x10 5 M -1 s -1 , 6.0x10 5 M -1 s -1 , 6.5x10 5 M -1 s -1 , 7.0x10 5 M -1 s -1 , 7.5x10 5 M -1 s -1 , 8.0x 10 5 M -1 s -1 , 8.5x10 5 M -1 s -1 , 9.0x10 5 M -1 s -1 , 9.5x10 5 M -1 s -1 or 1.0x10 6 M -1 s -1When binding to TNFR2, the polypeptides described herein (eg, single-chain polypeptides, antibodies, antigen-binding fragments and constructs thereof) may exhibit a low k off values, because these peptides are able to interact with different TNFR2 epitopes with high affinity. Residues in these epitopes can form strong intermolecular contacts with TFNR2, which can slow the dissociation of the antibody-TNFR2 complex. This high receptor affinity can be manifested as a low k off For example, when complexed with TNFR2, the polypeptides described herein may exhibit a -3 s -1 K off Value (for example, 1.0x10 -3 s -1 , 9.5x10 -4 s -1 , 9.0x10 -4 s -1 , 8.5x10 -4 s -1 ,8.0x10 -4 s -1 , 7.5x10 -4 s -1 ,7.0x10 -4 s -1 , 6.5x10 -4 s -1 , 6.0x10 -4 s -1 , 5.5x10 -4 s -1 , 5.0x10 -4 s -1 , 4.5x10 -4 s -1 , 4.0x10 -4 s -1 , 3.5x10 -4 s -1 , 3.0x10 -4 s -1 , 2.5x10 -4 s -1 , 2.0x10 -4 s -1 , 1.5x10 -4 s -1 , 1.0x10 -4 s -1 , 9.5x10 -5 s -1 , 9.0x10 -5 s -1 , 8.5x10 -5 s -1 ,8.0x10-5 s -1 , 7.5x10 -5 s -1 ,7.0x10 -5 s -1 , 6.5x10 -5 s -1 , 6.0x10 -5 s -1 , 5.5x10 -5 s -1 , 5.0x10 -5 s -1 , 4.5x10 -5 s -1 , 4.0x10 -5 s -1 , 3.5x10 -5 s -1 , 3.0x10 -5 s -1 , 2.5x10 -5 s -1 , 2.0x10 -5 s -1 , 1.5x10 -5 s -1 or 1.0x10 -5 s -1 ).
[0374] Epitopes in TNFR2 bound by agonistic TNFR2 polypeptides
[0375] Agonistic TNFR2 polypeptides described herein, such as dominant agonistic TNFR2 polypeptides (e.g., single chain polypeptides, antibodies, antigen-binding fragments and constructs thereof), can specifically bind to one or more of the following residues of TNFR2:
[0376] (a) amino acids 56-60 of SEQ ID NO: 1 within human TNFR2 (KCSPG);
[0377] (b) amino acids 101-107 of SEQ ID NO: 1 within human TNFR2 (CSSDQVET);
[0378] (c) amino acids 115-142 of SEQ ID NO: 1 within human TNFR2
[0379] (NRICTCRPGWYCALSKQEGCRLCAPLRK);
[0380] (d) amino acids 26-45 of SEQ ID NO: 1 within human TNFR2
[0381] (QTAQMCCSKCSPGQHAKVFC);
[0382] (e) amino acids 90-109 of SEQ ID NO: 1 within human TNFR2
[0383] (REQNRICTCRPGWYCALSKQ);
[0384] (f) amino acids 98-117 of SEQ ID NO: 1 within human TNFR2
[0385] (CRPGWYCALSKQEGCRLCAP);
[0386] (g) amino acids 106-125 of SEQ ID NO: 1 within human TNFR2
[0387] (LSKQEGCRLCAPLRKCRPGF);
[0388] (h) amino acids 108-127 of SEQ ID NO: 1 within human TNFR2
[0389] (KQEGCRLCAPLRKCRPGFGV); and / or
[0390] (i) an equivalent epitope within TNFR2 of a non-human mammal (such as a non-human mammal described herein) that has at least 85% sequence identity (e.g., 85%, 90%, 95%, 97%, 99% or 100% sequence identity) to any of the above epitopes, and / or an epitope that contains one or more conservative amino acid substitutions relative to any of the above epitopes.
[0391] In some embodiments, the agonistic TNFR2 polypeptides described herein, e.g., dominant agonistic TNFR2 polypeptides (e.g., single chain polypeptides, antibodies, antigen-binding fragments and constructs thereof) do not bind to an epitope containing residues 142-146 of SEQ ID NO: 1 or more or all of human TNFR2 (KCRPG, SEQ ID NO: 41).
[0392] One exemplary procedure that can be used to predict the proliferative, regenerative, healing or protective activity of a TNFR2 polypeptide described herein is for determining the affinity of an antibody or antibody fragment for a peptide containing the KCSPG motif (SEQ ID NO: 40), such as a linear or cyclic peptide containing the motif. The peptide can be structurally pre-organized in a manner that mimics the three-dimensional orientation of the KCSPG motif (SEQ ID NO: 40), for example, by one or more conformational constraints (e.g., main chain or side chain to side chain cyclization). For example, an agonist TNFR2 polypeptide described herein can bind to a peptide containing the KCSPG motif (SEQ ID NO:40) with an affinity that is greater than, for example, 10-fold, 15-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, 200-fold, 300-fold, 400-fold, 500-fold, 600-fold, 700-fold, 800-fold, 900-fold, 1000-fold, or more than 1000-fold, than the affinity of the agonist polypeptide for a peptide containing the KCRPG amino acid sequence (SEQ ID NO:41).
[0393] Agonistic TNFR2 Antibody TNFRAG1
[0394] Exemplary agonist TNFR2 polypeptides described herein, such as single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof, can include one or more, or all, of the CDRs of TNFRAG1, which are monoclonal antibodies that can specifically bind to TNFR2 at epitopes that promote TNFR2 signal transduction, thereby promoting Treg cell and MDSC proliferation, TNFR2+ parenchymal cell regeneration, healing and protection, and T effector cell (e.g., CD8+T effector cell) death. For example, CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and / or CDR-L3 of TNFRAG1, and variants of these CDRs (e.g., variants exhibiting conservative amino acid substitutions relative to these CDR sequences) can be used to generate additional agonist TNFR2 polypeptides (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs) of the present disclosure, for example, by antibody humanization methods described herein or known in the art.
[0395] The agonistic TNFR2 polypeptides (e.g., single-chain polypeptides, antibodies, and antigen-binding fragments) of the present disclosure can exhibit binding properties that are the same or similar to those of TNFRAG1. In particular, TNFRAG1 specifically binds to human TNFR2 at one or more of the following residues:
[0396] (a) amino acids 56-60 of SEQ ID NO: 1 (KCSPG);
[0397] (b) amino acids 101-107 of SEQ ID NO: 1 (CSSDQVET);
[0398] (c) amino acids 115-142 of SEQ ID NO: 1
[0399] (NRICTCRPGWYCALSKQEGCRLCAPLRK);
[0400] (d) amino acids 26-45 of SEQ ID NO: 1 (QTAQMCCSKCSPGQHAKVFC);
[0401] (e) amino acids 90-109 of SEQ ID NO: 1 (REQNRICTCRPGWYCALSKQ);
[0402] (f) amino acids 98-117 of SEQ ID NO: 1
[0403] (CRPGWYCALSKQEGCRLCAP);
[0404] (g) amino acids 106-125 of SEQ ID NO: 1
[0405] (LSKQEGCRLCAPLRKCRPGF); and / or
[0406] (h) amino acids 108-127 of SEQ ID NO: 1
[0407] (KQEGCRLCAPLRKCRPGFGV).
[0408] TNFRAG1 may contain one or both of the heavy chain variable regions shown below in SEQ ID NO: 14 and SEQ ID NO: 15. The CDRs in each of these regions are shown in bold:
[0409]
[0410] In addition, TNFRAG1 contains the light chain variable region shown below in SEQ ID NO: 42. The CDRs in this region are shown in bold.
[0411]
[0412] The following sections provide detailed descriptions of methods that can be used to prepare human polypeptides, humanized polypeptides, primatized polypeptides, chimeric polypeptides, and other polypeptides (e.g., single chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs), e.g., based on the molecular characteristics of TNFRAG1.
[0413] Fully human antibodies, humanized antibodies, primatized antibodies and chimeric antibodies
[0414] The antibodies described herein include fully human antibodies, humanized antibodies, primatized antibodies and chimeric antibodies containing one or more, or all CDR sequences of TNFRAG1. In addition, the antibodies described herein include fully human antibodies, humanized antibodies, primatized antibodies and chimeric antibodies, which contain one or more, or all of the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2 and CDR-L3 sequences, wherein one or more, or all of the CDR sequences have at least 85% sequence identity (e.g., 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity) with the corresponding CDR sequences of TNFRAG1. The agonistic TNFR2 antibodies described herein further include fully human antibodies, humanized antibodies, primatized antibodies, and chimeric antibodies that contain one or more, or all, of the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 sequences, wherein one or more, or all, of the CDR sequences contain one or more (e.g., up to 3) amino acid substitutions (e.g., one or more conservative amino acid substitutions) relative to the corresponding CDR sequences, and are also important for the consensus heavy chain framework sequence, versions of which can also be found in human heavy chain sequences.
[0415] For example, one strategy that can be used to design the humanized antibodies described herein is to align the sequences of the heavy chain variable region and the light chain variable region of TNFRAG1 with the heavy chain variable region and the light chain variable region of the common human antibody. The common human antibody heavy chain and light chain sequences are known in the art (e.g., see the "VBASE" human germline sequence database; see also Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242, 1991; Tomlinson et al., J. Mol. Biol. 227: 776-98, 1992; and Cox et al., Eur. J. Immunol. 24: 827-836, 1994; the disclosures of which are incorporated herein by reference). In this way, variable domain framework residues and CDRs can be identified by sequence alignment (see Kabat, supra). To generate a humanized TNFR2 agonist antibody, one or more CDRs of, for example, a consensus human antibody can be substituted with the corresponding CDR of, for example, TNFRAG1. Exemplary variable domains of consensus human antibodies include the heavy chain variable domain:
[0416]
[0417] and light chain variable domain:
[0418]
[0419] As identified in U.S. Pat. No. 6,054,297; the disclosure of which is incorporated herein by reference (the CDRs shown in bold are determined according to the method of Chothia, et al., J. Mol. Biol, 196:901-917, 1987). These amino acid substitutions can be made, for example, by recombinantly expressing polynucleotides encoding the heavy and light chains of humanized antibodies in host cells using methods known in the art or described herein.
[0420] Similarly, this strategy can also be used to generate primatized agonistic TNFR2 antibodies, as it can replace, for example, one or more, or all, of the CDRs of a primate antibody consensus sequence, e.g., one or more, or all of the CDRs of TNFRAG1. Consensus primate antibody sequences are known in the art (see, e.g., U.S. Pat. Nos. 5,658,570; 5,681,722; and 5,693,780; the disclosures of each of which are incorporated herein by reference).
[0421] In some embodiments, it may be desirable to introduce specific framework residues other than CDR sequences from an agonistic TNFR2 antibody (such as TNFRAG1) into the heavy and / or light chain variable domains of a human antibody. For example, U.S. Pat. No. 6,054,297 identifies several examples in which it may be advantageous to retain certain framework residues from a specific antibody heavy or light chain variable region in the resulting humanized antibody. In some embodiments, the framework residues may interact non-covalently with the antigen, thereby contributing to the affinity of the antibody for the target antigen. In some embodiments, a single framework residue may modulate the conformation of the CDR and thus indirectly affect the interaction of the antibody with the antigen. Certain framework residues may form an interface between the VH and VL domains and may therefore contribute to the overall antibody structure. In some cases, framework residues may constitute functional glycosylation sites (e.g., Asn-X-Ser / Thr), which may determine antibody structure and antigen affinity when attached to a carbohydrate moiety. In the above cases, it may be beneficial to retain certain framework residues of the TNFR2 agonist antibody (e.g., TNFRAG1) in, for example, a humanized or primatized agonist antibody or antigen-binding fragment thereof, because various framework residues can contribute to high epitope affinity and improved biochemical activity of the antibody or antigen-binding fragment thereof.
[0422] The antibodies described herein also include antibody fragments, Fab domains, F(ab') molecules, F(ab') 2Molecules, single chain variable fragments (scFv), tandem scFv fragments, diabodies, triabodies, dual variable domain immunoglobulins, multispecific antibodies, bispecific antibodies and heterospecific antibodies, which (i) contain one or more, or all, of the CDRs of TNFRAG1, and / or (ii) have one or more, or all, of the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2 and CDR-L3 sequences, wherein one or more, or all, of the CDR sequences have at least 85% sequence identity (e.g., 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity) with the corresponding CDR sequences of TNFRAG1. These molecules can be recombinantly expressed, for example, by incorporating polynucleotides encoding these proteins into expression vectors for transfection in eukaryotic or prokaryotic cells using techniques described herein or known in the art, or chemically synthesized, for example, by solid phase peptide synthesis methods described herein or known in the art.
[0423] The polypeptides described herein further include antibody-like scaffolds that contain, for example, one or more, or all, of the CDRs of TNFRAG1, or wherein one or more, or all, of the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 sequences have at least 85% sequence identity (e.g., 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) with the corresponding CDR sequences of TNFRAG1 and / or contain one or more (e.g., up to 3) amino acid substitutions (e.g., one or more conservative amino acid substitutions) relative to the corresponding CDR sequences of TNFRAG1. Examples of antibody-like scaffolds include those containing the tenth fibronectin type III domain ( 10 Fn3) protein, which contains BC, DE and FG structural loops similar to those of typical antibodies. 10 The tertiary structure of the Fn3 domain is similar to that of the IgG heavy chain variable region, and those skilled in the art can 10 The residues of the BC, DE and FG loops of Fn3 are replaced with residues of the corresponding CDR sequences of TNFRAG1, for example, one or more, or all, of the CDR sequences of TNFRAG1, or a sequence having at least 85% sequence identity (e.g., 90%, 95%, 97%, 99% or 100% sequence identity) with any one or more of these CDR sequences, or a sequence containing amino acid substitutions (such as conservative or non-conservative amino acid substitutions (e.g., up to 3 amino acid substitutions)) relative to one or more of these CDR sequences are transplanted onto the fibronectin scaffold. This can be accomplished by recombinantly expressing the modified 10 Fn3 domains are used to achieve this (e.g., using the vectors and techniques described herein).10 Examples of Fn3 domains as antibody-like scaffolds for grafting CDRs from antibodies onto the BC, DE, and FG structural loops are reported in WO 2000 / 034784, WO 2009 / 142773, WO 2012 / 088006, and US Pat. No. 8,278,419; the disclosures of each of which are incorporated herein by reference.
[0424] Molecular determinants of TNFR2 affinity and agonism
[0425] The polypeptides of the present disclosure can exhibit a series of common structural features that give rise to a TNFR2 agonist phenotype (e.g., a dominant TNFR2 agonist phenotype). For example, the amino acid sequence of each CDR-H1 in TNRAG1 was compared with two other agonistic TNFR2 monoclonal antibodies, TNFRAG2 and TNFRAG3, demonstrating that these antibodies have conserved common CDR-H1 sequences, as shown below:
[0426] GYTFTDYN(I / L)(TNFRAG1 CDR-H1,SEQ ID NO:45)
[0427] GFTFTDYD(TNFRAG2 CDR-H1,SEQ ID NO:46)
[0428] GYTFTD YI(TNFRAG3 CDR-H1,SEQ ID NO:47)
[0429] G(Y / F)TFTDY(N / D)-(consensus sequence, SEQ ID NO:48)
[0430] Alignment of the sequences revealed shared CDR-H1 motifs, such as the motif GZ shown below 1 TFZ 3 Z 2 YZ 3 Z 4 (SEQ ID NO: 2), wherein each Z 1 is independently a naturally occurring amino acid including a side chain including an aromatic substituent, each Z 2 are independently naturally occurring amino acids that include anionic side chains at physiological pH, each Z 3 are independently naturally occurring amino acids comprising polar, uncharged side chains at physiological pH, and each Z 4is independently leucine or isoleucine.The agonist TNFR2 polypeptides of the present disclosure may have a CDR-H1 sequence as described in any one of SEQ ID NO:45-SEQ ID NO:47 above, and / or a CDR-H1 represented by the conserved motif of SEQ ID NO:2.
[0431] Nucleic Acids and Expression Systems
[0432] The agonist TNFR2 polypeptides described herein (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) can be prepared by any of a variety of established techniques. For example, the agonist TNFR2 antibodies or antigen-binding fragments thereof described herein can be prepared by recombinantly expressing immunoglobulin light chain and heavy chain genes in host cells. To recombinantly express the antibodies, host cells can be transfected with one or more recombinant expression vectors carrying DNA fragments encoding the immunoglobulin light and heavy chains of the antibodies, so that the light and heavy chains are expressed in the host cells and optionally secreted into the culture medium in which the host cells are cultured, and the antibodies can be recovered from the culture medium. Standard recombinant DNA methods are used to obtain the antibody heavy and light chain genes, incorporate the genes into recombinant expression vectors, and introduce the vectors into host cells, such as Molecular Cloning; A Laboratory Manual, 2nd Edition (Sambrook, Fritsch and Maniatis (eds.), Cold Spring Harbor, NY, 1989), Current Protocols in Molecular Biology (Ausubel et al., eds., Greene Publishing Associates, 1989), and U.S. Pat. No. 4,816,397; the disclosures of each of which are incorporated herein by reference.
[0433] Vectors for expressing agonistic TNFR2 polypeptides
[0434] Viral genomes provide a rich source of vectors that can be used to efficiently deliver exogenous genes to the genome of cells (e.g., eukaryotic or prokaryotic cells). Viral genomes are particularly useful vectors for gene delivery because the polynucleotides contained in such genomes are usually incorporated into the genome of target cells by general or specialized transduction. These processes are part of the natural viral replication cycle and do not require the addition of proteins or reagents to induce gene integration. Examples of viral vectors include retroviruses, adenoviruses (e.g., Ad5, Ad26, Ad34, Ad35, and Ad48), parvoviruses (e.g., adeno-associated viruses), coronaviruses, negative-strand RNA viruses (e.g., orthomyxoviruses (e.g., influenza viruses)), rhabdoviruses (e.g., rabies and vesicular stomatitis viruses), paramyxoviruses (e.g., measles and Sendai viruses), positive-strand RNA viruses (such as picornaviruses and alphaviruses), and double-stranded DNA viruses (including adenoviruses|herpesviruses (e.g., herpes simplex virus type 1 and type 2, Epstein-Barr virus, cytomegalovirus)) and poxviruses (e.g., vaccinia, modified vaccinia Ankara virus (MVA), fowlpox, and canarypox). For example, other viruses that can be used to deliver polynucleotides encoding the antibody light and heavy chains or antibody fragments described herein include Norwalk virus, togavirus, flavivirus, reovirus, papillomavirus, hepadnavirus, and hepatitis virus. Examples of retroviruses include: avian leukosis-sarcoma, mammalian C-type, B-type virus, D-type virus, HTLV-BLV group, lentivirus, foamy virus (Coffin, JM, Retroviridae: The viruses and their replication, In Fundamental Virology, 3rd edition, BN Fields et al., ed., Lippincott-Raven Publishers, Philadelphia, 1996). Other examples include murine leukemia virus, murine sarcoma virus, mouse mammary tumor virus, bovine leukemia virus, feline leukemia virus, feline sarcoma virus, avian leukemia virus, human T-cell leukemia virus, baboon endogenous virus, gibbon leukemia virus, Mason Pfizer monkey virus, simian immunodeficiency virus, simian sarcoma virus, Rous sarcoma virus and lentivirus. Other examples of vectors are described in, for example, McVey et al., (U.S. Pat. No. 5,801,030); the disclosures of each of which are incorporated herein by reference.
[0435] Non-viral vectors, such as plasmids, are also well known in the art, including but not limited to prokaryotic and eukaryotic vectors (e.g., yeast and bacterial-based plasmids), and plasmids for expression in mammalian cells. Methods for introducing vectors into host cells and isolating and purifying expressed proteins are also well known in the art (e.g., Molecular Cloning; A Laboratory Manual, Second Edition (Sambrook, Fritsch and Maniatis (eds.) Cold Spring Harbor, NY, 1989)).
[0436] Genome Editing Technology
[0437] In addition to viral vectors, a variety of other methods have been developed for integrating genes, such as those that combine antibody light and heavy chains, single-chain polypeptides, single-chain variable fragments (scFv), tandem scFvs, Fab domains, F(ab') 2 The invention relates to a method for incorporating polynucleotides encoding agonist TNFR2 polypeptides (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, or constructs thereof) into prokaryotic or eukaryotic cells. A method for incorporating polynucleotides encoding agonist TNFR2 polypeptides (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, or constructs thereof) into prokaryotic or eukaryotic cells includes the use of transposons. Transposons are polynucleotides encoding transposases, containing a target polynucleotide sequence or a target gene flanked by excision sites at the 5' and 3' positions. Once the transposon has been delivered into the cell, expression of the transposase gene begins, and an active enzyme is produced that cuts the target gene from the transposon. This activity is mediated by site-specific recognition of the transposon excision site by the transposase. In some embodiments, these excision sites can be terminal repeats or inverted terminal repeats. Once excised from the transposon, the target gene can be integrated into the genome of the prokaryotic or eukaryotic cell by catalyzing the cutting of similar excision sites present in the nuclear genome by the transposase. This allows the gene encoding the agonist TNFR2 polypeptide described herein to be inserted into the cleaved nuclear DNA at the excision site, followed by ligation of the target gene to the phosphodiester bond of the prokaryotic or eukaryotic cell genomic DNA to complete the integration process. In some embodiments, the transposon is a retrotransposon, so that the gene encoding the polypeptide is first transcribed into an RNA product, then reverse transcribed into DNA, and then incorporated into the prokaryotic or eukaryotic cell genome. Exemplary transposon systems include the piggybac transposon (as described in detail in WO 2010 / 085699) and the sleeping beauty transposon (as described in detail in US20050112764); the disclosures of each of which are incorporated herein by reference.
[0438] Another useful method for integrating nucleic acid molecules encoding agonist TNFR2 polypeptides (e.g., single-chain polypeptides, antibodies, or antigen-binding fragments thereof) into the genome of prokaryotic or eukaryotic cells is the clustered regularly interspaced short palindromic repeats (CRISPR) / Cas system, which originally evolved as an adaptive defense mechanism in bacteria and archaea to resist viral infection. The CRISPR / Cas system consists of palindromic repeat sequences and the associated Cas9 nuclease within plasmid DNA. This combination of DNA and protein is achieved by first integrating exogenous DNA into the CRISPR locus to guide site-specific DNA cleavage of the target sequence. Polynucleotides containing these exogenous sequences and the repeat spacer elements of the CRISPR locus are sequentially transcribed in the host cell to produce guide RNAs, which can then be annealed to the target sequence and the Cas9 nuclease is localized to the site. In this way, highly site-specific cas9-mediated DNA cleavage can be performed in the exogenous polynucleotides because the interaction that places cas9 near the target DNA molecule is controlled by RNA:DNA hybridization. As a result, in theory, one can design the CRISPR / Cas system to cut any target DNA molecule. This technology has been utilized for editing eukaryotic genomes (Hwang et al., Nat. Biotech., 31:227-229, 2013) and can be used as an effective means for site-specific editing of eukaryotic or prokaryotic genomes to cleave DNA prior to incorporation of a polynucleotide encoding an agonist TNFR2 polypeptide (e.g., a single-chain polypeptide, an antibody, or an antigen-binding fragment thereof) as described herein. The use of CRISPR / Cas for regulating gene expression has been described in U.S. Pat. No. 8,697,359, the disclosure of which is incorporated herein by reference.
[0439] Prior to incorporating the polynucleotides encoding the TNFR2 antibodies or antibody fragments described herein, alternative methods for site-specific cleavage of genomic DNA include the use of zinc finger nucleases and transcription activator-like effector nucleases (TALENs). Unlike the CRISPR / Cas system, these enzymes do not contain guide polynucleotides to locate specific target sequences. Instead, target specificity is controlled by the DNA binding domains in these enzymes. Zinc finger nucleases and TALENs used in genome editing applications are described in Urnov et al. (Nat. Rev. Genet., 11:636-646, 2010); and Joung et al., (Nat. Rev. Mol. Cell. Bio. 14:49-55, 2013); which are incorporated herein by reference. Other genome editing techniques that can be used to incorporate polynucleotides encoding the antibodies described herein into the genome of prokaryotic or eukaryotic cells include the use of ARCUS, which can be rationally designed to site-specifically cleave genomic DNA. TMMeganucleases. Given the established structure-activity relationships for such enzymes, the use of these enzymes for incorporating polynucleotides encoding agonist TNFR2 polypeptides (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, or constructs thereof) described herein into the genome of prokaryotic or eukaryotic cells is particularly advantageous. Thus, single-chain meganucleases can be modified at certain amino acid positions to generate nucleases that selectively cleave DNA at desired positions. These single-chain nucleases have been extensively described, for example, in U.S. Pat. Nos. 8,021,867 and 8,445,251; the disclosures of each of which are incorporated herein by reference.
[0440] Polynucleotide sequence element
[0441] To express an agonist TNFR2 polypeptide described herein (e.g., a single chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof), polynucleotides encoding partial or full-length light and heavy chains, e.g., polynucleotides encoding one or more, or all, of the CDR sequences of an antibody or antigen-binding fragment thereof described herein, can be inserted into an expression vector such that the gene is operably linked to transcriptional and translational control sequences. The expression vector and expression control sequences are selected to be compatible with the expression host cell being used. The light chain gene encoding the TNFR2 polypeptide and the heavy chain polynucleotide can be inserted into separate vectors, or, optionally, both polynucleotides can be incorporated into the same expression vector using techniques described herein or known in the art.
[0442] In addition to the polynucleotides encoding the heavy and light chains of the antibodies (or the polynucleotides encoding the single-chain polypeptides, antibody fragments (e.g., scFv molecules), or constructs described herein), the recombinant expression vectors described herein may carry regulatory sequences that control the expression of the antibody chain genes in the host cell. The design of the expression vector, including the selection of regulatory sequences, may depend on factors such as the selection of the host cell to be transformed or the expression level of the desired protein. For example, regulatory sequences suitable for mammalian host cell expression include viral elements that direct high-level protein expression in mammalian cells, such as promoters and / or enhancers derived from cytomegalovirus (CMV) (such as CMV promoter / enhancer), Simian virus 40 (SV40) (such as SV40 promoter / enhancer), adenovirus (e.g., adenovirus major late promoter (AdMLP)) and polyoma virus. Viral regulatory elements and their sequences are described in, for example, U.S. Pat. No. 5,168,062, U.S. Pat. No. 4,510,245, and U.S. Pat. No. 4,968,615, the disclosures of which are each incorporated herein by reference.
[0443] In addition to the antibody chain genes and regulatory sequences, the recombinant expression vectors described herein may also carry other sequences, such as sequences that regulate the replication of the vector in the host cell (e.g., replication origin) and selectable marker genes. Selectable marker genes facilitate the selection of host cells into which the vector has been introduced (see, e.g., U.S. Patent Nos. 4,399,216, 4,634,665, and 5,179,017). For example, typically, the selectable marker gene confers tolerance to cytotoxic drugs such as G418, puromycin, blasticidin, hygromycin, or methotrexate in the host cells into which the vector has been introduced. Suitable selectable marker genes include dihydrofolate reductase (DHFR) genes (for DHFR" host cells with methotrexate selection / amplification) and neo genes (for G418 selection). In order to express the light and heavy chains of TNFR2 antibodies or TNFR2 antibody fragments, expression vectors containing polynucleotides encoding heavy and light chains can be transfected into host cells by standard techniques.
[0444] Polynucleotides encoding modified agonist TNFR2 polypeptides
[0445] Using the compositions and methods of the disclosure, agonistic TNFR2 polypeptides can be generated, for example, by introducing one or more CDRs from a given TNFR2 agonist polypeptide into a germline antibody sequence, such as a human germline antibody sequence in the case of developing human or humanized antibodies. For example, an agonist TNFR2 polypeptide described herein (e.g., a single-chain polypeptide, an antibody, an antigen-binding fragment thereof, or a construct thereof) can contain one or more, or all, of the CDRs of TNFRAG1 (as set forth in SEQ ID NO:2-SEQ ID NO:4 and SEQ ID NO:10-SEQ ID NO:13), or one or more, or all, of the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 sequences, wherein one or more, or all, of the CDR sequences have at least 85% sequence identity (e.g., 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) with the corresponding CDR sequence of TNFRAG1 or contain one or more (e.g., up to 3) amino acid substitutions (e.g., one or more conservative amino acid substitutions) relative to the corresponding CDR sequence of TNFRAG1. Optionally, the TNFR2 agonist polypeptide may exhibit differences in one or more framework regions relative to those of TNFRAG1, such as a framework region between CDR-H1 and CDR-H2. For example, one or more framework regions of TNFRAG1 may be replaced by framework regions of a human antibody. Exemplary framework regions include, for example, human framework regions described in US7,829,086 and primate framework regions described in EP 1945668; the disclosures of each of which are incorporated herein by reference. To produce nucleic acids encoding such TNFR2 antibodies, DNA fragments encoding, for example, at least one or two of the light chain variable region and the heavy chain variable region may be produced by chemical synthesis (e.g., by solid phase polynucleotide synthesis techniques), in vitro gene amplification (e.g., by polymerase chain reaction techniques), or by replicating polynucleotides in a host organism.
[0446] In some embodiments, a humanized agonist TNFR2 antibody can include one or more, or all, of a CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 sequence, wherein one or more, or all, of the CDR sequences have at least 85% sequence identity (e.g., 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) with the corresponding CDR sequence of TNFRAG1 or contain one or more (e.g., up to 3) amino acid substitutions (e.g., one or more conservative amino acid substitutions) relative to the corresponding CDR sequence of TNFRAG1. For example, this can be achieved by performing site-directed mutagenesis on germline DNA or cDNA and amplifying the resulting polynucleotide using polymerase chain reaction (PCR) according to established procedures. The germline DNA sequences of human heavy and light chain variable region genes are known in the art (e.g., see the "VBASE" human germline sequence database; see also Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242, 1991; Tomlinson et al., J. Mol. Biol. 227: 776-798, 1992; and Cox et al., Eur. J. Immunol. 24: 827-836, 1994; which are incorporated herein by reference). Chimeric nucleic acid constructs encoding human heavy and light chain variable regions containing one or more, or all, of the CDRs of TNFRAG1 or similar sequences described above can be generated, for example, using established cloning techniques known in the art. In addition, polynucleotides encoding heavy chain variable regions containing one or more, or all, of the CDRs of TNFRAG1 or similar sequences described above can be synthesized and used as templates for mutagenesis to generate variants described herein using conventional mutagenesis techniques. Alternatively, DNA fragments encoding the variant can be synthesized directly (eg, by established solid phase nucleic acid chemical synthesis procedures).
[0447] The DNA fragment encoding one or more, or all of the VH fragments containing the CDR-H1, CDR-H2 and CDR-H3 sequences of TNFRAG1 can be further manipulated by standard recombinant DNA techniques, for example, to convert the variable region gene into a full-length antibody chain gene, a Fab fragment gene or a scFv gene. In these manipulations, the DNA fragment encoding VL or VH is operably linked to another DNA fragment encoding another protein (such as an antibody constant region or a flexible linker).
[0448] For example, the isolated DNA encoding the VH region of the agonist TNFR2 antibody described herein can be converted to a full-length heavy chain gene (as well as a Fab heavy chain gene) by operably linking the DNA encoding the VH to another DNA molecule encoding the heavy chain constant region domains (CH1, CH2, CH3, and (optionally) CH4). The sequences of human heavy chain constant region genes are known in the art (see, e.g., Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242, 1991), and DNA fragments containing these regions can be obtained by standard PCR amplification. The heavy chain constant region can be an IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgM or IgD constant region, and in certain embodiments is an IgG1 constant region. For a Fab fragment heavy chain gene, the DNA encoding the VH can be operably linked to another DNA molecule encoding only the heavy chain CH1 domain.
[0449] The isolated DNA encoding the VL region of an agonist TNFR2 antibody can be converted to a full-length light chain gene (as well as a Fab light chain gene) by operably linking the DNA encoding the VL to another DNA molecule encoding the light chain constant region CL. The sequences of human light chain constant region genes are known in the art (see, e.g., Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition (USDepartment of Health and Human Services, NIH Publication No. 91-3242, 1991)), and DNA fragments comprising these regions can be obtained, for example, by amplifying polynucleotides encoding these regions in prokaryotic or eukaryotic cells, by PCR amplification, or by chemical polynucleotide synthesis. The light chain constant region can be a kappa (κ) or lambda (λ) constant region, but in certain embodiments is a κ constant region. To construct an scFv gene, the DNA fragments encoding VH and VL are operably linked to another fragment encoding a flexible linker, for example, a fragment encoding a flexible hydrophilic amino acid sequence (e.g., an amino acid sequence (Gly 4 Ser) 3 ) such that V H and V L The sequence can be expressed as a continuous single-chain protein, where V L and V HThe regions are connected by a linker (see, e.g., Bird et al., Science 242:423-426, 1988; Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883, 1988; McCafferty et al., Nature 348:552-554, 1990).
[0450] Recombinant DNA technology can also be used to remove part or all of the DNA encoding one or both of the light and heavy chains, which are not necessary for binding to TNFR2. Molecules expressed by such truncated DNA molecules are also covered by the antibodies described herein. In addition, bifunctional antibodies can be produced in which one heavy chain contains one or more, or all, of the CDRs of TNFRAG1, or similar CDR sequences as described above, and the other heavy chains and / or light chains are specific for antigens other than TNFR2. Such antibodies can be produced, for example, by cross-linking heavy chains and light chains containing one or more, or all, of the CDRs of TNFRAG1 or similar CDR sequences described above with the heavy chains and light chains of a second antibody specific for different antigens, for example, using standard chemical cross-linking methods (e.g., by forming disulfide bonds). Bifunctional antibodies can also be prepared by expressing nucleic acid molecules engineered to encode bifunctional antibodies in prokaryotic or eukaryotic cells.
[0451] Bispecific antibodies, i.e., antibodies that bind to TNFR2 and different antigens using the same binding site, can be produced by mutating amino acid residues in the light chain and / or heavy chain CDRs. In some embodiments, bispecific antibodies that bind to two antigens, such as TNFR2 and a second cell surface receptor, can be produced by mutating amino acid residues outside the antigen binding site (Bostrom et al., Science 323: 1610-1614, 2009). Bifunctional antibodies can be prepared by expressing polynucleotides engineered to encode bispecific antibodies.
[0452] The modified agonistic TNFR2 antibodies and antibody fragments described herein can also be produced by chemical synthesis (e.g., by the methods described in Solid Phase Peptide Synthesis, 2nd Edition, 1984, Pierce Chemical Co., Rockford, 111; which is incorporated herein by reference). Variant antibodies can also be generated using a cell-free synthesis platform (see, e.g., Chu et al., Biochemia No. 2, 2001 (Roche Molecular Biologicals); which is incorporated herein by reference).
[0453] Host cells expressing agonistic TNFR2 polypeptides
[0454] The polypeptides described herein (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) can be expressed in prokaryotic or eukaryotic host cells. In some embodiments, expression of polypeptides (e.g., single-chain polypeptides, antibodies, or antigen-binding fragments thereof) is performed in eukaryotic (e.g., mammalian) host cells to optimally secrete properly folded and immunologically active antibodies. Exemplary mammalian host cells for expressing recombinant antibodies or antigen-binding fragments thereof described herein include Chinese hamster ovary (CHO cells) (including DHFR CHO cells, described in Urlaub and Chasin (1980, Proc. Natl. Acad. Sci. USA 77:4216-4220), used with a DHFR selection marker, e.g., described in Kaufman and Sharp (1982, Mol. Biol. 159: 601-621), NSO myeloma cells, COS cells, 293 cells and SP2 / 0 cells. Other cell types that can be used to express antibodies and fragments thereof include bacterial cells, such as BL-21 (DE3) Escherichia coli cells, which can be transformed with vectors containing exogenous DNA according to established protocols. Other eukaryotic cells that can be used to express antibodies include yeast cells, such as auxotrophic strains of Saccharomyces cerevisiae, which can be transformed according to established procedures known in the art and selectively grown in incomplete medium. When a recombinant expression vector encoding an antibody gene is introduced into a mammalian host cell, the antibody is produced by culturing the host cell for a period of time sufficient to achieve expression of the antibody in the host cell or secretion of the antibody into the medium in which the host cell is grown.
[0455] The polypeptide (e.g., single-chain polypeptide, antibody, antigen-binding fragment thereof, and construct thereof) can be recovered from the culture medium using standard protein purification methods. The host cells can also be used to produce a portion of a complete antibody, such as a Fab fragment or a scFv molecule. Also included herein are methods of modifying the above procedures according to established protocols known in the art. For example, it may be desirable to transfect host cells with DNA encoding the light chain or the heavy chain (but not both) of the agonist TNFR2 antibodies described herein to produce an antigen-binding fragment of the antibody.
[0456] After the agonist TNFR2 polypeptides described herein (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, or constructs thereof) are produced by recombinant expression, they can be purified by any method known in the art, such as methods that can be used to purify immunoglobulin molecules, for example, by chromatography (e.g., ion exchange, affinity, particularly by selecting for affinity to TNFR2 after protein A or protein G, and by column chromatography), centrifugation, differential solubility, or by any other standard technique for purifying proteins. In addition, the agonist TNFR2 polypeptides described herein or fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art to facilitate purification or to produce therapeutic conjugates.
[0457] Once separated, the proteins can be purified, if desired, for example, by high performance liquid chromatography (see, e.g., Fisher, Laboratory Techniques in Biochemistry and Molecular Biology (Work and Burdon, eds., Elsevier, 1980); which is incorporated herein by reference) or by gel filtration chromatography (such as on Superdex TM The agonistic TNFR2 single chain polypeptide, antibody, antigen-binding fragment thereof, or construct was further purified using a ELISA 75 column (Pharmacia Biotech AB, Uppsala, Sweden).
[0458] A platform for the generation and affinity maturation of agonistic TNFR2 peptides
[0459] Epitope mapping of TNFR2 that promotes receptor agonism
[0460] Agonistic TNFR2 polypeptides (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) described herein can be generated by screening libraries of polypeptides (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) for functional molecules that bind to epitopes within TNFR2 that selectively promote receptor agonism rather than inhibition of the receptor. Such epitopes can be modeled by screening antibodies or antigen-binding fragments thereof against a series of linear or cyclic peptides that contain residues corresponding to the desired epitope within TNFR2.
[0461] For example, peptides containing a single fragment isolated from TNFR2 that promotes receptor excitation can be synthesized by peptide synthesis techniques described herein or known in the art. These peptides can be immobilized on a solid surface and screened for molecules (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) that bind to agonistic TNFR2 polypeptides using an ELISA-based screening platform with established procedures. Using this assay, peptides that specifically bind, for example, to TNFRAG1 with high affinity, therefore contain residues within the epitope of TNFR2 that preferentially bind to these antibodies. Peptides identified in this manner can be used to screen polypeptide libraries (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) to identify agonistic TNFR2 polypeptides. Moreover, since these peptides act as surrogates for epitopes within TNFR2 that promote receptor excitation, polypeptides generated using this screening technique can bind to the corresponding epitope in TNFR2 and are expected to be agonistic to receptor activity.
[0462] Screening libraries for agonistic TNFR2 peptides
[0463] Methods for high-throughput screening of polypeptide (e.g., single-chain polypeptide, antibody, antibody fragment or construct thereof) libraries for molecules that can bind to an epitope in TNFR2 (e.g., amino acids 56-60, 101-107 and / or 115-142 of SEQ ID NO: 1) include, but are not limited to, display technologies, including phage display, bacterial display, yeast display, mammalian display, ribosome display, mRNA display and cDNA display. The use of phage display to isolate ligands that bind to biologically relevant molecules has been reviewed, for example, by Felici et al. (Biotechnol. Annual Rev. 1: 149-183, 1995), Katz (Annual Rev. Biophys. Biomol. Struct. 26: 27-45, 1997) and Hoogenboom et al. (Immunotechnology 4: 1-20, 1998). Several random combinatorial peptide libraries have been constructed to select polypeptides that bind to different targets (e.g., cell surface receptors or DNA) (reviewed in Kay (Perspect. Drug Discovery Des. 2, 251-268, 1995), Kay et al., (Mol. Divers. 1: 139-140, 1996)). Proteins and multimeric proteins have been successfully displayed as functional molecules by phage (see EP 0349578A, EP 4527839A, EP 0589877A; Chiswell and McCafferty (Trends Biotechnol. 10, 80-84 1992)). In addition, functional antibody fragments (e.g., Fab, single-chain Fv [scFv]) have been expressed (McCafferty et al. (Nature 348:552-554, 1990), Barbas et al. (Proc. Natl. Acad Sci. USA 88:7978-7982, 1991), Clackson et al. (Nature 352:624-628, 1991)). These references are hereby incorporated by reference in their entirety.
[0464] (i) Phage display technology
[0465] For example, phage display technology can be used to screen polypeptide libraries (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) to screen for functional molecules in polypeptide libraries (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) that can bind to cyclic or multicyclic peptides containing epitopes within TNFR2 that can promote receptor activation (e.g., amino acids 56-60, 101-107, and / or 115-142 of SEQ ID NO: 1). For example, a polynucleotide library encoding single-chain antibody fragments (e.g., scFv fragments) containing random hypervariable regions can be obtained using established procedures (e.g., solid phase polynucleotide synthesis or error-prone PCR technology, see McCullum et al. (Meth. Mol. Biol., 634: 103-109, 2010); which is incorporated herein by reference). These randomized polynucleotides can then be incorporated into the viral genome so that the randomized antibody chains encoded by these genes are expressed on the surface of filamentous phage, for example, by covalent bonds between the antibody chains and the coat protein (e.g., pIII coat protein on the surface of M13 phage). This provides a physical connection between the genotype and phenotype of the antibody chain. In this way, the external antibody chains in the phage library displaying diverse antibody chains containing random mutations in the hypervariable region can be screened for the ability to bind to TNFR2 epitopes (e.g., amino acids 56-60, 101-107 and / or 115-142 of SEQ ID NO: 1) fixed to the surface using established procedures. For example, by forming a covalent bond between the peptide and the epitope tag (e.g., biotin) and incubating the peptide in the wells of a microtiter plate (these microtiter plates have previously been coated with a complementary tag (e.g., avidin) that binds to the tag attached to the peptide with high affinity), such peptides can be physically bound to the surface of the microtiter plate. Suitable epitope tags include, but are not limited to, maltose binding protein, glutathione-S-transferase, polyhistidine tags, FLAG tags, myc tags, human influenza hemagglutinin (HA) tags, biotin, streptavidin. Peptides containing epitopes presented by these molecules can be immobilized on a surface comprising complementary molecules, such as maltose, glutathione, nickel-containing complexes, anti-FLAG antibodies, anti-myc antibodies, anti-HA antibodies, streptavidin or biotin, respectively. Thus, phage can be incubated with the surface containing the immobilized TNFR2-derived peptide for a suitable period of time and in the presence of an appropriate buffer system (e.g., a system containing physiological salt concentrations, ionic strengths and maintained at physiological pH by a buffer) to allow the antibodies to bind to the bound peptide. The surface can then be washed (e.g., with a phosphate buffer containing 0.1% Tween-20) to remove phage that do not have antibody chains that interact with the TNFR2-derived peptide with an affinity greater than a certain threshold.
[0466] The affinity of the polypeptide remaining after this initial panning (i.e., screening) step can be adjusted by adjusting the conditions of the washing step (e.g., by including weakly acidic or basic components, or by including other TNFR2-derived peptides at low concentrations to compete with the immobilized peptide for antigen binding sites). In this way, the population of phage that remains bound to the surface of the microtiter plate after the washing step is enriched for phage that binds to TNFR2-derived peptide epitopes that promote receptor activation. The remaining phage can then be amplified by eluting the phage from the surface containing these peptides (e.g., by changing the environmental pH, ionic strength, or temperature), thereby reducing the strength of protein-protein interactions. The isolated phage can then be amplified, for example, by infecting bacterial cells, and the resulting phage can optionally be panned by additional screening iterations to further enrich the population for those phage that have higher affinity for agonistic TNFR2 polypeptides. After these panning stages, phage that display high affinity antibodies or antigen-binding fragments thereof can then be isolated, and the genomes of these phage can be sequenced to identify the polynucleotide and polypeptide sequences of the encoded antibodies. Phage display techniques such as these can be used to produce, for example, antibody chains, such as scFv fragments, tandem scFv fragments, and other antigen-binding fragments described herein that can be used as TNFR2 agonists. Exemplary phage display protocols for identifying antibody chains and antigen-binding fragments thereof that bind to a specific antigen with high affinity have been widely established and described in, for example, U.S. Pat. No. 7,846,892, WO 1997 / 002342, U.S. Pat. No. 8,846,867, and WO 2007 / 132917; the disclosures of each of which are incorporated herein by reference. Similar phage display techniques can be used to produce antibody-like scaffolds described herein (e.g., 10 Fn3 domain), the antibody-like scaffold binds to an epitope within TNFR2 that promotes receptor activation (e.g., amino acids 56-60, 101-107, and / or 115-142 of SEQ ID NO: 1). Exemplary phage display protocols for identifying antibody-like scaffold proteins are described, for example, in WO 2009 / 086116; the disclosure of which is incorporated herein by reference).
[0467] (ii) Cell-based display technology
[0468] Other in vitro display technologies that utilize the connection between the genotype and phenotype of solvent-exposed polypeptides include yeast and bacterial display. Yeast display technology is established in the art and generally has advantages because a large number of antibodies (usually up to 30,000) can be presented on the surface of a single yeast cell (see, e.g., Boder et al. (Nat Biotechno. 15:553, 1997); which is incorporated herein by reference). Yeast cells of larger size on filamentous phages can implement another screening strategy because people can use flow cytometry to analyze and sort yeast libraries. For example, a library of bacterial cells or yeast cells can be produced using established procedures, and the bacterial cells or yeast cells express polypeptides (e.g., single-chain polypeptides, antibodies and antigen-binding fragments thereof) containing randomized hypervariable regions (see, e.g., U.S. Patent Nos. 7,749,501 and US2013 / 0085072; their teachings are each incorporated herein by reference). For example, a large library of yeast cells expressing polynucleotides encoding the original scFv fragments can be prepared using established procedures (de Bruin et al., Nat Biotechnol 17:397, 1999; which is incorporated herein by reference). The yeast cells expressing these polynucleotides can then be incubated with two different fluorescent molecules in the panning step: one dye binds to a conserved residue in the antibody, thereby reflecting the amount of antibody displayed, and the other dye fluoresces at a different wavelength and binds to the antigen, thus indicating the amount of antigen bound. For example, one skilled in the art can use a TNFR2-derived peptide containing amino acids 56-60, 101-107, and / or 115-142 of SEQ ID NO: 1 conjugated to an epitope tag (e.g., biotin), optionally at the N-terminus or C-terminus of the peptide or at residues that are not expected to interfere with antibody-antigen binding. This allows a fluorescent dye labeled with a complementary tag (e.g., avidin) to be localized to the antibody-antigen complex. This can provide great flexibility and immediate feedback on the progress of the selection. In contrast to phage display, by normalizing the antibody display level, antibodies with higher affinity rather than higher expression levels can be easily selected. In fact, antibodies with affinities that differ only by a factor of two can be distinguished and sorted (Van Antwerp and Wittrup (Biotechnol Prog 16:31, 2000)).
[0469] (iii) Nucleotide display technology
[0470] Display techniques utilizing in vitro translation of randomized polynucleotide libraries also provide a powerful method for generating agonistic TNFR2 polypeptides described herein. For example, random DNA libraries encoding polypeptides (e.g., single-chain polypeptides, antibodies, and antigen-binding fragments thereof) containing mutations within a specified hypervariable region can be obtained, for example, using established PCR-based mutagenesis techniques described herein. The polynucleotides of these libraries can contain transcription regulatory sequences, such as promoters and transcription termination sequences, and can additionally encode sequences that increase the translation rate of the resulting mRNA construct (e.g., IRES sequences, 5' and 3' UTRs, polyadenylation tracts, etc.). These polynucleotide libraries can be incubated in an appropriate buffer solution containing RNA polymerase and RNA nucleoside triphosphates (NTPs) to transcribe the DNA sequences into expressible mRNA molecules, which can then be translated by ribosomal subunits of varying sizes, aminoacyl tRNA molecules, and translation initiation and elongation factors present in the solution (e.g., using In vitro protein synthesis kit, New England Designed mRNA modifications can keep the antibody product covalently bound to the mRNA template via a chemical bond to puromycin (e.g., see Keefe (Curr. Protoc. Mol. Biol., Chapter 24, Unit 24.5 2001); which is incorporated herein by reference). Thus, this genotype-phenotype link can be used to select antibodies that bind to TNFR2-derived peptides by incubating the mRNA-antibody fusion construct with the peptide immobilized on a surface and panning in a manner similar to phage display technology (see, e.g., WO 2006 / 072773; which is incorporated herein by reference).
[0471] Optionally, the polypeptides described herein (e.g., single-chain polypeptides, antibodies, and antigen-binding fragments thereof) can be produced using similar techniques, except that the antibody product can be non-covalently bound to the ribosome-mRNA complex, rather than covalently bound via a puromycin linker. This platform, called ribosome display, has been described in, for example, U.S. Pat. No. 7,074,557; which is incorporated herein by reference. Alternatively, antibodies can be produced using cDNA display, which is a technique similar to mRNA display, except that the cDNA is covalently bound to the antibody product via a puromycin linker, rather than mRNA. cDNA display technology has the following advantages: the panning step can be performed under increasingly stringent conditions, for example, under conditions of adjusting salt concentration, ionic strength, pH, and / or ambient temperature, to screen for antibodies with particularly high affinity for TNFR2-derived peptides. This is due to the higher natural stability of double-stranded cDNA relative to single-stranded mRNA. cDNA display screening technology is described in, for example, Ueno et al. (Methods Mol. Biol., 805: 113-135, 2012); which is incorporated herein by reference.
[0472] In addition to generating the agonistic TNFR2 polypeptides described herein (e.g., single chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof), in vitro display techniques (e.g., those described herein and those known in the art) also provide methods for improving the affinity of the agonistic TNFR2 polypeptides described herein. For example, rather than screening libraries of antibodies and antigen-binding fragments thereof containing completely random hypervariable regions, one can screen narrower libraries of antibodies and antigen-binding fragments thereof that have targeted mutations at specific sites within the hypervariable regions. This can be accomplished, for example, by assembling libraries of polynucleotides encoding antibodies or antigen-binding fragments thereof that encode random mutations only at specific sites within the hypervariable regions. These polynucleotides can then be expressed using, for example, ribosome display, mRNA display, or cDNA display technology in, for example, filamentous phage, bacterial cells, yeast cells, mammalian cells, or in vitro to screen for antibodies or antigen-binding fragments thereof that specifically bind to TNFR2 epitopes with improved binding affinity. For example, yeast display is well suited for affinity maturation and has been previously used to increase the affinity of single chain antibodies to K. D is 48 fM (Boder et al. (Proc Natl Acad Sci USA 97:10701, 2000)).
[0473] Other in vitro techniques that can be used for the generation and affinity maturation of agonistic TNFR2 polypeptides (e.g., single-chain polypeptides, antibodies, and antigen-binding fragments thereof) described herein include screening combinatorial libraries of antibodies or antigen-binding fragments thereof for functional molecules that are capable of specifically binding to TNFR2-derived peptides. Combinatorial antibody libraries can be obtained, for example, by expressing polynucleotides encoding randomized hypervariable regions of antibodies or antigen-binding fragments thereof in eukaryotic or prokaryotic cells. This can be achieved, for example, using gene expression techniques described herein or known in the art. Heterogeneous mixtures of antibodies can be purified, for example, by protein A or protein G selection, sizing column chromatography, centrifugation, differential solubility, and / or by any other standard technique for protein purification. Libraries of combinatorial libraries thus obtained can be screened, for example, by incubating heterogeneous mixtures of these antibodies with peptides derived from TNFR2 that have been immobilized on a surface for a period of time sufficient to allow antibody-antigen binding. Unbound antibodies or fragments thereof are removed by washing the surface with an appropriate buffer (e.g., a solution buffered at physiological pH (about 7.4) and containing physiological salt concentration and ionic strength, and optionally containing a detergent such as TWEEN-20). Antibodies that remain bound can then be detected, for example, using an ELISA-based detection scheme (see, e.g., U.S. Pat. No. 4,661,445; the disclosure of which is incorporated herein by reference).
[0474] Additional techniques for screening combinatorial libraries of polypeptides (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) for those polypeptides that specifically bind to TNFR2-derived peptides include screening of one-bead-one-compound libraries of antibody fragments. Antibody fragments can be chemically synthesized on solid beads composed of hydrophilic, water-swellable materials (e.g., using established split-polymerization solid-phase peptide synthesis protocols) such that each bead displays a single antibody fragment. The heterogeneous bead mixture can then be incubated with the TNFR2-derived peptide, which is optionally labeled with a detectable moiety (e.g., a fluorescent dye) or conjugated to an epitope tag (e.g., biotin, avidin, FLAG tag, HA tag), and subsequently detected by treatment with a complementary tag (e.g., avidin, biotin, anti-FLAG antibody, anti-HA antibody). Beads containing antibody fragments that specifically bind to TNFR2-derived peptides can be identified by analyzing the fluorescence properties of the beads after incubation with fluorescently labeled antigen or complementary tags (e.g., by confocal fluorescence microscopy or by fluorescence-activated bead sorting; see, e.g., Muller et al. (J. Biol. Chem., 16500-16505, 1996); which is incorporated herein by reference). Thus, beads containing antibody fragments that specifically bind to TNFR2-derived peptides can be separated from those beads that do not contain high-affinity antibody fragments. The sequence of the antibody fragment that specifically binds to TNFR2-derived peptides can be determined by techniques known in the art, including, for example, Edman degradation, tandem mass spectrometry, matrix-assisted laser desorption time-of-flight mass spectrometry (MALDI-TOF MS), nuclear magnetic resonance (NMR), and 2D gel electrophoresis, among others (see, e.g., WO 2004 / 062553; the disclosures of each of which are incorporated herein by reference).
[0475] Negative screening of peptides
[0476] In addition to the above methods for screening single-chain polypeptides, antibodies or antibody fragments that specifically bind to an epitope derived from human TNFR2 that promotes receptor activation, the method can also perform negative screening to eliminate antibodies or antibody fragments that can also bind to an epitope that promotes receptor antagonism (such as the KCRPG sequence). This can be achieved using any of the above methods or variants thereof, for example, such that the antibodies or antibody fragments screened are those that have been previously identified as having agonistic TNFR2 activity. Exemplary techniques for negative screening include those described above or known in the art, such as phage display, yeast display, bacterial display, ribosome display, mRNA display, cDNA display, or surface-based combinatorial library screening (e.g., in an ELISA format). This screening technique represents a useful strategy for identifying agonistic TNFR2 antibodies or antibody fragments, because antibodies or antibody fragments that are able to bind to a TNFR2 epitope containing the KCRPG sequence lack or significantly reduce agonistic activity.
[0477] Immunization of non-human mammals
[0478] Another strategy that can be used to generate the agonistic TNFR2 antibodies and antigen-binding fragments thereof described herein includes immunizing non-human mammals. Examples of non-human mammals that can be immunized to generate the agonistic TNFR2 antibodies and fragments thereof described herein include rabbits, mice, rats, goats, guinea pigs, hamsters, horses, and sheep, as well as non-human primates. For example, established procedures for immunizing primates are known in the art (see, e.g., WO 1986 / 6004782; which is incorporated herein by reference). Immunization represents a reliable method for generating monoclonal antibodies by exploiting the antigen specificity of B lymphocytes. For example, monoclonal antibodies can be prepared by the Kohler-Millstein method (e.g., described in EP 0110716; which is incorporated herein by reference), wherein spleen cells from non-human animals (e.g., primates) are immunized with antigenic peptides derived from TNFR2 that promote receptor activation. The clonally expanded B lymphocytes generated by immunization can be isolated from the animal serum and then fused with myeloma cells to form hybridomas. Hybridomas are particularly useful agents for producing antibodies because these immortalized cells can provide persistent antigen-specific antibodies. Antibodies from such hybridomas can then be isolated using techniques known in the art, for example, by purifying the antibodies from the cell culture medium by affinity chromatography using reagents such as protein A or protein G.
[0479] Agonist TNFR2 Peptide Conjugate
[0480] Prior to administering an agonist TNFR2 polypeptide (e.g., single-chain polypeptide, antibody, and antigen-binding fragment thereof) described herein to a mammalian subject (e.g., a human), it may be desirable to conjugate the antibody or fragment thereof to a second molecule, e.g., to modulate the in vivo activity of the antibody. Agonist TNFR2 antibodies and fragments thereof may be conjugated to other molecules at the N-terminus or C-terminus of the light or heavy chain of the antibody using any of a variety of established conjugation strategies well known in the art. Examples of pairs of reactive functional groups that can be used to covalently link an agonist TNFR2 antibody or fragment thereof to another molecule include, but are not limited to, thiol pairs, carboxylic acids and amino groups, ketones and amino groups, aldehydes and amino groups, thiols and α,β-unsaturated moieties (such as maleimide or dehydroalanine), thiols and α-haloamides, carboxylic acids and hydrazides, aldehydes and hydrazides, and ketones and hydrazides.
[0481] Agonistic TNFR2 polypeptides (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) can be directly covalently attached to another molecule by chemical conjugation as described. Alternatively, fusion proteins containing agonistic TNFR2 antibodies and fragments thereof can be recombinantly expressed from cells (e.g., eukaryotic cells or prokaryotic cells). For example, this can be achieved by incorporating a polynucleotide encoding the fusion protein into the nuclear genome of the cell (e.g., using techniques described herein or known in the art). Optionally, the antibodies and fragments thereof described herein can be linked to a second molecule by forming a covalent bond between the antibody and a linker. The linker can then be conjugated to another molecule, or the linker can be conjugated to another molecule prior to being linked to the agonistic TNFR2 antibody or fragment thereof. Examples of linkers that can be used to form conjugates include polypeptide linkers, such as those containing naturally occurring or non-naturally occurring amino acids. In some embodiments, it may be desirable to include D-amino acids in the linker because these residues are not present in naturally occurring proteins and are therefore more resistant to degradation by endogenous proteases. Fusion proteins containing polypeptide joints can be prepared using chemical synthesis techniques, such as those described herein, or by recombinantly expressing polynucleotides encoding fusion proteins in cells (e.g., prokaryotic or eukaryotic cells). Joints can be prepared using a variety of strategies well known in the art, and depending on the reactive components of the joint, can be cleaved by enzymatic hydrolysis, photolysis, hydrolysis under acidic conditions, hydrolysis under alkaline conditions, oxidation, disulfide reduction, nucleophilic cleavage, or organometallic cleavage (Leriche et al., Bioorg. Med. Chem., 20: 571-582, 2012).
[0482] Drug peptide conjugates
[0483] The agonist TNFR2 polypeptides described herein (e.g., single-chain polypeptides, antibodies, and antigen-binding fragments thereof) can be additionally conjugated, mixed, or administered separately with a therapeutic agent, such as an agent for treating autoimmunity and / or inflammation. Exemplary agents that can be conjugated, mixed, or administered separately with the agonist TNFR2 polypeptides described herein include Bacillus Calmette-Guérin (BCG). Additional agents that can be conjugated, mixed, or administered separately with the agonist TNFR2 polypeptides described herein include nonsteroidal anti-inflammatory drugs (NSAIDs), such as (i) salicylic acid derivatives, including acetylsalicylic acid (aspirin), diflunisal, and sulfasalazine, (ii) para-aminophenol derivatives, including acetaminophen, (iii) fenamates, including mefenamic acid, meclofenamate, and flufenamic acid, (iv) propionic acid derivatives, including ibuprofen, naproxen, fenoprofen, ketoprofen, flurbiprofen, and oxaprozin, and (v) enoic acid (oxicam) derivatives, including piroxicam and tenoxicam. Additional agents that can be conjugated, mixed, or administered separately with the agonist TNFR2 polypeptides described herein include glucocorticoids. The agonist TNFR2 polypeptides described herein can be additionally or alternatively conjugated, mixed, or administered separately with disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, leflunomide, gold compounds, sulfasalazine, azathioprine, cyclophosphamide, antimalarials, D-penicillamine, and cyclosporin. Additional agents that can be conjugated, mixed, or administered separately with the agonist TNFR2 polypeptides described herein include infliximab, etanercept, adalimumab, golimumab, and pecillimumab polyethylene glycol, among others. For example, additional agents that can be conjugated, mixed, or administered separately with the agonist TNFR2 polypeptides of the present disclosure are described in, for example, Li et al., Front. Pharmacol. 8:460, 2017, the disclosure of which is incorporated herein by reference in its entirety.
[0484] In some embodiments, the agonist TNFR2 polypeptides described herein are conjugated, admixed, or administered separately with an immunotherapeutic agent, such as an anti-CTLA-4 agonist, an anti-PD-1 agonist, an anti-PD-L1 agonist, an anti-PD-L2 agonist, an anti-CD27 agonist, an anti-CD30 agonist, an anti-CD40 agonist, an anti-4-1BB agonist, an anti-GITR agonist, an anti-OX40 agonist, an anti-TRAILR1 agonist, an anti-TRAILR2 agonist, an anti-TWEAK agonist, an anti-TWEAKR agonist, an anti-cell surface lymphocyte protein agonist, an anti-BRAF agonist, an anti-MEK agonist, an anti-CD33 agonist, an anti-CD20 agonist, an anti-HLA-DR agonist, an anti-HLA class I agonist, an anti-CD52 agonist, an anti-A33 agonist, an anti-GD3 agonist, an anti-PSMA agonist, an anti-Ceacan 1 agonist, an anti-Galedin 9 agonist, an anti-HVEM agonist, an anti-VISTA agonist, an anti-B7 H4 agonist, anti-HHLA2 agonist, anti-CD155 agonist, anti-CD80 agonist, anti-BTLA agonist, anti-CD160 agonist, anti-CD28 agonist, anti-CD226 agonist, anti-CEACAM1 agonist, anti-TIM3 agonist, anti-TIGIT agonist, anti-CD96 agonist, anti-CD70 agonist, anti-CD27 agonist, anti-LIGHT agonist, anti-CD137 agonist, anti-DR4 agonist, anti-CR5 agonist, anti-TNFRS agonist, anti-TNFR1 agonist, anti-FAS agonist, anti-CD95 agonist, anti-TRAIL agonist, anti-DR6 agonist, anti-EDAR agonist, anti-NGFR agonist, anti-OPG agonist, anti-RANKL agonist, anti-LTβ receptor agonist, anti-BCMA agonist, anti-TACI agonist, anti-BAFFR agonist, anti-EDAR2 agonist, anti-TROY agonist and anti-RELT agonist. For example, the immunotherapeutic agent can be an anti-CTLA-4 agonist, an anti-PD-1 agonist, or an anti-PD-L1 agonist.
[0485] In some embodiments, the immunotherapeutic agent is selected from the group consisting of an agonist anti-CTLA-4 antibody or antigen-binding fragment thereof, an agonist anti-PD-1 antibody or antigen-binding fragment thereof, an agonist anti-PD-L1 antibody or antigen-binding fragment thereof, an agonist anti-PD-L2 antibody or antigen-binding fragment thereof, an agonist anti-CD27 antibody or antigen-binding fragment thereof, an agonist anti-CD30 antibody or antigen-binding fragment thereof, an agonist anti-CD40 antibody or antigen-binding fragment thereof, an agonist anti-4-1BB antibody or antigen-binding fragment thereof, an agonist anti-GITR antibody or antigen-binding fragment thereof, an agonist anti-OX40 antibody or antigen-binding fragment thereof. The invention further comprises an antigen-binding fragment thereof, an agonist anti-TRAILR1 antibody or an antigen-binding fragment thereof, an agonist anti-TRAILR2 antibody or an antigen-binding fragment thereof, an agonist anti-TWEAK antibody or an antigen-binding fragment thereof, an agonist anti-TWEAKR antibody or an antigen-binding fragment thereof, an agonist anti-cell surface lymphocyte protein antibody or an antigen-binding fragment thereof, an agonist anti-BRAF antibody or an antigen-binding fragment thereof, an agonist anti-MEK antibody or an antigen-binding fragment thereof, an agonist anti-CD33 antibody or an antigen-binding fragment thereof, an agonist anti-CD20 antibody or an antigen-binding fragment thereof, an agonist anti-HLA-DR antibody or an antigen-binding fragment thereof, an agonist anti-HLA class I antibody or an antigen-binding fragment thereof, an agonist anti-CD52 antibody or an antigen-binding fragment thereof, an agonist anti-A33 antibody or an antigen-binding fragment thereof, an agonist anti-GD3 antibody or an antigen-binding fragment thereof, an agonist anti-PSMA antibody or an antigen-binding fragment thereof, an agonist anti-Ceacan 1 antibody or an antigen-binding fragment thereof, an agonist anti-Galedin 9 antibody or an antigen-binding fragment thereof, an agonist anti-HVEM antibody or an antigen-binding fragment thereof, an agonist anti-VISTA antibody or an antigen-binding fragment thereof, an agonist anti-B7H4 antibody or antigen-binding fragment thereof, agonist anti-HHLA2 antibody or antigen-binding fragment thereof, agonist anti-CD155 antibody or antigen-binding fragment thereof, agonist anti-CD80 antibody or antigen-binding fragment thereof, agonist anti-BTLA antibody or antigen-binding fragment thereof, agonist anti-CD160 antibody or antigen-binding fragment thereof, agonist anti-CD28 antibody or antigen-binding fragment thereof, agonist anti-CD226 antibody or antigen-binding fragment thereof, agonist anti-CEACAM1 antibody or antigen-binding fragment thereof, agonist anti-TIM3 antibody or antigen-binding fragment thereof, agonist anti-TIGIT antibody or antigen-binding fragment thereof, agonist anti-CD96 antibody or antigen-binding fragment thereof, agonist anti-CD70 antibody or antigen-binding fragment thereof, agonist anti-CD27 antibody or antigen-binding fragment thereof, agonist anti-LIGHT antibody or antigen-binding fragment thereof, agonist anti-CD137 antibody or antigen-binding fragment thereof, agonist anti-DR4 antibody or antigen-binding fragment thereof, agonist anti-CR5 antibody or antigen-binding fragment thereof and antigen-binding fragments thereof, agonist anti-TNFRS antibodies or antigen-binding fragments thereof, agonist anti-TNFR1 antibodies or antigen-binding fragments thereof, agonist anti-FAS antibodies or antigen-binding fragments thereof, agonist anti-CD95 antibodies or antigen-binding fragments thereof, agonist anti-TRAIL antibodies or antigen-binding fragments thereof, agonist anti-DR6 antibodies or antigen-binding fragments thereof, agonist anti-EDAR antibodies or antigen-binding fragments thereof, agonist anti-NGFR antibodies or antigen-binding fragments thereof, agonist anti-OPG antibodies or antigen-binding fragments thereof, agonist anti-RANKL antibodies or antigen-binding fragments thereof, agonist anti-LTβ receptor antibodies or antigen-binding fragments thereof, agonist anti-BCMA antibodies or antigen-binding fragments thereof, agonist anti-TACI antibodies or antigen-binding fragments thereof, agonist anti-BAFFR antibodies or antigen-binding fragments thereof, agonist anti-EDAR2 antibodies or antigen-binding fragments thereof, agonist anti-TROY antibodies or antigen-binding fragments thereof, and agonist anti-RELT antibodies or antigen-binding fragments thereof. For example, the immunotherapeutic agent can be an agonistic anti-CTLA-4 antibody or an antigen-binding fragment thereof, an agonistic anti-PD-1 antibody or an antigen-binding fragment thereof, or an agonistic anti-PD-L1 antibody or an antigen-binding fragment thereof.
[0486] In some embodiments, the immunotherapeutic agent is an agonistic anti-cell surface lymphocyte protein antibody or antigen-binding fragment thereof, such as an antibody or antigen-binding fragment thereof that binds to and promotes the activity of one or more of the following: CD1, CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD9, CD10, CD11, CD12, CD13, CD14, CD15, CD16, CD17, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32, CD33, CD34, CD35, CD36, CD37, CD38, CD39, CD40, CD41, CD42, CD43, CD44, CD45, CD46, CD47, CD48, CD49, CD50, CD51, CD52, CD53, CD54, CD55, CD56, CD57, CD58, CD59, CD60, CD61, CD62, CD63, CD64, CD65 8. CD39, CD40, CD41, CD42, CD43, CD44, CD45, CD46, CD47, CD48, CD49, CD50, CD51, CD52, CD53, CD54, CD55, CD56, CD57, CD58, CD59, CD60, CD61, CD62, CD6 3. CD64, CD65, CD66, CD67, CD68, CD69, CD70, CD71, CD72, CD73, CD74, CD75, CD76, CD77, CD78, CD79, CD80, CD81, CD82, CD83, CD84, CD85, CD86, CD87, CD8 8. CD89, CD90, CD91, CD92, CD93, CD94, CD95, CD96, CD97, CD98, CD99, CD100, CD101, CD102, CD103, CD104, CD105, CD106, CD107, CD108, CD109, CD110, CD C D132, CD133, CD134, CD135, CD136, CD137, CD138, CD139, CD140, CD141, CD142, CD143, CD144, CD145, CD146, CD147, CD148, CD149, CD150, CD151, CD152, CD153, CD154, CD155, CD156, CD157, CD158, CD159, CD160, CD161, CD162, CD163, CD164, CD165, CD166, CD167, CD168, CD169, CD170, CD171, CD172, CD173,CD174, CD175, CD176, CD177, CD178, CD179, CD180, CD181, CD182, CD183, CD184, CD185, CD186, CD187, CD188, CD189, CD190, CD191, CD192, CD193, CD194, CD195, CD196, CD197, CD198, CD199, CD200, CD201, CD202, CD203, CD204, CD205, CD206, CD207, CD208, CD209, CD210, CD211, CD212, CD213, CD214, CD215, CD216, CD217, CD218, CD219, CD220, CD221, CD222, CD223, CD224, CD225, CD226, CD227, CD228, CD229, CD230, CD231, CD232, CD233, CD234, CD235, CD236, CD237, CD238, CD239, CD240, CD241, CD242, CD243, CD244, CD245, CD246, CD247, CD248, CD249, CD250, CD251, CD252, CD253, CD254, CD255, CD256, CD257, CD258, CD259, CD260, CD261, CD262, CD263, CD264, CD265, CD266, CD267, CD268, CD269, CD270, CD271, CD272, CD273, CD274, CD275, CD276, CD277, CD278, CD279, CD280, CD281, CD282, CD283, CD284, CD285, CD286, CD287, CD288, CD289, CD290, CD291, CD292, CD293, CD294, CD295, CD296, CD297, CD298, CD299, CD300, CD301, CD302, CD303, CD304, CD305, CD306, CD307, CD308, CD309, CD310, CD311, CD312, CD313, CD314, CD315, CD316, CD317, CD318, CD319 and / or CD320.
[0487] In some embodiments, the immunotherapeutic agent is an agent that binds to a chemokine or lymphokine (e.g., a polypeptide, an antibody, an antigen binding fragment thereof, a single-chain polypeptide, or a construct thereof). For example, the immunotherapeutic agent may be an agent that binds to and activates one or more or all of CXCL1, CXCL2, CXCL3, CXCL8, CCL2, and CCL5 (e.g., a polypeptide, an antibody, an antigen binding fragment thereof, a single-chain polypeptide, or a construct thereof). In some embodiments, the immunotherapeutic agent may be an agent that binds to and activates one or more or all of CCL3, CCL4, CCL8, and CCL22 (e.g., a polypeptide, an antibody, an antigen binding fragment thereof, a single-chain polypeptide, or a construct thereof).
[0488] Labeled TNFR2 peptide
[0489] In some embodiments, the agonist TNFR2 single-chain polypeptide, antibody, antigen-binding fragment thereof, or construct described herein is conjugated to another molecule (e.g., an epitope tag) for the purpose of purification or detection. Examples of such molecules useful in protein purification include those that present a structural epitope that can be recognized by a second molecule. This is a common strategy for purifying proteins by affinity chromatography, in which a molecule is immobilized on a solid support and exposed to a heterogeneous mixture containing a target protein conjugated to a molecule that can bind to the immobilized compound. For the purpose of molecular recognition, examples of epitope tag molecules that can be conjugated to agonist TNFR2 polypeptides include, but are not limited to, maltose binding protein, glutathione-S-transferase, polyhistidine tags, FLAG tags, myc tags, human influenza hemagglutinin (HA) tags, biotin, streptavidin. Conjugates containing epitopes presented by these molecules can be recognized by complementary molecules such as maltose, glutathione, nickel-containing complexes, anti-FLAG antibodies, anti-myc antibodies, anti-HA antibodies, streptavidin, or biotin, respectively. For example, one can purify an agonist TNFR2 antibody or fragment thereof described herein that has been conjugated to an epitope tag from a complex mixture of other proteins and biomolecules (e.g., DNA, RNA, carbohydrates, phospholipids, etc.) by treating the mixture with a solid phase resin containing a complementary molecule that can selectively recognize and bind to the epitope tag of the agonist TNFR2 antibody or fragment thereof. Examples of solid phase resins include agarose beads, which are compatible with purification in aqueous solutions.
[0490] The agonist TNFR2 polypeptides described herein can also be covalently attached to fluorescent molecules, e.g., to detect the antibody or antigen-binding fragment thereof by fluorometry and / or by direct observation using a fluorescent microscope. Exemplary fluorescent molecules that can be conjugated to the antibodies described herein include green fluorescent protein, cyan fluorescent protein, yellow fluorescent protein, red fluorescent protein, phycoerythrin, allophycocyanin, hoechst, 4',6-diamidino-2-phenylindole (DAPI), propidium iodide, fluorescein, coumarin, rhodamine, tetramethylrhodamine, and cyanine. Additional examples of fluorescent molecules suitable for conjugation to the antibodies described herein are well known in the art and are described in detail in, e.g., U.S. Patent Nos. 7,417,131 and 7,413,874, each of which is incorporated herein by reference.
[0491] Agonistic TNFR2 polypeptides containing fluorescent molecules are particularly useful for monitoring the cell surface localization properties of the antibodies and fragments thereof described herein. For example, cultured mammalian cells (e.g., Treg cells) can be exposed to an agonistic TNFR2 polypeptide described herein that has been covalently conjugated to a fluorescent molecule and then analyzed using conventional fluorescence microscopy techniques known in the art. Confocal fluorescence microscopy is a particularly effective method for determining the localization of agonistic TNFR2 polypeptides on the cell surface because each plane of the cell can be analyzed to distinguish antibodies or fragments thereof that have been internalized into the interior of the cell by receptor-mediated endocytosis (e.g., by receptor-mediated internalization) from antibodies or fragments thereof that are bound to the outer surface of the cell membrane. In addition, cells can be treated with an agonistic TNFR2 antibody conjugated to a fluorescent molecule that emits visible light at a specific wavelength (e.g., fluorescein that fluoresces at about 535 nm) and another fluorescent molecule that is known to be located at a specific site on the surface of a Treg cell and fluoresces at a different wavelength (e.g., a molecule that localizes to CD25 and fluoresces at about 599 nm). The resulting emission pattern can be observed by confocal fluorescence microscopy, and the images from the two wavelengths can be merged to reveal information about the location of the agonistic TNFR2 antibody or antigen-binding fragment thereof on the surface of Treg cells relative to other receptors.
[0492] Bioluminescent proteins can also be incorporated into fusion proteins for the detection and visualization of agonistic TNFR2 polypeptides, such as single-chain polypeptides, antibodies, or fragments thereof. Bioluminescent proteins, such as luciferase and aequorin, emit light in a chemical reaction with a substrate (e.g., luciferin and coelenterazine). Exemplary bioluminescent proteins suitable for use as diagnostic sequences and methods of use thereof are described in, for example, U.S. Pat. Nos. 5,292,658, 5,670,356, 6,171,809, and 7,183,092, each of which is incorporated herein by reference. Agonistic TNFR2 antibodies or fragments thereof labeled with bioluminescent proteins are useful tools for detecting the antibodies described herein following in vitro assays. For example, the presence of an agonistic TNFR2 antibody that has been conjugated to a bioluminescent protein can be detected in a complex mixture of additional proteins by separating the components of the mixture using gel electrophoresis methods known in the art (e.g., native gel analysis), followed by transferring the separated proteins to a membrane for Western blotting. Agonistic TNFR2 polypeptides can be detected in a mixture of other proteins by treating the membrane with an appropriate luciferase substrate and then visualizing the mixture of proteins on the membrane using established protocols.
[0493] The polypeptides described herein (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) can also be conjugated to molecules containing radionuclides, so that the antibodies or fragments thereof described herein can be detected by analyzing the radioactive emission pattern of the nucleus. Alternatively, the agonist TNFR2 antibody or fragment thereof can be directly modified by incorporating the radionuclides into the antibody during the preparation of the protein. Methionine ( 35 S), nitrogen ( 15 N) or carbon ( 13 C) can be incorporated into the antibodies or fragments thereof described herein by, for example, culturing bacteria in a medium supplemented with nutrients containing these isotopes. Optionally, tyrosine derivatives containing radioactive halogens can be incorporated into the agonist TNFR2 polypeptide by, for example, culturing bacterial cells in a medium supplemented with radiolabeled tyrosine. Tyrosine functionalized with a radioactive halogen at the C2 position of the phenol system has been shown to be rapidly incorporated into growing polypeptide chains in vivo using endogenous translation enzymes (U.S. Pat. No. 4,925,651; which is incorporated herein by reference). Halogens include fluorine, chlorine, bromine, iodine, and astatine. In addition, following isolation and purification from cell culture, the agonist TNFR2 polypeptides described herein can be modified by functionalizing the polypeptides with radioactive isotopes. Halogens represent a class of isotopes that can be readily incorporated into purified proteins by aromatic substitution on tyrosine or tryptophan, for example, by reaction of one or more of these residues with an electrophilic halogen species. Examples of radioactive halogen isotopes include 18 F. 75 Br,77 Br, 122 I. 123 I. 124 I. 125 I. 129 I. 131 I or 211 At.
[0494] Another alternative strategy for incorporating radioisotopes is to covalently attach a chelating group to an agonistic TNFR2 polypeptide, such as a single-chain polypeptide, antibody, fragment thereof, or construct. The chelating group can be covalently attached to an agonistic TNFR2 antibody or fragment thereof by attachment to a reactive functional group such as a thiol, amino group, alcohol, or carboxylic acid. The chelating group can then be modified to contain any of a variety of metallic radioisotopes, including but not limited to, 125 I. 67 Ga, 111 In, 99 Tc, 169 Yb, 186 Re, 123 I. 124 I. 125 I. 131 I. 99m Tc, 111 In, 64 Cu, 67 Cu, 186 Re, 188 Re, 177 Lu, 90 Y. 77 As, 72 As, 86 Y. 89 Zr, 211 At 212 Bi, 213 Bior 225 Ac and other radionuclides.
[0495] In some embodiments, it may be desirable to covalently conjugate a polypeptide described herein (e.g., a single-chain polypeptide, an antibody, a fragment thereof, or a construct thereof) to a chelating group capable of binding metal ions from heavy elements or rare earth ions, such as Gd 3+ , Fe 3 + , Mn 3+ or Cr 2+Conjugates containing chelate groups that coordinate to such paramagnetic metals can be used in MRI imaging applications. Paramagnetic metals include, but are not limited to, chromium (III), manganese (II), iron (II), iron (III), cobalt (II), nickel (II), copper (II), praseodymium (III), neodymium (III), samarium (III), gadolinium (III), terbium (III), dysprosium (III), holmium (III), erbium (III), and ytterbium (III). In this manner, agonistic TNFR2 polypeptides can be detected by MRI spectroscopy. For example, an agonistic TNFR2 antibody or fragment thereof conjugated to a chelate group that binds to a paramagnetic ion can be administered to a mammalian subject (e.g., a human patient) to monitor the distribution of the antibody after administration. This can be achieved by administering the antibody to the patient by any of the routes of administration described herein, such as intravenous administration, and then analyzing the location of the administered antibody by recording an MRI of the patient according to an established protocol.
[0496] Agonistic TNFR2 polypeptides (e.g., single-chain polypeptides, antibodies, antigen-binding fragments thereof, and constructs thereof) can be conjugated to other molecules to improve the solubility and stability of the protein in aqueous solution. Examples of such molecules include PEG, PSA, bovine serum albumin (BSA), and human serum albumin (HSA), among others. For example, an agonistic TNFR2 polypeptide can be conjugated to a carbohydrate moiety to evade detection of the antibody or its fragment by the immune system of the patient being treated. This process of hyperglycosylation reduces the immunogenicity of the therapeutic protein by sterically inhibiting the interaction of the protein with the B cell receptor. Alternatively, an agonistic TNFR2 antibody or fragment thereof can be conjugated to a molecule that prevents clearance from human serum and improves the pharmacokinetic characteristics of the antibodies described herein. Exemplary molecules that can be conjugated or inserted into the TNFR2 antibodies or fragments thereof described herein to attenuate clearance and improve the pharmacokinetic characteristics of these antibodies and fragments include salvage receptor binding epitopes. These epitopes are found within the Fc region of IgG immunoglobulins and have been shown to bind to Fc receptors and extend the half-life of antibodies in human serum. Insertion of a salvage receptor binding epitope into a TNFR2 antibody or fragment thereof can be accomplished, for example, as described in US Pat. No. 5,739,277; which is incorpo...
Claims
1. An antibody or antigen-binding fragment thereof that specifically binds to human tumor necrosis factor receptor 2 (TNFR2) at an epitope defined by one or more amino acids within cysteine-rich domain (CRD) 1 (CRD1), CRD2 and / or CRD3 and does not specifically bind to human TNFR2 at an epitope defined by one or more amino acids within CRD4, wherein the antibody or antigen-binding fragment thereof comprises the following complementarity determining regions (CDRs): (a) CDR-heavy chain 1 (CDR-H1) consisting of the amino acid sequence of GYTFTDYNI (SEQ ID NO: 3) or GYTFTDYNL (SEQ ID NO: 4); (b) CDR-H2, which consists of the amino acid sequence INPNYDST (SEQ ID NO: 10); (c) CDR-H3, which consists of the amino acid sequence CARGNSWYFDV (SEQ ID NO: 11); (d) CDR-L1, which consists of the amino acid sequence SSVRY (SEQ ID NO: 12); (e) CDR-L2, which consists of the amino acid sequence LTS; and (f) CDR-L3, which consists of the amino acid sequence CQQWSSNPLT (SEQ ID NO: 13).
2. The antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment thereof comprises a human IgG1 or IgG2 heavy chain constant 1 (CH1) domain comprising a deletion or substitution at cysteine residue 127.
3. The antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment thereof comprises distance to the antigen binding site.
4. The antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment thereof comprises a framework region having: JDJSJJJX 1 YX 2 X 3 LqCy 4 LJS (SEQ ID NO: 5) or an amino acid sequence of 10 or more residues of SEQ ID NO: 5, wherein each J is independently a naturally occurring amino acid; each X 1 independently A, V or F; each X 2 independently M or I; each X 3 is independently E or Q; and each X 4 are independently S or R. 5 . The antibody or antigen-binding fragment thereof according to claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a human IgG1 or IgG2 CH1 domain comprising a deletion or substitution at cysteine residue 127.
6. The antibody or antigen-binding fragment thereof according to claim 1, wherein the CH1 domain comprises a C127S mutation. 7 . The antibody or antigen-binding fragment thereof according to claim 2 , wherein the IgG1 CH1 domain has an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:
6. 8 . The antibody or antigen-binding fragment thereof according to claim 7 , wherein the IgG1 CH1 domain has an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:
6. 9 . The antibody or antigen-binding fragment thereof according to claim 8 , wherein the IgG1 CH1 domain has an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:
6. 10 . The antibody or antigen-binding fragment thereof according to claim 2 , wherein the IgG1 CH1 domain has the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO:
7. 11 . The antibody or antigen-binding fragment thereof according to claim 2 , wherein the IgG2 CH1 domain has an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:
8. 12 . The antibody or antigen-binding fragment thereof according to claim 11 , wherein the IgG2 CH1 domain has an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:
8. 13 . The antibody or antigen-binding fragment thereof according to claim 12 , wherein the IgG2 CH1 domain has an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:
8. 14 . The antibody or antigen-binding fragment thereof according to claim 2 , wherein the IgG2 CH1 domain has the amino acid sequence of SEQ ID NO: 8 or SEQ ID NO:
9.
15. The antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment thereof has an IgG3 or IgG4 isotype.
16. The antibody or antigen-binding fragment thereof of claim 3, wherein the antigen-binding sites are spaced to distance.
17. The antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment thereof has an IgG1 isotype.
18. The antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment thereof has an IgG3 isotype.
19. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof specifically binds to human TNFR2 at an epitope defined by one or more amino acids within CRD1.
20. The antibody or antigen-binding fragment thereof of claim 19, wherein the epitope is defined by one or more of amino acid residues 56-60 (KCSPG) of SEQ ID NO:
1.
21. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof specifically binds human TNFR2 at an epitope defined by one or more amino acids within CRD2.
22. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof specifically binds human TNFR2 at an epitope defined by one or more amino acids within CRD3.
23. The antibody or antigen-binding fragment thereof of claim 1, wherein the CDR-H1 has the amino acid sequence GYTFTDYNI (SEQ ID NO: 3).
24. The antibody or antigen-binding fragment thereof of claim 1, wherein the CDR-H1 has the amino acid sequence GYTFTDYNL (SEQ ID NO: 4).
25. The antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable domain (V H ) having an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO:
14. H ).
26. The antibody or antigen-binding fragment thereof according to claim 25, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable domain (V H ) having an amino acid sequence of SEQ ID NO:
14. H ).
27. The antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable domain (V H ) having an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO:
15. H ).
28. The antibody or antigen-binding fragment thereof according to claim 27, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable domain (V H ) having an amino acid sequence of SEQ ID NO:
15. H ).
29. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof comprises a non-natural constant region.
30. The antibody or antigen-binding fragment thereof of claim 29, wherein the non-natural constant region is a human constant region.
31. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof lacks all or part of an Fc domain, lacks all or part of a native Fc domain, or lacks an Fc domain.
32. The antibody or antigen-binding fragment thereof of claim 4, wherein the antibody or antigen-binding fragment thereof comprises a framework region having: TJDJSJJJX 1 YX 2 X 3 LqCy 4 LJS (SEQ ID NO: 5), wherein each J is independently a naturally occurring amino acid; each X 1 independently A, V or F; each X 2 independently M or I; each X 3 is independently E or Q; and each X 4 are independently S or R.
33. The antibody or antigen-binding fragment thereof of claim 4, wherein the antibody or antigen-binding fragment thereof comprises a framework region having an amino acid sequence selected from the group consisting of: (a) TVDKSSSTAYMELRSLTS (SEQ ID NO: 16) or an amino acid sequence having up to two conservative amino acid substitutions relative to said sequence; (b) TADTSSSNTAYIQLSSLTS (SEQ ID NO: 17) or an amino acid sequence having up to two conservative amino acid substitutions relative to said sequence; (c) TADTSTDTAYMELSSLRS (SEQ ID NO: 18) or an amino acid sequence having up to two conservative amino acid substitutions relative to said sequence; (d) TRDTSISTAYMELSRLTS (SEQ ID NO: 19) or an amino acid sequence having up to two conservative amino acid substitutions relative to said sequence; (e) TFYMELSSLRS (SEQ ID NO: 20) or an amino acid sequence having up to two conservative amino acid substitutions relative to said sequence; (f) TRDTSISTAYMELNRLTS (SEQ ID NO: 21) or an amino acid sequence having up to two conservative amino acid substitutions relative to said sequence; (g) TRDTSTNTVYMELTSLRS (SEQ ID NO: 22) or an amino acid sequence having up to two conservative amino acid substitutions relative to said sequence; and (h) TADTSTDRAYMELSSLRS (SEQ ID NO: 23) or an amino acid sequence having up to two conservative amino acid substitutions relative to said sequence.
34. The antibody or antigen-binding fragment thereof of claim 4, wherein the framework region is located between the CDR-H2 and the CDR-H3.
35. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof specifically binds to the TNFR2 at an epitope within the following position: (a) amino acids 56-60 of SEQ ID NO: 1 (KCSPG); (b) amino acids 101-107 of SEQ ID NO: 1 (CSSDQVET); (c) amino acids 115-142 of SEQ ID NO: 1 (NRICTCRPGWYCALSKQEGCRLCAPLRK); (d) amino acids 26-45 of SEQ ID NO: 1 (QTAQMCCSKCSPGQHAKVFC); (e) amino acids 90-109 of SEQ ID NO: 1 (REQNRICTCRPGWYCALSKQ); (f) amino acids 98-117 of SEQ ID NO: 1 (CRPGWYCALSKQEGCRLCAP); (g) amino acids 106-125 of SEQ ID NO: 1 (LSKQEGCRLCAPLRKCRPGF); or (h) amino acids 108-127 of SEQ ID NO: 1 (KQEGCRLCAPLRKCRPGFGV).
36. The antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment thereof (a) Activation of TNFR2 signaling; (b) With a K of no more than 10 nM D Binds to TNFR2; (c) binds to TNFR2 to form a 4 M -1 s -1 K on Antibody-antigen complex; (d) binds to TNFR2 to form an antibody-antigen complex, and wherein the complex has no more than 10 -3 s -1 K off Dissociation; (e) promote the proliferation of T regulatory (Treg) cells; (f) directly kill CD8+ T cells or promote their death; (g) promoting an increase in the level of one or more mRNA molecules encoding a protein selected from the group consisting of cIAP2, TRAF2, Etk, VEGFR2, PI3K, Akt, a protein involved in angiogenesis pathway, IKK complex, RIP, NIK, MAP3K, a protein involved in NFkB pathway, NIK, JNK, AP-1, MEK, MKK3, NEMO, IL2R, Foxp3, IL2, TNF, lymphotoxin, lymphotoxin alpha, and lymphotoxin beta; (h) promoting an increase in the level of one or more proteins selected from the group consisting of: cIAP2, TRAF2, Etk, VEGFR2, PI3K, Akt, proteins involved in angiogenesis pathways, IKK complex, RIP, NIK, MAP3K, proteins involved in NFkB pathways, NIK, JNK, AP-1, MEK, MKK3, NEMO, IL2R, Foxp3, IL2, TNF, lymphotoxin, lymphotoxin alpha, and lymphotoxin beta; or (i) promotes an increase in itaconate levels when administered to a human subject.
37. The antibody or antigen-binding fragment thereof according to claim 36, in: (a) the antibody or antigen-binding fragment thereof has a K of no greater than 1 nM D Binds to TNFR2; (b) the antibody or antigen-binding fragment thereof binds to TNFR2 to form a 5 M -1 s -1 K on Antibody-antigen complex; (c) the antibody or antigen-binding fragment thereof is not more than 10 -4 s -1 K off Dissociate from TNFR2; or (d) The Treg cells express CD25 Hi and CD45RA Low ;or (e) The MEK is MEK1 or MEK7.
38. The antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment thereof is a single-chain polypeptide.
39. A polynucleotide encoding the antibody or antigen-binding fragment thereof according to claim 1.
40. A polynucleotide encoding the single-chain polypeptide according to claim 38.
41. A vector comprising the polynucleotide according to claim 39.
42. The vector of claim 41, wherein the vector is an expression vector.
43. The vector according to claim 42, wherein the expression vector is a eukaryotic expression vector.
44. The vector of claim 41, wherein the vector is a viral vector.
45. The vector of claim 44, wherein the viral vector is selected from the group consisting of adenovirus (Ad), retrovirus, poxvirus, adeno-associated virus, baculovirus, herpes simplex virus, and vaccinia virus.
46. The vector of claim 45, wherein the adenovirus is a serotype 2, 5, 11, 12, 24, 26, 34, 35, 40, 48, 49, 50, 52, or Pan9 adenovirus, or a human, chimpanzee, or rhesus monkey adenovirus.
47. The vector of claim 45, wherein the retrovirus is a gammaretrovirus or a lentivirus.
48. The vector of claim 45, wherein the vaccinia virus is a modified vaccinia Ankara virus (MVA).
49. An isolated host cell comprising the vector of claim 41.
50. The host cell of claim 49, wherein the host cell is a prokaryotic cell.
51. The host cell of claim 49, wherein the host cell is a eukaryotic cell.
52. The host cell of claim 51, wherein the eukaryotic cell is a mammalian cell.
53. The host cell of claim 52, wherein the mammalian cell is a CHO cell or a HEK cell.
54. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1-38, wherein at least 50% of the antibody or antigen-binding fragment thereof in the pharmaceutical composition exists in a single disulfide-bonded isoform.
55. The pharmaceutical composition of claim 54, wherein 75% to 99.9% of the antibody or antigen-binding fragment thereof in the pharmaceutical composition is present in a single disulfide-bonded isoform.
56. The pharmaceutical composition of claim 54, wherein the antibody or antigen-binding fragment thereof produces a detectable band when analyzed by gel electrophoresis under non-reducing conditions.
57. The pharmaceutical composition of claim 54, wherein the single disulfide-bonded isotype is IgG2-B.
58. A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof according to any one of claims 1-38, a polynucleotide according to claim 39 or 40, a vector according to any one of claims 41-48, or a host cell according to any one of claims 49-53, and a pharmaceutically acceptable carrier or excipient.
59. The pharmaceutical composition of claim 54, wherein the antibody or antigen-binding fragment thereof is present in the pharmaceutical composition in an amount of 0.001 mg / ml to 100 mg / ml.
60. The pharmaceutical composition of claim 54, wherein the pharmaceutical composition further comprises an additional therapeutic agent.
61. The pharmaceutical composition of claim 60, wherein the additional therapeutic agent is an immunotherapeutic agent.
62. The pharmaceutical composition of claim 61, wherein the immunotherapeutic agent is selected from the group consisting of anti-CTLA-4 agonists, anti-PD-1 agonists, anti-PD-L1 agonists, anti-PD-L2 agonists, anti-CD27 agonists, anti-CD30 agonists, anti-CD40 agonists, anti-4-1BB agonists, anti-GITR agonists, anti-OX40 agonists, anti-TRAILR1 agonists, anti-TRAILR2 agonists, anti-TWEAK agonists, anti-TWEAKR agonists, anti-cell surface lymphocyte protein agonists, anti-BRAF agonists, anti-MEK agonists, anti-CD33 agonists, anti-CD20 agonists, anti-HLA-DR agonists, anti-HLA class I agonists, anti-CD52 agonists, anti-A33 agonists, anti-GD3 agonists, anti-PSMA agonists, anti-Ceacan 1 agonists, anti-Galedin 9 agonists, anti-HVEM agonists, anti-VISTA agonists, anti-B7 H4 agonist, anti-HHLA2 agonist, anti-CD155 agonist, anti-CD80 agonist, anti-BTLA agonist, anti-CD160 agonist, anti-CD28 agonist, anti-CD226 agonist, anti-CEACAM1 agonist, anti-TIM3 agonist, anti-TIGIT agonist, anti-CD96 agonist, anti-CD70 agonist, anti-CD27 agonist, anti-LIGHT agonist, anti-CD137 agonist, anti-DR4 agonist, anti-CR5 agonist, anti-TNFRS agonist, anti-TN FR1 agonist, anti-FAS agonist, anti-CD95 agonist, anti-TRAIL agonist, anti-DR6 agonist, anti-EDAR agonist, anti-NGFR agonist, anti-OPG agonist, anti-RANKL agonist, anti-LTβ receptor agonist, anti-BCMA agonist, anti-TACI agonist, anti-BAFFR agonist, anti-EDAR2 agonist, anti-TROY agonist and anti-RELT agonist, optionally wherein the immunotherapeutic agent is an agonistic anti-PD-1 antibody or an agonistic anti-PD-L1 antibody.
63. The pharmaceutical composition of claim 62, wherein the immunotherapeutic agent is selected from the group consisting of an agonist anti-CTLA-4 antibody or an antigen-binding fragment thereof, an agonist anti-PD-1 antibody or an antigen-binding fragment thereof, an agonist anti-PD-L1 antibody or an antigen-binding fragment thereof, an agonist anti-PD-L2 antibody or an antigen-binding fragment thereof, an agonist anti-CD27 antibody or an antigen-binding fragment thereof, an agonist anti-CD30 antibody or an antigen-binding fragment thereof, an agonist anti-CD40 antibody or an antigen-binding fragment thereof, an agonist anti-4-1BB antibody or an antigen-binding fragment thereof, an agonist anti-GITR antibody or an antigen-binding fragment thereof, an agonist anti-OX40 An agonist antibody or antigen-binding fragment thereof, an agonist anti-TRAILR1 antibody or antigen-binding fragment thereof, an agonist anti-TRAILR2 antibody or antigen-binding fragment thereof, an agonist anti-TWEAK antibody or antigen-binding fragment thereof, an agonist anti-TWEAKR antibody or antigen-binding fragment thereof, an agonist anti-cell surface lymphocyte protein antibody or antigen-binding fragment thereof, an agonist anti-BRAF antibody or antigen-binding fragment thereof, an agonist anti-MEK antibody or antigen-binding fragment thereof, an agonist anti-CD33 antibody or antigen-binding fragment thereof, an agonist anti-CD20 antibody or antigen-binding fragment thereof, an agonist anti-HLA-DR antibody or antigen-binding fragment thereof, an agonist anti-HLA Class I antibodies or antigen-binding fragments thereof, agonistic anti-CD52 antibodies or antigen-binding fragments thereof, agonistic anti-A33 antibodies or antigen-binding fragments thereof, agonistic anti-GD3 antibodies or antigen-binding fragments thereof, agonistic anti-PSMA antibodies or antigen-binding fragments thereof, agonistic anti-Ceacan 1 antibodies or antigen-binding fragments thereof, agonistic anti-Galedin 9 antibodies or antigen-binding fragments thereof, agonistic anti-HVEM antibodies or antigen-binding fragments thereof, agonistic anti-VISTA antibodies or antigen-binding fragments thereof, agonistic anti-B7H4 antibody or antigen-binding fragment thereof, agonist anti-HHLA2 antibody or antigen-binding fragment thereof, agonist anti-CD155 antibody or antigen-binding fragment thereof, agonist anti-CD80 antibody or antigen-binding fragment thereof, agonist anti-BTLA antibody or antigen-binding fragment thereof, agonist anti-CD160 antibody or antigen-binding fragment thereof, agonist anti-CD28 antibody or antigen-binding fragment thereof, agonist anti-CD226 antibody or antigen-binding fragment thereof, agonist anti-CEACAM1 antibody or antigen-binding fragment thereof, agonist anti-TIM3 antibody or antigen-binding fragment thereof, agonist anti-TIGIT antibody or antigen-binding fragment thereof, agonist anti-CD96 antibody or antigen-binding fragment thereof, agonist anti-CD70 antibody or antigen-binding fragment thereof, agonist anti-CD27 antibody or antigen-binding fragment thereof, agonist anti-LIGHT antibody or antigen-binding fragment thereof, agonist anti-CD137 antibody or antigen-binding fragment thereof, agonist anti-DR4 antibody or antigen-binding fragment thereof, agonist anti-CR5 antibody or antigen-binding fragment thereof and antigen-binding fragments thereof, agonist anti-TNFRS antibodies or antigen-binding fragments thereof, agonist anti-TNFR1 antibodies or antigen-binding fragments thereof, agonist anti-FAS antibodies or antigen-binding fragments thereof, agonist anti-CD95 antibodies or antigen-binding fragments thereof, agonist anti-TRAIL antibodies or antigen-binding fragments thereof, agonist anti-DR6 antibodies or antigen-binding fragments thereof, agonist anti-EDAR antibodies or antigen-binding fragments thereof, agonist anti-NGFR antibodies or antigen-binding fragments thereof, agonist anti-OPG antibodies or antigen-binding fragments thereof, agonist anti-RANKL antibodies or antigen-binding fragments thereof, agonist anti-LTβ receptor antibodies or antigen-binding fragments thereof, agonist anti-BCMA antibodies or antigen-binding fragments thereof, agonist anti-TACI antibodies or antigen-binding fragments thereof, agonist anti-BAFFR antibodies or antigen-binding fragments thereof, agonist anti-EDAR2 antibodies or antigen-binding fragments thereof, agonist anti-TROY antibodies or antigen-binding fragments thereof, and agonist anti-RELT antibodies or antigen-binding fragments thereof.
64. The pharmaceutical composition of claim 62, wherein the immunotherapeutic agent is an anti-CTLA-4 agonist or an anti-PD-1 agonist.
65. The pharmaceutical composition of claim 64, wherein the immunotherapeutic agent is an agonistic anti-CTLA-4 antibody or an antigen-binding fragment thereof, or an agonistic anti-PD-1 antibody or an antigen-binding fragment thereof.
66. A method for producing the antibody or antigen-binding fragment thereof according to claim 1, the method comprising expressing a polynucleotide encoding the antibody or antigen-binding fragment thereof in a host cell, and recovering the antibody or antigen-binding fragment thereof from the host cell culture medium.
67. Use of an antibody or antigen-binding fragment thereof according to any one of claims 1-38, a polynucleotide according to claim 39 or 40, a vector according to any one of claims 41-48, or a host cell according to any one of claims 49-53 in the preparation of a medicament for promoting proliferation of Treg cells in a human subject, wherein the human subject suffers from a disease or condition selected from the following: type I diabetes, psoriasis, myasthenia gravis, inflammatory bowel disease, multiple sclerosis, graft-versus-host disease, allograft rejection, rheumatoid arthritis, autoimmune lymphoproliferative syndrome, and allergy.
68. The use according to claim 67, wherein the allergy is selected from the group consisting of food allergies, seasonal allergies, pet allergies, urticaria, hay fever, allergic conjunctivitis, poison ivy allergy, oak allergy, mold allergy, drug allergy, dust allergy, cosmetic allergy and chemical allergy.
69. The use according to claim 67, wherein the allograft rejection is selected from the group consisting of skin graft rejection, bone graft rejection, vascular tissue graft rejection, ligament graft rejection and organ graft rejection.
70. The use according to claim 69, wherein the ligament graft rejection is selected from the group consisting of: cricothyroid ligament graft rejection, periodontal ligament graft rejection, suspensory ligament graft rejection, volar radiocarpal ligament graft rejection, dorsal radiocarpal ligament graft rejection, ulnar collateral ligament graft rejection, radial collateral ligament graft rejection, mammary suspensory ligament graft rejection, anterior sacroiliac ligament graft rejection, posterior sacroiliac ligament graft rejection, sacrotuberous ligament graft rejection, sacrospinous ligament graft rejection, arcuate pubic ligament graft rejection, suprapubic ligament graft rejection, anterior cruciate ligament graft rejection, lateral collateral ligament graft rejection, posterior cruciate ligament graft rejection, medial collateral ligament graft rejection, cranial cruciate ligament graft rejection, caudal cruciate ligament graft rejection, and knee ligament graft rejection.
71. The use according to claim 69, wherein the organ transplant rejection is selected from the group consisting of: cardiac transplant rejection, lung transplant rejection, kidney transplant rejection, liver transplant rejection, pancreatic transplant rejection, intestinal transplant rejection and thymus transplant rejection.
72. The use according to claim 67, wherein the graft-versus-host disease is derived from a bone marrow transplant or one or more blood cells selected from the group consisting of hematopoietic stem cells, common myeloid progenitor cells, common lymphoid progenitor cells, megakaryocytes, monocytes, basophils, eosinophils, neutrophils, macrophages, T cells, B cells, natural killer cells and dendritic cells.
73. purposes of a combination comprising an antibody or its antigen-binding fragment according to any one of claims 1-38 and an immunotherapeutic agent in the preparation of a medicament for promoting the proliferation of Treg cells in a human subject, wherein the human subject suffers from a disease or condition selected from the group consisting of type I diabetes, psoriasis, myasthenia gravis, inflammatory bowel disease, multiple sclerosis, graft-versus-host disease, allograft rejection, rheumatoid arthritis, autoimmune lymphoproliferative syndrome, and allergy.
74. The use of claim 73, wherein the immunotherapeutic agent is selected from the group consisting of anti-CTLA-4 agonists, anti-PD-1 agonists, anti-PD-L1 agonists, anti-PD-L2 agonists, anti-CD27 agonists, anti-CD30 agonists, anti-CD40 agonists, anti-4-1BB agonists, anti-GITR agonists, anti-OX40 agonists, anti-TRAILR1 agonists, anti-TRAILR2 agonists, anti-TWEAK agonists, anti-TWEAKR agonists, anti-cell surface lymphocyte protein agonists, anti-BRAF agonists, anti-MEK agonists, anti-CD33 agonists, anti-CD20 agonists, anti-HLA-DR agonists, anti-HLA class I agonists, anti-CD52 agonists, anti-A33 agonists, anti-GD3 agonists, anti-PSMA agonists, anti-Ceacan 1 agonists, anti-Galedin 9 agonists, anti-HVEM agonists, anti-VISTA agonists, anti-B7 H4 agonist, anti-HHLA2 agonist, anti-CD155 agonist, anti-CD80 agonist, anti-BTLA agonist, anti-CD160 agonist, anti-CD28 agonist, anti-CD226 agonist, anti-CEACAM1 agonist, anti-TIM3 agonist, anti-TIGIT agonist, anti-CD96 agonist, anti-CD70 agonist, anti-CD27 agonist, anti-LIGHT agonist, anti-CD137 agonist, anti-DR4 agonist, anti-CR5 agonist, anti-TNFRS agonist, anti-TN FR1 agonist, anti-FAS agonist, anti-CD95 agonist, anti-TRAIL agonist, anti-DR6 agonist, anti-EDAR agonist, anti-NGFR agonist, anti-OPG agonist, anti-RANKL agonist, anti-LTβ receptor agonist, anti-BCMA agonist, anti-TACI agonist, anti-BAFFR agonist, anti-EDAR2 agonist, anti-TROY agonist and anti-RELT agonist, optionally wherein the immunotherapeutic agent is an agonistic anti-PD-1 antibody or an agonistic anti-PD-L1 antibody.
75. The use of claim 74, wherein the immunotherapeutic agent is selected from the group consisting of an agonist anti-CTLA-4 antibody or antigen-binding fragment thereof, an agonist anti-PD-1 antibody or antigen-binding fragment thereof, an agonist anti-PD-L1 antibody or antigen-binding fragment thereof, an agonist anti-PD-L2 antibody or antigen-binding fragment thereof, an agonist anti-CD27 antibody or antigen-binding fragment thereof, an agonist anti-CD30 antibody or antigen-binding fragment thereof, an agonist anti-CD40 antibody or antigen-binding fragment thereof, an agonist anti-4-1BB antibody or antigen-binding fragment thereof, an agonist anti-GITR antibody or antigen-binding fragment thereof, an agonist anti-OX40 antibody or antigen-binding fragment thereof. or antigen-binding fragments thereof, agonistic anti-TRAILR1 antibodies or antigen-binding fragments thereof, agonistic anti-TRAILR2 antibodies or antigen-binding fragments thereof, agonistic anti-TWEAK antibodies or antigen-binding fragments thereof, agonistic anti-TWEAKR antibodies or antigen-binding fragments thereof, agonistic anti-cell surface lymphocyte protein antibodies or antigen-binding fragments thereof, agonistic anti-BRAF antibodies or antigen-binding fragments thereof, agonistic anti-MEK antibodies or antigen-binding fragments thereof, agonistic anti-CD33 antibodies or antigen-binding fragments thereof, agonistic anti-CD20 antibodies or antigen-binding fragments thereof, agonistic anti-HLA-DR antibodies or antigen-binding fragments thereof, agonistic anti-HLA Class I antibodies or antigen-binding fragments thereof, agonistic anti-CD52 antibodies or antigen-binding fragments thereof, agonistic anti-A33 antibodies or antigen-binding fragments thereof, agonistic anti-GD3 antibodies or antigen-binding fragments thereof, agonistic anti-PSMA antibodies or antigen-binding fragments thereof, agonistic anti-Ceacan 1 antibodies or antigen-binding fragments thereof, agonistic anti-Galedin 9 antibodies or antigen-binding fragments thereof, agonistic anti-HVEM antibodies or antigen-binding fragments thereof, agonistic anti-VISTA antibodies or antigen-binding fragments thereof, agonistic anti-B7H4 antibody or antigen-binding fragment thereof, agonist anti-HHLA2 antibody or antigen-binding fragment thereof, agonist anti-CD155 antibody or antigen-binding fragment thereof, agonist anti-CD80 antibody or antigen-binding fragment thereof, agonist anti-BTLA antibody or antigen-binding fragment thereof, agonist anti-CD160 antibody or antigen-binding fragment thereof, agonist anti-CD28 antibody or antigen-binding fragment thereof, agonist anti-CD226 antibody or antigen-binding fragment thereof, agonist anti-CEACAM1 antibody or antigen-binding fragment thereof, agonist anti-TIM3 antibody or antigen-binding fragment thereof, agonist anti-TIGIT antibody or antigen-binding fragment thereof, agonist anti-CD96 antibody or antigen-binding fragment thereof, agonist anti-CD70 antibody or antigen-binding fragment thereof, agonist anti-CD27 antibody or antigen-binding fragment thereof, agonist anti-LIGHT antibody or antigen-binding fragment thereof, agonist anti-CD137 antibody or antigen-binding fragment thereof, agonist anti-DR4 antibody or antigen-binding fragment thereof, agonist anti-CR5 antibody or antigen-binding fragment thereof and antigen-binding fragments thereof, agonist anti-TNFRS antibodies or antigen-binding fragments thereof, agonist anti-TNFR1 antibodies or antigen-binding fragments thereof, agonist anti-FAS antibodies or antigen-binding fragments thereof, agonist anti-CD95 antibodies or antigen-binding fragments thereof, agonist anti-TRAIL antibodies or antigen-binding fragments thereof, agonist anti-DR6 antibodies or antigen-binding fragments thereof, agonist anti-EDAR antibodies or antigen-binding fragments thereof, agonist anti-NGFR antibodies or antigen-binding fragments thereof, agonist anti-OPG antibodies or antigen-binding fragments thereof, agonist anti-RANKL antibodies or antigen-binding fragments thereof, agonist anti-LTβ receptor antibodies or antigen-binding fragments thereof, agonist anti-BCMA antibodies or antigen-binding fragments thereof, agonist anti-TACI antibodies or antigen-binding fragments thereof, agonist anti-BAFFR antibodies or antigen-binding fragments thereof, agonist anti-EDAR2 antibodies or antigen-binding fragments thereof, agonist anti-TROY antibodies or antigen-binding fragments thereof, and agonist anti-RELT antibodies or antigen-binding fragments thereof.
76. The use according to claim 74, wherein the immunotherapeutic agent is an anti-CTLA-4 agonist or an anti-PD-1 agonist.
77. The use according to claim 76, wherein the immunotherapeutic agent is an agonistic anti-CTLA-4 antibody or an antigen-binding fragment thereof, or an agonistic anti-PD-1 antibody or an antigen-binding fragment thereof.
78. The use of claim 73, wherein the antibody or antigen-binding fragment thereof and the immunotherapeutic agent are formulated as separate compositions.
79. Use of a combination comprising an antibody or antigen-binding fragment thereof according to any one of claims 1-38 and an additional agent in the preparation of a medicament for promoting proliferation of Treg cells in a human subject, wherein the additional agent is selected from the group consisting of TNFα, agonist TNFα mutant protein and Bacillus Calmette-Guérin (BCG), and the human subject suffers from a disease or condition selected from the following: type I diabetes, psoriasis, myasthenia gravis, inflammatory bowel disease, multiple sclerosis, graft-versus-host disease, allograft rejection, rheumatoid arthritis, autoimmune lymphoproliferative syndrome and allergy.
80. The use of claim 79, wherein the antibody or antigen-binding fragment thereof and the additional agent are formulated as separate compositions.
81. The use of claim 67, wherein the medicament is formulated to provide the antibody or antigen-binding fragment thereof in an amount of 0.001 mg / kg to 100 mg / kg.
82. A kit comprising the pharmaceutical composition of claim 58.
83. The kit of claim 82, wherein the pharmaceutical composition of the kit comprises the antibody or antigen-binding fragment thereof.
84. The kit of claim 82, wherein the pharmaceutical composition of the kit comprises the polynucleotide.
85. The kit of claim 82, wherein the pharmaceutical composition of the kit comprises the carrier.
86. The kit of claim 85, wherein the kit further comprises instructions for transfecting the vector into a host cell.
87. The kit of claim 86, wherein the kit further comprises instructions for expressing the antibody or antigen-binding fragment thereof from the vector in the host cell.
88. The kit of claim 82, wherein the pharmaceutical composition of the kit comprises the host cell.
89. The kit of claim 88, wherein the kit further comprises reagents useful for expressing the antibody or antigen-binding fragment thereof in the host cell.
90. A kit comprising the pharmaceutical composition of claim 54.
91. The kit of claim 82, further comprising instructions for administering the pharmaceutical composition to a human subject.
92. The kit of claim 82, further comprising instructions for preparing or using the pharmaceutical composition.
Citation Information
Patent Citations
Monoclonal antibodies against melanocytes and melanomas
EP0110716A2
Recombinant antibodies and methods for their production
EP0239400A2
A method for reducing the immunogenicity of antibody variable domains
EP0519596A1
Resurfacing of rodent antibodies
EP0592106A1
Engineered antibodies with new world primate framework regions
EP1945668A1
